Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS3850752 A
Publication typeGrant
Publication dateNov 26, 1974
Filing dateOct 29, 1971
Priority dateNov 10, 1970
Also published asCA967464A, CA967464A1, DE2155658A1, DE2155658B2, DE2155658C3
Publication numberUS 3850752 A, US 3850752A, US-A-3850752, US3850752 A, US3850752A
InventorsA Schuurs, Weemen B Van
Original AssigneeAkzona Inc
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Process for the demonstration and determination of low molecular compounds and of proteins capable of binding these compounds specifically
US 3850752 A
Abstract
The invention relates to a process for the demonstration and determination of a low molecular compound, such as a hapten, or a protein or antibody capable of binding this compound specifically, contacting a fluid containing such a compound or protein to be determined with a given quantity of the coupling product of such a low molecular compound and an enzyme, and with a given quantity of the component to be determined, which component is brought in an insoluble form, and determining the enzyme activity of the liquid or solid phase of the resulting reaction mixture.
Images(3)
Previous page
Next page
Claims  available in
Description  (OCR text may contain errors)

United States Patent [191 Schuurs et al.

[4 ]*Nov. 26, 1974 1 PROCESS FOR THE DEMONSTRATION AND DETERMINATION OF LOW MOLECULAR COMPOUNDS AND OF PROTEINS CAPABLE OF BINDING THESE COMPOUNDS SPECIFICALLY [75] Inventors: Antonius Hermanus Wilhelmus Maria Schuurs; Bauke Klass Van Weemen, both of Oss, Netherlands [73] Assignee: Akzona Incorporated, Asheville,

[ Notice: The portion of the term of this patent subsequent to Apr. 4, 1989, has been disclaimed.

[22] Filed: Oct. 29, 1971 21 Appl. No.: 193,702

[30] Foreign Application Priority Data Nov. 10, 1970 Netherlands 7016396 [52] US. Cl 195/1035 R, 195/99, 195/63, 424/12 [51] Int. Cl. G01n 31/14, GOln 33/16 8] Field of Search 195/1035 R; 23/253 TP,

[56] References Cited UNITED STATES PATENTS 3,615,222 10/1971 Mead 23/230 B 3,654,090 4/1972 Schuurs et a1. 195/1015 R OTHER PUBLICATIONS Chemical Abstracts 65: ll 124b, (1966). Spector et 11]., 168: 1348. 8. Science," (June 12, 1970).

Primary Examiner-Alvin E. Tanenholtz Attorney, Agent, or Firm-Hugo E. Weisberger [57] ABSTRACT with a given quantity of the component to be deter-- mined, which component is brought in an insoluble form, and determining the enzyme activity of the liquid or solid phase of the resulting reaction mixture.

13 Claims, 6 Drawing Figures PATENT Tia/261974 SHEET 10F 3 O O mu 5 1 N 0.25 0.06 CONCENTRATION ANN-TESTOSTERONE-CELLULOSE (mg/ml) FIG. 2

ng TESTOSTERONE IN THE SAMPLE I PATE NLNNZ SHEET 2M 3 3,850,752

FIG. 3

/o ENZYME ACTIVITY IN SUPERNATANT LIQUID O l I l l l 64 I6 4 l 0.25 0.06 CONCENTRATION ANTI-OESTRADIOL-CELLULOSE (mg/ml) FIG 4 5 lm OESTRADIOL 2 J M Q TESTOSTERONLPROGESTERONE gzo- ANTIOESTRADIOL-CELLULOSE sm /mfl ON. L l l I N O 4 I6 64 256 I024 4096 PATEIIIEDIIUVZBIQYI 3.850.752

suecrsor'a FIG.5

IOO

/o ENZYME ACTIVITY IN SUPERNATANT LIQUID O 8 l I l l I I I6 4 I 0.25 0.06 CONCENTRATION OF ANTPFOLATE-CELLULOSE (mg/ml) FIG, 6

Q g, FOLIC ACID l E 80- E z 5 I GLUTAMIC ACID 40- q I g GLY, ASP, LA I 2 I 4 8 I6 32 64 I28 CONCENTRATION IN ng/mI PROCESS FOR THE DEMONSTRATION AND DETERMINATION OF LOW MOLECULAR COMPOUNDS AND OF PROTEINS CAPABLE OF BINDING THESE COMPOUNDS SPECIFICALLY For the determination of low molecular substances occurring in low concentrations, such as steroid hormones in body fluids, methods have been developed using proteins capable of binding the substance to be determined specifically. These methods are based on the competition between the substance to be determined in the sample and a known quantity of the same substance which is labelled radioactive, for a limited quantity of specific binding protein. The unknown quantity of bindable substance then determines what portion of the radioactive labelled substance is bound by the specific binding protein.

It is also possible to determine by these methods an unknown quantity of specific binding protein by reacting a sample containing an unknown quantity of specific binding protein with a given quantity of bindable radioactive labelled substance.

in the literature it is common practice to distinguish these determination methods according to the nature of the specific binding protein employed, although the underlying principle of all determinations is identical. Thus, for example, they speak of competitive protein binding assays when they employ receptor or transport proteins occurring in the body, and of radioimmunological determinations when they employ antisubstances.

For both types of determinations radioactive labelled substances are required. The work with these substances requires the presence of precious measuring apparatuses, good laboratory facilities and a highly qualified staff. These high requirements prevent a general application of these determination, especially in smaller laboratories.

A process has now been found for the demonstration and determination of a component of the reaction between a low molecular compound and a protein capable of binding this compound specifically using the binding affinity of such components for each other,

characterized in that the determination is performed with a given quantity of the coupling product of the low molecular compound and an enzyme, and with a given quantity of a component of the said reaction which has been made insoluble, and the enzyme activity of the liquid or the solid phase of the resulting reaction mixture is determined, which activity is a measure for the quantity of the reaction component to be determined.

The method found can often by employed for the determination of haptens, which may be regarded as a special group of low molecular compounds, and their anti-substances. These substances mostly occur in low concentrations. According to the original definition of K. Landsteiner haptens are protein-free substances whose chemical configuration is such that they can react with specific antibodies, but not such that they are capable of causing the formation of anitbodies. In order to be able yet to make antibodies against haptens, the haptens must be coupled to polypeptides before being injected into the test animal. In the determination of a low molecular compound the substance to be determined and its coupling product with an enzyme enter into competition for a given quantity of the insoluble specific binding protein. The more low molecular compound the sample contains, the less opportunity the soluble enzyme conjugate of that compound has to combine with the insoluble specific binding protein and the more of the conjugate will remain in the liquid phase, in which the enzyme activity can be measured in a simple manner.

In the determination of a specific binding protein with the same reagents the soluble protein to be determined and the insoluble protein enter into competition for a given quantity of the conjugate of the corresponding low molecular compound and an enzyme. If the content of specific binding protein of the sample is higher, the insoluble protein will bind less of the enzyme conjugate, and consequently more enzyme remains in the liquid phase.

A specific binding protein having two or more binding possibilities can also be demonstrated and determined according to the invention, i.e. with the enzyme conjugate and. with the low molecular compound in an insoluble form. The liquid phase of the reaction mixture then contains the conjugate bound to the specific binding protein and in the solid phase the complex of enzyme conjugate specific binding protein insoluble low molecular compound. The more of the protein to be determined there is in the sample, the more enzyme activity the liquid phase will possess.

By means of an assay curve for a certain system in which increasing contents of substance to be determined have been set off against the enzyme activity found, preferably in the liquid phase, the quantity of substance to be determined in the sample can be derived from a value of enzyme activity found.

The most important reagents of this detennination method is the coupling product of the low molecular substance and an enzyme, for convenience hereinafter also called enzyme conjugate, which on the one hand can react with the specific binding protein, via the low molecular component and on the other hand possesses enzyme activity. This reagent is prepared by a method described for similar products. The second reagent, the insoluble component in the reaction system, serves to facilitate the separation between various enzymecontaining fractions of the reaction mixture. Addition of this reagent causes the fonnation of a solid phase in addition to a liquid phase. The present determinations can in principle be performed without an insoluble component of the reaction system. In that case the various fractions with enzyme activity will have to be separated by, for example, chromatographic or electrophoretic route or gelfiltration. For practical reasons such a determination is less attractive, however,

The enzyme activity of a fraction of the reaction mixture is demonstrated or measured by incubating that fraction with a substrate and other substances required for processing the relative enzyme: reaction. For preference a reaction is used in which a coloured compound is formed or removed whose absorption can also be measured quantitatively in an easy manner.

Low molecular substances which are eligible for demonstration by the new method and have a molecular weight of up to about 1500 are for example: steroids, vitamin B folinic acid, thyroxine and triiodothyronine, releasing factors, histamine, serotonin and other biogenic amines, digoxine, digitoxin, prostaglandins, adrenalin, nor-adrenalin, vegetable hormones such as auxin, kinetin and gibberellic acid, and antibiotics such as penicillin.

The method of demonstrating specific binding proteins for low molecular substances can be employed for, for example, the determination of antibody against penicillin or for the determination of intrinsic factor.

The preparation of conjugates of enzymes and lowmolecular substances can take place in various manners. Some low molecular substances may already possess groups that can be cross-linked with reactive groups at the surface of the enzyme, while other substances will have to be provided with such groups by organic chemical reactions. It stands to reason that the original binding properties of the low molecular compound and the activity of the enzyme may not change essentially during this process. The groups of the enzyme which are particularly suited for coupling reactions are amino and carboxyl groups. If the modified or unmodified low molecular substance also possesses such groups, the coupling can be performed by, for example, reactions known from the peptide synthesis. Furthermore such substances as glutaraldehyde, difluorodinitrodiphenylsulfon, toluene diisocyanate, diand trichloros-triazine can be employed for the coupling reaction.

Specific examples of the coupling of haptens to proteins are described in, for example, Methods in Immunology and lmmunochemistry, vol. I. The methods described are used for the preparation of conjugates for immunisation but they can also be used for the preparation of conjugates of the low molecular substance and an enzyme which are essential in the invention.

The choice of the enzyme that is to be a component of the conjugate (low molecular substance-enzyme) depends on properties such as the specific activity (a high conversion rate enhances the sensitivity of the test system) and the simplicity of the determination of the enzyme. The determination of an enzyme which catalyses a conversion involving coloured reaction components, is simple. Such colorimetric determinations can be automatized in a simple manner.

According to the invention it is also possible to use enzymes which catalyse conversions involving reaction components that can be determined spectrophotometrically or fluorimetrically. These determinations can also be automatized.

For the preparation of the conjugates enzymes such as catalase, peroxidase, B-glucuronidase, fl-D- glucosidase, B-D-galactosidase, urease, glucoseoxidase and galactose-oxidase are preferred, particularly the group of the oxide reductases.

The insoluble specific binding protein or the insoluble low molecular compound to be used in the present determination can be prepared by a known method, for example, by cross-linking with chloroformic acidethylester, by covalent binding with insoluble carriers such as agarose, cross-linked dextran or filter paper, or by physical coupling to insoluble carriers such as plastic objects.

The form in which the reagents can be used are manifold. The component of the reaction system conjugated with an enzyme can be freeze-dried or dissolved in a buffer. Furthermore a solid carrier, for example, a strip of paper impregnated with the conjugate, can be employed.

The insoluble component can be brought in the form of particles of various sizes, such as grains, platelets and rods, or in the form of a strip of some or other carrier material.

For the performance of the process according to the invention a test pack in preferably employed, chiefly composed of:

a. a given quantity of the coupling product of the low molecular compound and an enzyme;

b. a corresponding quantity of one of the components of the reaction system in an insoluble form;

c. a substrate for the determination of the activity of the enzyme employed.

If required, the test pack can also contain the necessary auxiliaries for making a dilution series of the sample to be examined for a quantitative determination, such as test tubes, pipettes and flasks of diluent. For the determination of a hapten or its antibody the test pack contains at least:

a. a given quantity of the coupling product of this hapten and an enzyme;

b. a corresponding quantity of a component of the reaction system in an insoluble form, haptenantibody;

c. a substrate for the determination of the enzyme activity.

The invention is illustrated further by the following examples, which are not to be construed as limiting.

Example I Determination of testosterone A. Preparation of testosterone-S-HRP One hundred milligrams of testosterone-3-(O-carboxymethyl)-oxim and 0.143 ml of tri-nbutylamine were dissolved in 5 ml of dioxan. The solution was cooled down to 2C and then 0.03 ml of isobutylchlorocarbonate were added. After 30 minutes the solution was added to mg of HRP (horse radish peroxidase) in a mixture of 9 ml of water and 6 ml of dioxan, and adjusted to pH 9 with 0.1 N NaOH. This solution was stirred for 4 hours at 2C and dialysed overnight. The precipitate obtained after the dialysate had been adjusted to pH 4.6 was centrifuged after having been left to stand overnight, suspended in 10 ml of water and dissolved by means of caustic soda solution. The material was precipitated three times with 15 ml of acetone at pH 4.5, dissolved in 15 ml of water which had been adjusted at pH 7.8 with caustic soda solution, dialysed and finally lyophilized.

B. Preparation of testosterone-Zl-BSA This conjugate was prepared in the same manner as the testosterone-B-HRP, but the starting materials were 50 mg of testosterone-3-(O-carboxymethyl)- oxim and mg of BSA (bovine serum albumin).

C. Preparation of antibodies against testosterone-3- BSA Five rabbits were injected intrarnuscularly with increasing dosages of testosterone-3-BSA in complete Freunds adjuvant (0.5, 1 and 2 mg) at intervals of 3 weeks. Two weeks after the last injection the animals were injected intravenously with 2 mg of antigen dissolved in physiological salt. One week after that blood was taken from the animals. The antibodies formed against BSA were removed by treating the serum portionwise with BSA-maminobenzyloxymethyl cellulose, prepared in accordance with Gurvichs method (see D). D. Preparation of anti-testosterone cellulose This substance was prepared in accordance with Gurvichs method as described in Biokhimiya 26, 934 (1961):

1. Preparation of aminocellulose:

Fifty grams of Whatman cellulose, which had been frequently washed and decanted, were suspended in 100 ml of a 0.7 sodium acetate solution containing 2 gm of N(m-nitrobenzoxy methylpyridine. The mixture was dried at 6080C and heated for 40 minutes at 125C. The resulting product was thoroughly washed with distilled water, dried at 80C, washed with benzene and dried again. Fifty grams of the dried product were reduced by suspension in 300 ml of a 15% Na S O solution and stirred for 30 minutes at 5060C. The product was filtered and washed with successively distilled water, 30% acetic acid and again with distilled water.

2. Treatment with ammoniacal copper solution:

Forty millilitres of sulphuric acid, 20 ml of 50% nitric acid and 140 ml of distilled water were heated, while stirring, to 90C, after which 5.9 gm of CuO were added in small portions. The solution was boiled for 2 hours and completed to 500 ml with distilled water. Eighty millilitres of this solution were transferred into an icebath and added to 160 ml of cold 4 N NaOI-I, while stirring. After being stirred for 30 minutes, the precipitate was washed twice with distilled water and dissolved in 80 ml of 25% ammonia. To this solution was gradually added 1 gm of aminocellulose. The mixture was stirred for 1.5 hours, after which 40 ml of boiling water were added, whereupon the solution was quickly cooled down to 0C. The solution was neutralized with 10% sulphuric acid, after whichthe aminocellulose flocculated. It was washed with cold distilled watel.

3. Preparation of 'y-globulin:

To rabbit anti-testosterone serum were added 180 mg of Na SO per ml of serum. The mixture was stirred for 1 hour at room temperature, after which the resulting precipitate was centrifuged, washed twice with an 18% Na SO solution and taken up in so much 0.05 M sodium borate of pH 8.6 that the protein concentration was about 10 mg/ml.

4. Binding 'y-globulin to aminocellulose Aminocellulose (350 mg) was suspended in distilled water (50 ml). The suspension was cooled down to 0C. Ten millilitres of a 36% hydrochloric acid were added and after that dropwise 10 ml of a 10% NaNO solution. The suspension was centrifuged, washed with cold distilled water and then with 0.05 M sodium borate of pH 8.6. The cellulose was suspended in 43 ml of 0.05 M sodium borate of pH 8.6. To this suspension were added 7 ml of the 'y-globulin solution prepared. The mixture was stirred for 26 hours at 4C, centrifuged and washed with 0.02 M phosphate buffer of pH 6.0. From the antiserum of each of the 5 immunized rabbits a cellulose suspension was prepared (A E respectively).

E. Determination of testosterone by means of testosterone-3-HRP and anti-testosterone cellulose The following test system was built up: I Immunoreaction buffer of pH 6.0 and containing 2% sheep serum.

II Enzyme reaction 0.5 ml of the supernatant liquid was incubated at room temperature with 1.5 ml of substrate for 30 minutes. The extinction was measured at 460 nm.

The enzyme substrate contained 10 ,ul of 30% hydrogen peroxide and 20 mg of S-aminosalicylic acid in 150 ml of 0.02 M phosphate buffer of pH 6.2.

FIG. 1 shows the measure in which testosterone3- HRP is bound by the anti-testosteronecellulose preparations made. In this case only buffer was added as a sample in the test system. If cellulose is added instead of anti-testosterone-cellulose, more than of the enzyme activity will remain behind in the supernatant liquid. The preparations B, D and E proved to bind hardly any testosterone-3- HRP, but A and C did.

FIG. 2 shows the results of incubation of a testosterone dilution series with testosterone-3-HRP and four different concentrations of anti-testosteronecellulose C 1 mg/ml (I), 2 mg/ml (II), 4 mg/ml (III) and 16 mg/ml (IV). It is obvious that with this system a quantity of about 10 ngm of testosterone can be demonstrated.

EXAMPLE III Determination of ,oestradiol A. Oestradiol-l7-succinyl-HRP was prepared by the mixed anhydride method described in example I A, using 50 mg of oestradiol-l7-hemisuccinate and 50 mg of HRP as starting materials.

B. Oestradiol-17-succinyl-BSA was prepared by the mixed anhydride method described in example I A, using mg of oestradiol-l7-hemisuccinate and mg of BSA as starting materials.

C. For the preparation of antibodies against oestradiol-l7-succinyl-BSA five rabbits were immunized in accordance with the scheme described in example I C. The sera were absorbed with BSA- m-amino-benzyloxymethyl-cellulose.

D. Anti-oestradiol-cellulose was prepared in the same manner as the anti-testosterone-cellulose described in example I D. From each of the immunized rabbits a cellulose preparation was made, numbered 16 up to 20 inclusive.

E. The test was performed analogous to that for testosterone as described in example I E.

FIG. 3 and 4 show a few results. FIG. 3 shows that the immunization yielded 3 usable antisera, of which As 17 has the highest titre.

FIG. 4 shows the test system in which anti-oestradiolcellulose 17 is used in a concentration of 8 mg/ml. The system does not discriminate between oestron and 17B-oestradiol. 17a-oestradiol and especially oestriol show a smaller cross-reaction. Testosterone and progesterone influence the system only in very high concentrations.

Example Ill Determination of antibodies against penicillin Penicilloyl-catalase Thirty milligrams of benzyl penicillinic acid were dissolved in ml of 96% ethanol and added dropwise to 200 mg of catalase in 45 ml of 0.1 M phosphate buffer of pH 7.5. The reaction process was continued for 2 hours, the pH being maintained between 7.2 and 8.2 with 0.5 N NaOH. The reaction mixture was dialysed against 6 X 3 l of 0.02 M phosphate buffer of pH 7.0.

In the same manner 250 mg of benzyl penicillinic acid were coupled to 5 gm of m-aminobenzyloxymethyl-cellulose prepared by Gurvichs method. Biokhimiya 26, 934 (1961). The coupling product was not dialysed however, but washed on a glass filter.

It proved to be possible to demonstrate over -sensitiveness to penicillin in humans in the following manner.

0.2 ml of a sample of non-haemolysed serum were mixed with 0.5 ml of a solution of penicilloyl-catalase (1 800). After 30 minutes mg of the penicilloyl-maminobenzyloxymethyl-cellulose were added. The mixture was rotated, for 30 minutes after which the enzyme activity in the supernatant liquid was determined by adding 0.02 ml of it to 2.8 ml of 0.05 M phosphate buffer of pH 6.8, which contained 1.2 a] of 30% H 0 and following the decrease in the extinction at 240 nm. In the serum from patients who were hyper-sensitive to penicillin less enzyme activity was found in the liquid than in checking with rabbit serum. The serum from normal human beings in these tests did not deviate considerably from normal rabbit serum.

Example IV Determination of folic acid A. Preparation of folate-glucose-oxidase Two hundred milligrams of glucose-oxidase (140 lU/mg) were dissolved in 10 ml of PBS (phosphate buffered saline, a phosphate-containing physiological salt solution) of pH 7.0. Thirty milligrams of l-cyclohexyl-3-( 2-morpholino-ethyl carbodiimide (MCDI) were added and then 24 mg of folic acid. The reaction process lasted 2 hours, after which a thorough dialysis was performed against PBS of pH 7.0.

B. Preparation of folate-MBSA (methylated bovine serum albumin) Folate-MBSA was prepared by Ricker and Stollars process described in Biochemistry 6, 2001 (1967). Twenty-five milligrams of MCDI were added to 50 mg of MBSA in 5 ml of water and then mg of folic acid. Two hours later a yellow precipitate had formed. Finally the whole reaction mixture was dialysed against physiological salt for a considerable time.

C. Preparation of antiserum against folate-MBSA On the days 0, 21 and 42 four rabbits were each injected intramuscularly with 2 mg of folate-MBSA in complete Freunds adjuvant and on day 35 intravenously with 2 mg of folate-MBSA in physiological salt. On day 49 the animals were exsanguinated.

D. Anti-folate cellulose was prepared by the process described in example I D.

E. Test system for folic acid One hundred ul of sample and 700 p.l of anti-folate cellulose suspension were rotated for 3 hours. Two hundred ul of folate-glucose-oxidase (l 1500) were added. The mixture was rotated again for 3 hours and centrifuged, after which the enzyme activity in the supernatant liquid was determined. This was done by mixing 0.5 ml ofit with a solution of 50 mg of glucose, 10 ,ugm of HRP and 1 mg of 5-aminosalicylic acid in 2.5 ml of 0.05N phosphate buffer of pH 6.0 and measuring the extinction after 30 minutes at 460 nm.

FIG. 5 shows the percentage of enzyme bound against the concentration of an anti-folatecellulose.

FIG. 6 shows the sensitivity of the test system in an anti-folate-cellulose concentration of 2 mg/ml and the effect of glycine, asparagine, alanine and glutamic acid.

Example V Determination of digoxin A. Preparation of digoxin-HRP To 22 mg of digoxin, suspended in 1 ml of absolute ethanol, was added dropwise, while stirring, 1 ml of 0.1 M sodium metaperiodate. After 25 minutes 0.3 ml of 0.1 M ethyleneglycol was added. Five minutes later this mixture was added dropwise, while stirring, to a solution 32 mg of horse radish peroxidase (HRP) in 1 ml of distilled water, which had been adjusted to pH 9.5 with a 5% K CO solution. During the reaction the pH was maintained at 9-9.5 with 5% K CO When the pH had become stable 15 mg of NaBH, in 1 ml of distilled water was added. After 3 hours the pH was adjusted to 6.5 with l M formic acid. One hour later 1 M NH OH was added till a pH of 8.5 had been reached. The mixture was dialysed overnight against cold running water. Finally the pH was adjusted at 4.5 with 0.1 N hydrochloric acid. The mixture was left to stand at room temperature for 1 hour and 4 hours at 4C to obtain a precipitate which was centrifuged for 1 hour at 1000 g. The precipitate was dissolved in 5 ml of 0.1 M Nail-[C0 thoroughly dialysed and freeze-dried.

B. Preparation of digoxin-BSA Digoxin bovine serum albumin (BSA) was prepared in the same manner as the above digoxin-HRP, but the starting materials were 436 mg of digoxin and 560 mg of BSA, the quantities of the other reagents having been raised in the same ratio as the digoxin.

C. Preparation of antibodies against digoxin Five rabbits were each injected with 400, 800 and 1600 ugm of digoxin-BSA respectively, at fortnightly intervals. The immunogen was mixed with complete Freunds adjuvant and administered intramuscularly. A fortnight after the last injection the animals were injected intravenously with 800 ugm of digoxin-BSA in physiological salt. Ten days later the animals were bleeded. The serum was adsorbed with BSA-m-aminobenzyloxymethylcellulose. D. Preparation of anti-digoxin-cellulose Anti-digoxin-cellulose was prepared by Gurvichs method as described in example 1 D. E. Determination of digoxin A dilution series was prepared of digoxin in 0.1 M phosphate buffer of pH 7.5 containing 0.9% NaCl, 0.5% Tween-20 and 1.0% of BSA. The dilution series was of from 0.1-100 ngm/ml. One millilitre of a digoxin solution was mixed with 0.1 ml of digoxin-HRP in a suitable dilution, after which 2 mg of antidigoxin-cellulose suspended in 0.4 ml of buffer were added. The mixture was rotated for 6 hours at room temperature, after which it was centrifuged and the enzyme activity in the supernatant liquid determined.

Addition of 0.8 ngm of digoxin proved to cause a measurable increase of enzyme activity in the supernatant liquid. Digitoxin only showed a slight cross-reaction in the system whereas cholesterol, cortisol, oestradiol, testosterone and progesterone did not show any cross-action in the system.

Example VII Determination of transcortine The reagents used for the determination of cortisol, as described in Example IV, were also employed for the determination of transcortine.

Of a dilution series of transcortine of from O 1280 ngm/ml 0.5 ml was incubated for 15 minutes at 4C with 0.2 ml of cortisol-2l-galactose-oxidase in a suit- 10 able dilution. To this dilution series 0.3 ml of transcortine-Sepharose mg/ml) were added and the mixture was rotated for 15 minutes at 4C. The activity in the supernatant liquid was measured as described in example VI. 15 A sample containing 40 ngm/ml of transcortine proved to cause a measurable increase of enzyme activity in the supernatant liquid, whereas in the presence of 320 ngm/ml all the enzyme activity was found in the supernatant liquid.

What is claimed is:

1. Process for the demonstration and determination of a low molecular weight organic compound by means of an antibody against said low molecular weight compound, comprising the steps of:

a. providing a given quantity of the coupling product of said low molecular weight organic compound with an enzyme;

b. providing a corresponding given quantity of an insolubilized antibody against said low molecular weight organic compound;

Example VI Determination of cortisol A. Preparation of cortisol-2l-galactose-oxidase Fifty mg of cortisol-Zl-hemisuccinate and 100 mg of galactose-oxidase were coupled by the mixed anhydride technique as described in example I A. B. Preparation of insoluble transcortine One hundred milligrams of transcortine, purified by DEAE, cellulose, and hydroxyl apatite chromatography respectively, were coupled to 3 gm Sepharose 4 B by the CNBr method, as follows. Three grams of Sepharose 4 B suspension were activated by mixing it with 4 ml of a 2.5% (w/v) CNBr solu tion in distilled water, after which the pH was adjusted between 10 and 11 with 1 N NaOI-l, at which value it was maintained for 6 minutes. The Sepharose was washed with icewaterand with 0.1 M NaHCO Then 100 mg of transcortine in 20 ml of 0.1 M NaHCO were added and the suspension was shakenfor 24 hours at 4C. After being washed with'successively 0.5 M NaI-ICO 0.05 M citrate buffer of pH 1.1 and 0.05 M phosphate buffer of pH 6.0, the Sepharose was kept in the last buffer,

2. The process of claim 1 in which said low molecular weight organic compound is a hapten.

3. The process of claim 1 in which said enzyme is an oxido-reductase.

4. Process for the demonstration and determination of a low molecular weight organic compound by means of a protein capable of reacting to bind said low molecular weight organic compound specifically, comprising the steps of:

to which 0.1% merthiolate had been added. C. Determination of cortisol Of a cortisol-containing sample (standard, plasma or urine) 0.5 ml were extracted twice with methylene chloride (2 X 3 ml). The combined extraction liquids wereevaporated to dryness. The residue was .a. providing a given quantity of the coupling product taken up in 0.5 ml of physiological salt solution and mixed with 0.2 ml of cortisol-2l-galactose-oxidase s z i :Z ggi wlght orgamc compound m a.smtable concentraum? and 1 b. providing a corresponding given quantity of an incomne'sepharose Suspens lon (5 solubilized specific binding protein having more ture was rotate? for mmutes and cenm' than one valency capable of reacting to bind said fuged, after which the enzyme activity in the superlow molecular weight organic compound specifb natant liquid was determined by adding 0.5 m1 of Cally;

it to m1 of Substrate cotlsistillg 9 mg of c. contacting a sample of a fluid containing the low galactose, zofng S'ammOSahCYhC and 10 molecular weight organic compound to be deterof Permdase 150 ml of 002 M Phosphate mined with said components (a) and (b) to form a buffer of pH 6.0. Thirty minutes later the extinction was measured at 460 nm.

Five ngm/ml of cortisol in the sample caused a measurable increase of the enzyme activity in the supernatant liquid. Corticosterone and progesterone 6 reaction mixture; and

d. determining the enzyme activity of the liquid or the solid phase of the resulting reaction mixture, which activity is a measure of the quantity of low molecular weight organic compound to be deter mined.

5. The process of claim 4 in which said enzyme is an oxido-reductase.

6. Process for the demonstration and determination of a specific binding protein having two or more binding sites by means of a low molecular weight organic compound capable of reacting to bind said protein specifically; comprising the steps of:

a. providing a given quantity of the coupling product of said low molecular weight organic compound and an enzyme;

b. providing a corresponding given quantity of an insolubilized specific binding protein having two or more binding sites capable of binding said low molecular weight organic compound;

c. contacting a sample of a fluid containing the protein to be determined with said components (a) and (b) to form a reaction mixture; and

d. determining the enzyme activity of the liquid phase of the resulting reaction mixture, which activity is a measure of the quantity of the specific binding protein to be determined.

7. The process of claim 6 in which said protein is an antibody.

8. A diagnostic pack for the demonstration and determination of a low molecular weight organic compound by means of an antibody against said low molecular weight organic compound, comprising:

a. a given quantity of the coupling product of said low molecular weight organic compound with an enzyme;

b. a corresponding given quantity of an insolubilized antibody against said low molecular weight organic compound; and

c. a substrate for the determination of the enzyme activity of said enzyme.

9. The diagnostic pack of claim 8 in which said enzyme is an oxido-reductase.

10. A diagnostic pack for the demonstration and determination of a low molecular weight organic compound by means of a protein capable of reacting to bind said low molecular weight organic compound spe cifically, comprising:

a. a given quantity of the coupling product of said low molecular weight organic compound with an enzyme;

b. a corresponding given quantity of an insolubilized specific binding protein capable of reacting to bind said low molecular weight organic compound specifically; and

c. a substrate for the determination of the enzyme activity of said enzyme.

11. The diagnostic pack of claim 10 in which said enzyme is an oxido-reductase.

12. A diagnostic pack for the demonstration and determination of a hapten by means of an antibody against said hapten, comprising:

a. a given quantity of the coupling product of said hapten with an enzyme;

b. a corresponding given quantity of an insolubilized antibody against said hapten; and

c. a substrate for the determination of the enzyme activity of said enzyme.

13. The diagnostic pack of claim 12 in which said enzyme is an oxido-reductase.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION PATENT NO. 3,850,752 A Page: 1 of 2 DATED November 26, 1974 vE 0 (5) Schuurs et a1.

It is certified that error appears in the above-identifiedpatent and that said Letters Patent is hereby corrected as shown below:

On the front page of the patent (disclosing the inventors, assignee, Abstract, References Cited, under [21] Appl No. 193,702" the following heading and contents thereunder:

Related U.S. Application Data p In column 1, beneath the title "PROCESS FOR THE DEMONSTRATION AND DETERMINATION OF LOW MOLECULAR COMPOUNDS AND OF PROTEINS CAPABLE OF BINDING THESE COMPOUNDS SPECIFICALLY" Insert the following paragraph:

This application is a continuation-in-part of Ser. No. 762,120, filed September '24, 1968, issued as U.S. Pat. 3,654,090 on April 4, 1972.

In column 4, line 25, change to In column 5, lines 31 32, place "aminocellulose" in quotation marks. I

In column 5, line 48, place "aminocellulose" in quotation marks.

In column 5, line 49, place "aminocellulose" in quotation marks.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION PATENT NO. 3,850,752 Page 2 of 2 DATED November 26, 1974 INVENTQR(S) Schuurs et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In column 7, line 20, change to "z".

Signed and Scaled this Twelfth Day Of Ju1y1983 [SEAL] A nest:

GERALD J. MOSSINGHOFF Arresting Officer Commissioner of Parents and Trademarks

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3615222 *Sep 4, 1968Oct 26, 1971New England Nuclear CorpMethod and apparatus for measuring the amount of a component in a biological fluid
US3654090 *Sep 24, 1968Jul 20, 1982 Title not available
Non-Patent Citations
Reference
1 *Chemical Abstracts 65: 11124b, (1966).
2 *Spector et al., 168: 1348, 8, Science, (June 12, 1970).
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US3905871 *Oct 10, 1974Sep 16, 1975Syva CoLactam conjugates to enzymes
US3966556 *Jun 20, 1974Jun 29, 1976Syva CompanyCompounds for enzyme amplification assay methadone analogs
US3975237 *Jun 20, 1974Aug 17, 1976Syva CompanyCompounds for enzyme amplification assay - - ecgonine analogs
US4039385 *Jan 19, 1976Aug 2, 1977Syva CompanyCardiac glycoside enzyme conjugates
US4040907 *Dec 29, 1975Aug 9, 1977Syva CompanyIodothyronine enzyme conjugates
US4043872 *Dec 29, 1975Aug 23, 1977Syva CompanyPolyiodothyronine immunoassay
US4046636 *May 24, 1976Sep 6, 1977Syva CompanyDiazepam enzyme conjugates
US4061466 *Oct 14, 1975Dec 6, 1977Ingvar Gosta Holger SjoholmBiologically active composition and the use thereof
US4096138 *Dec 8, 1975Jun 20, 1978Scherr George HImmunological test procedure
US4098876 *Oct 26, 1976Jul 4, 1978Corning Glass WorksReverse sandwich immunoassay
US4134792 *Dec 6, 1976Jan 16, 1979Miles Laboratories, Inc.Specific binding assay with an enzyme modulator as a labeling substance
US4166767 *Mar 16, 1977Sep 4, 1979Dainippon Pharmaceutical Co., Ltd.Insolubilized antibody
US4191613 *Jan 19, 1977Mar 4, 1980Syva CompanyMalate dehydrogenase conjugates for enzyme immunoassays
US4203802 *Dec 5, 1977May 20, 1980Syva CompanyInhibitable enzyme amplification assay
US4248965 *Oct 3, 1977Feb 3, 1981Mochida Seiyaku Kabushiki KaishaImmunochemical process of measuring physiologically active substances
US4250253 *Mar 9, 1978Feb 10, 1981Snamprogetti S.P.A.Composition adapted for the determination of tri-iodo thyronine and diagnosis method employing same
US4269938 *Mar 8, 1979May 26, 1981Eastman Kodak CompanyAssay of peroxidatively active materials
US4282325 *May 7, 1979Aug 4, 1981Syva CompanyEnzyme bound corticosteroids
US4289748 *May 31, 1979Sep 15, 1981United States Of AmericaUltrasensitive enzymatic radioimmunoassay method
US4299916 *Dec 26, 1979Nov 10, 1981Syva CompanyPreferential signal production on a surface in immunoassays
US4323647 *Oct 15, 1980Apr 6, 1982University Of MiamiSteric hindrance enzyme immunoassay
US4343896 *May 1, 1980Aug 10, 1982Akzona IncorporatedMethod and test pack for the demonstration and determination of an antigen or antibody
US4347312 *Mar 20, 1980Aug 31, 1982Research Triangle InstituteDetection of antibiotics in milk
US4350761 *May 15, 1980Sep 21, 1982Yamasu Shoyu Kabushiki KaishaMethod of and reagents for quantitative analysis of cyclic nucleotides
US4376825 *Dec 30, 1980Mar 15, 1983Syva CompanyEnzyme amplification compounds for assays for androgens
US4391904 *Apr 17, 1981Jul 5, 1983Syva CompanyTest strip kits in immunoassays and compositions therein
US4419453 *Sep 30, 1982Dec 6, 1983The Dow Chemical CompanyImmunological agglutination assays with dyed or colored latex and kits
US4443365 *Jun 24, 1981Apr 17, 1984Dainippon Pharmaceutical Company LimitedMethod for determination of the valproic acid and reagents therein
US4467030 *May 15, 1981Aug 21, 1984Boehringer Mannheim GmbhDetermination of the thyroxine-binding index in serum
US4506009 *Mar 30, 1982Mar 19, 1985University Of CaliforniaHeterogeneous immunoassay method
US4530900 *Sep 13, 1982Jul 23, 1985Seragen Diagnostics Inc.Soluble insoluble polymers in enzymeimmunoassay
US4535057 *Jul 26, 1982Aug 13, 1985Amf IncorporatedImmunoassay employing monoclonal herpes simplex antibody and biotin-avidin detection system
US4604365 *May 28, 1982Aug 5, 1986Electro-Nucleonics, Inc.Immunoprecipitation assay
US4713347 *Jan 14, 1985Dec 15, 1987Sensor Diagnostics, Inc.Measurement of ligand/anti-ligand interactions using bulk conductance
US4786594 *May 14, 1986Nov 22, 1988Syntex (U.S.A.) Inc.Enzyme immunoassay
US5047330 *Jan 6, 1988Sep 10, 1991Commissariat A L'energie AtomiqueCompound labelled by the acetyl cholinesterase of Electrophorus electricus, its preparation process and its use as a tracer or marker in enzymoimmunological determinations
US5268298 *Apr 26, 1991Dec 7, 1993Life Technologies, Inc.System for delivering oxygen to a cell culture medium
US5354692 *Sep 8, 1992Oct 11, 1994Pacific Biotech, Inc.Analyte detection device including a hydrophobic barrier for improved fluid flow
US5391483 *Jul 1, 1992Feb 21, 1995Eastman Kodak CompanyLigand analogs for immunoassays derived from dicarboxylic acid oxidation products
US5516639 *Jul 22, 1993May 14, 1996Mayo Foundation For Medical Education And ResearchAntibodies specific for human prostate glandular kallkrein
US5587294 *Oct 28, 1994Dec 24, 1996Assay Research, Inc.Method and kit for measuring endogenous cytokines
US5589344 *Jun 15, 1994Dec 31, 1996Johnson & Johnson Clinical Diagnostics, Inc.Test kit and method for competitive specific binding assay
US5605800 *Jun 6, 1995Feb 25, 1997Institut PasteurMethod of detecting and characterizing a nucleic acid or a sequence of the latter, and enzymatic reactant for the application of this method
US5614504 *Apr 21, 1995Mar 25, 1997The University Of South FloridaMethod of making inosine monophosphate derivatives and immunopotentiating uses thereof
US5624804 *Oct 1, 1992Apr 29, 1997The Rockefeller UniversityImmunochemical detection of In vivo advanced glycosylation end products
US5629408 *Jun 7, 1995May 13, 1997The Rockefeller UniversityImmunochemical isolation of in vivo advanced glycosylation endproducts
US5637467 *Mar 29, 1995Jun 10, 1997Behringwerke AgHeterogeneous assay using a pendulous drop
US5652346 *Mar 6, 1996Jul 29, 1997Johnson & Johnson Clinical Diagnostics, Inc.Dicarboxylic acid oxidation products
US5683887 *Jun 7, 1995Nov 4, 1997The Rockefeller UniversityImmunochemical detection of in vivo advanced glycosylation endproducts
US5684144 *Feb 7, 1994Nov 4, 1997University Of North TexasEscherichia coli csrA gene, protein encoded thereby, and methods of use thereof
US5702704 *Jun 7, 1995Dec 30, 1997The Rockefeller UniversityAntibodies to in vivo advanced glycosylation endproducts
US5703206 *Aug 3, 1994Dec 30, 1997Univ RockefellerMacrophage inflammatory protein 2 (MIP-2)
US5712101 *Jun 7, 1995Jan 27, 1998The Rockefeller UniversityImmunochemical detection of in vivo advanced glycosylation endproducts
US5717074 *Jun 7, 1995Feb 10, 1998The Rockefeller UniversityMacrophage-derived inflammatory mediator (MIP-2)
US5726023 *Jun 6, 1995Mar 10, 1998University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US5728807 *Jun 21, 1995Mar 17, 1998Ramot-University Authority For Applied Research And Industrial Development, Ltd.Mutated proteins associated with ataxia-telangiectasia
US5733546 *Jun 7, 1995Mar 31, 1998The Rockefeller UniversityImmunochemical detection of in vivo advanced glycosylation endproducts
US5777093 *Jul 28, 1995Jul 7, 1998Ramot-University Authority For Applied Research & Industrial Development Ltd.cDNAs associated with ataxia-telangiectasia
US5801005 *Mar 31, 1995Sep 1, 1998University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5837535 *Feb 15, 1996Nov 17, 1998Henry Ford Health SystemNeuronal-neonatal gene: neuronatin
US5840322 *Dec 19, 1996Nov 24, 1998Ramot-University Authority For Applied Research & Industrial Devel. Ltd.Anti-oral-microbial adhesion fraction derived from vaccinium
US5843673 *Jun 7, 1995Dec 1, 1998Curators Of The University Of MissouriMethod of screening for endometriosis
US5846538 *Jun 7, 1995Dec 8, 1998University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the her-2/neu oncogene is associated
US5858661 *Apr 8, 1996Jan 12, 1999Ramot-University Authority For Applied Research And Industrial DevelopmentAtaxia-telangiectasia gene and its genomic organization
US5869445 *Apr 1, 1996Feb 9, 1999University Of WashingtonMethods for eliciting or enhancing reactivity to HER-2/neu protein
US5874423 *Sep 12, 1996Feb 23, 1999Yissum Research Development Co. Of The Hebrew University Of JerusalemDigitalis-like compounds
US5876712 *Jun 6, 1995Mar 2, 1999University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US5876928 *Jun 6, 1995Mar 2, 1999Institut PasteurMethod of detecting and characterizing a nucleic acid or a sequence of the latter, and enzymatic reactant for the application of this method
US5882644 *Mar 22, 1996Mar 16, 1999Protein Design Labs, Inc.Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US5939524 *Dec 9, 1991Aug 17, 1999The Scripps Research InstitutePlatelet GPIII P1A1 and P1A2 epitopes, their preparation and use
US5955262 *Sep 8, 1992Sep 21, 1999Institut PasteurMethod of detecting and characterizing a nucleic acid or reactant for the application of this method
US5965379 *Oct 28, 1997Oct 12, 1999Cytimmune Sciences Inc.Method for measuring endogenous cytokines
US6001968 *Aug 17, 1994Dec 14, 1999The Rockefeller UniversityOB polypeptides, modified forms and compositions
US6008335 *Sep 19, 1997Dec 28, 1999Cedars-Sinai Medical CenterMethods of screening for ulcerative colitis and Crohn's disease
US6013471 *Dec 17, 1996Jan 11, 2000Hybritech IncorporatedDNA encoding hK2 variant polypeptides
US6048837 *Jun 7, 1995Apr 11, 2000The Rockefeller UniversityOB polypeptides as modulators of body weight
US6060260 *Feb 27, 1998May 9, 2000Dade Behring Inc.Methods for reducing adsorption in an assay
US6075122 *Jun 6, 1995Jun 13, 2000University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US6093796 *Dec 17, 1996Jul 25, 2000Mayo Foundation For Medical Education And ResearchRecombinant hK2 polypeptide
US6093809 *May 6, 1997Jul 25, 2000University Technology CorporationTelomerase
US6103234 *Jun 7, 1995Aug 15, 2000The Rockefeller UniversityComposition comprising an antibody to macrophage-derived inflammatory mediator (MIP-2)
US6103237 *Mar 26, 1996Aug 15, 2000Hybritech IncorporatedStable variant hK2 polypeptide
US6124439 *Jun 7, 1995Sep 26, 2000The Rockefeller UniversityOB polypeptide antibodies and method of making
US6124448 *Jun 7, 1995Sep 26, 2000The Rockfeller UniversityNucleic acid primers and probes for the mammalian OB gene
US6127338 *Apr 1, 1998Oct 3, 2000Calyx Therapeutics, Inc.Orally active fraction of momordica charantia, active peptides thereof, and their use in the treatment of diabetes
US6129917 *Mar 21, 1997Oct 10, 2000The University Of Georgia Research Foundation, Inc.Immunogenic compositions comprising porphyromonas gingivalis proteins and/or peptides and methods
US6180411Jul 30, 1998Jan 30, 2001The Regents Of The University Of CaliforniaLight-triggered indicators that memorize analyte concentrations
US6187563Aug 4, 1999Feb 13, 2001Yale UniversityβIV-spectrin-polypeptides and nucleic acids encoding same
US6200749May 3, 1996Mar 13, 2001Ramot-University Authority For Applied Research And Industrial Development Ltd.Mutated forms of the ataxia-telangiectasia gene and method to screen for a partial A-T phenotype
US6207153May 22, 1997Mar 27, 2001Viventia Biotech, Inc.Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US6228575Feb 7, 1997May 8, 2001Affymetrix, Inc.Chip-based species identification and phenotypic characterization of microorganisms
US6228638Jul 9, 1998May 8, 2001University Of North Texas, Health Science Center At Fort WorthEscherichia coli CSRB gene and RNA encoded thereby
US6235486Jun 19, 1998May 22, 2001Mayo Foundation For Medical Education & ResearchMethod for detection of breast cancer
US6261836May 9, 1997Jul 17, 2001Geron CorporationTelomerase
US6284496Jan 2, 1998Sep 4, 2001University Of South FloridaDNA vector for determining the presence of out-of-reading-frame mutations
US6294334Sep 28, 1999Sep 25, 2001Board Of Regents, The University Of Texas SystemGenetic test for equine severe combined immunodeficiency disease
US6303344Jun 24, 1999Oct 16, 2001Maxygen, Inc.Methods and compositions for polypeptide engineering
US6309853Jun 7, 1995Oct 30, 2001The Rockfeller UniversityModulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6312901Sep 10, 1999Nov 6, 2001Burstein Technologies, Inc.Spatially addressable, cleavable reflective signal elements, assay device and method
US6319713Jun 25, 1999Nov 20, 2001Maxygen, Inc.Methods and compositions for polypeptide engineering
US6331275Aug 3, 2000Dec 18, 2001Burstein Technologies, Inc.Spatially addressable, cleavable reflective signal elements, assay device and method
US6335160Dec 18, 1996Jan 1, 2002Maxygen, Inc.Methods and compositions for polypeptide engineering
US6342349Jul 21, 1998Jan 29, 2002Burstein Technologies, Inc.Optical disk-based assay devices and methods
US6344443Jul 8, 1999Feb 5, 2002University Of South FloridaPeptide antagonists of tumor necrosis factor alpha
US6350730Jun 7, 1995Feb 26, 2002The Rockefeller UniversityOB polypeptides and modified forms as modulators of body weight
US6355484Jun 24, 1999Mar 12, 2002Maxygen, Inc.Methods and compositions for polypeptides engineering
US6391854Jul 31, 2000May 21, 2002Calyx Therapeutics, Inc.Orally active fraction of momordica charantia, active peptides thereof, and their use in the treatment of diabetes
US6406855Nov 22, 2000Jun 18, 2002Maxygen, Inc.Methods and compositions for polypeptide engineering
US6410687Apr 13, 1999Jun 25, 2002The Regents Of The University Of CaliforniaPolypeptides for the detection of microtubule depolymerization inhibitors
US6429304Nov 28, 2000Aug 6, 2002The Regents Of The University Of CaliforniaNucleic acids encoding a katanin p60 subunit
US6433155Sep 24, 1997Aug 13, 2002Tanox, Inc.Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US6440682 *May 24, 2000Aug 27, 2002Detroit R&D Inc.Detection of hypertension using immunoreactive metabolic products
US6455253Apr 27, 2000Sep 24, 2002Maxygen, Inc.Methods and compositions for polypeptide engineering
US6458557Nov 19, 1998Oct 1, 2002Genencor International, Inc.Enhancing growth in gram-positive microorganisms using formate supplementation and inactivation of formate-associated transport proteins
US6471956Jun 7, 1995Oct 29, 2002The Rockefeller UniversityOb polypeptides, modified forms and compositions thereto
US6475789Aug 14, 1997Nov 5, 2002University Technology CorporationHuman telomerase catalytic subunit: diagnostic and therapeutic methods
US6479263Apr 11, 1997Nov 12, 2002Baylor College Of MedicineMethod for detection of micrometastatic prostate cancer
US6482389Oct 16, 1998Nov 19, 2002University Of South FloridaMethod to diagnose and monitor cellular immune deficiencies
US6482608 *May 26, 2000Nov 19, 2002The Salk Institute For Biological StudiesCloning and recombinant production of CRF receptor(S)
US6495343Jan 17, 1995Dec 17, 2002The Salk Institute For Biological StudiesCloning and recombinant production of CRF receptor(s)
US6506553Mar 30, 1995Jan 14, 2003Ortho Diagnostics Systems, Inc.Method for diagnosis of Epstein-Barr virus associated disease
US6506579Jul 14, 1998Jan 14, 2003Genencor International, Inc.Increasing production of proteins in gram-positive microorganisms using SecG
US6521421Jul 15, 1998Feb 18, 2003Genencor International, Inc.Expression vectors encoding Bacillus subtilis disulfide bond isomerase and methods of secreting proteins in gram-positive microorganisms using the same
US6521440Sep 8, 1998Feb 18, 2003Genencor International, Inc.Proteases from gram-positive organisms
US6531130Jun 28, 2000Mar 11, 2003The Board Of Trustees Of The Leland Stanford UniversityTreatment of demyelinating autoimmune disease with ordered peptides
US6531277Mar 19, 1998Mar 11, 2003The Curators Of The University Of MissouriEndometriosis-specific secretory protein
US6537815Dec 13, 2000Mar 25, 2003University Of North Texas, Health Science Center At Fort WorthMethod of altering the expression of csrB to modify the properties of a cell
US6544792Jun 14, 2000Apr 8, 2003Genencor International, Inc.Production of secreted polypeptides
US6579678Oct 20, 2000Jun 17, 2003Maxygen, Inc.Methods and compositions for polypeptide engineering
US6596501Feb 23, 1999Jul 22, 2003Fred Hutchinson Cancer Research CenterMethod of diagnosing autoimmune disease
US6599731Dec 17, 1998Jul 29, 2003Genencor International, Inc.Proteases from gram positive organisms
US6610839Oct 1, 1997Aug 26, 2003Geron CorporationPromoter for telomerase reverse transcriptase
US6613514Apr 27, 2000Sep 2, 2003Maxygen, Inc.Methods and compositions for polypeptide engineering
US6617110Nov 22, 2000Sep 9, 2003Geron CorporationCells immortalized with telomerase reverse transcriptase for use in drug screening
US6630328Jul 5, 2001Oct 7, 2003Genencor International, Inc.Increasing production of proteins in gram-positive microorganisms
US6638905Nov 12, 1998Oct 28, 2003The Salk Institute For Biological StudiesCloning and recombinant production of CFR receptor(s)
US6642027Nov 14, 2001Nov 4, 2003Genecor International, Inc.Production of secreted polypeptides
US6653072Jun 24, 1999Nov 25, 2003Maxygen, Inc.Methods and compositions for polypeptide engineering
US6664370Jul 15, 1999Dec 16, 2003University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US6673623Sep 12, 2000Jan 6, 2004Novocure, Inc.Methods and compositions that control lipid production
US6673914Jan 21, 1999Jan 6, 2004John Wayne Cancer InstituteHuman tumor-associated gene
US6699969Nov 28, 2000Mar 2, 2004The Regents Of The University Of CaliforniaAssays for the detection of microtubule depolymerization inhibitors
US6723550Jul 14, 1998Apr 20, 2004Genencor International, Inc.Proteases from gram-positive organisms
US6759243Dec 6, 2000Jul 6, 2004Board Of Trustees Of The University Of IllinoisHigh affinity TCR proteins and methods
US6770449Jan 30, 2001Aug 3, 2004Duke UniversityMethods of assaying receptor activity and constructs useful in such methods
US6770622Jun 8, 2001Aug 3, 2004Gary A. JarvisN-terminally truncated galectin-3 for use in treating cancer
US6787318Jun 1, 2000Sep 7, 2004Roskamp Research Institute, LlcAssay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
US6794179Jul 2, 2002Sep 21, 2004Genencor International, Inc.Proteases from gram positive organisms
US6808880Jan 19, 2001Oct 26, 2004Geron CorporationMethod for detecting polynucleotides encoding telomerase
US6833261Mar 26, 2003Dec 21, 2004Genencor International, Inc.Proteases from gram-positive organisms
US6833265Aug 17, 2001Dec 21, 2004Genencor International, Inc.Proteases from gram-positive organisms
US6833441Aug 1, 2001Dec 21, 2004Abmaxis, Inc.Compositions and methods for generating chimeric heteromultimers
US6844433Jun 2, 2003Jan 18, 2005Affymetrix, Inc.Nucleic acid labeling compounds
US6849440Mar 26, 2003Feb 1, 2005Genencor International, Inc.Proteases from gram-positive organisms
US6852695Mar 21, 2002Feb 8, 2005Theracos, Inc.Orally active fraction of momordica charantia, active peptides thereof, and their use in the treatment of diabetes
US6858711Jun 13, 2001Feb 22, 2005Affymetrix, Inc.Labeling reagents
US6864059Dec 5, 2002Mar 8, 2005Affymetrix, Inc.Biotin containing C-glycoside nucleic acid labeling compounds
US6872537Apr 13, 1999Mar 29, 2005Regents Of The University Of CaliforniaAssays for the detection of microtubule depolymerization inhibitors
US6872807Jun 12, 2003Mar 29, 2005Genencor International, Inc.Proteases from gram positive organisms
US6875582Aug 18, 2000Apr 5, 2005Omniscience Pharmaceuticals, Inc.Methods and targets of antibiotic resistance
US6881562Mar 26, 2003Apr 19, 2005Genencor International, Inc.Proteases from gram-positive organisms
US6884590Oct 15, 1999Apr 26, 2005Cedars-Sinai Medical CenterMethods of screening for ulcerative colitis and crohn's disease
US6905868Dec 23, 2002Jun 14, 2005Genencor International, Inc.Proteases from gram-positive organisms
US6911333Mar 26, 2003Jun 28, 2005Genencor International, Inc.Proteases from gram-positive organisms
US6921664Jan 18, 2002Jul 26, 2005Regents Of The University Of ColoradoTelomerase
US6924094Nov 28, 2000Aug 2, 2005Affymetrix, Inc.Chip-based species identification and phenotypic characterization of microorganisms
US6927285Nov 12, 1999Aug 9, 2005Geron CorporationGenes for human telomerase reverse transcriptase and telomerase variants
US6946296Sep 12, 2001Sep 20, 2005Maxygen, Inc.Methods and compositions for polypeptide engineering
US6953573Oct 6, 1998Oct 11, 2005University Of WashingtonCompounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US6958214Apr 12, 2001Oct 25, 2005Sequenom, Inc.Polymorphic kinase anchor proteins and nucleic acids encoding the same
US6965020Sep 11, 2001Nov 15, 2005Affymetrix, Inc.Nucleic acid labeling compounds
US6992176Feb 13, 2002Jan 31, 2006Technion Research & Development Foundation Ltd.Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US6998232Apr 4, 2001Feb 14, 2006Quark Biotech, Inc.Methods of diagnosing bladder cancer
US7005262Jan 18, 2002Feb 28, 2006Geron CorporationMethods for detecting nucleic acids encoding human telomerase reverse transcriptase
US7018812Nov 5, 2001Mar 28, 2006Duke UniversityModified G-protein coupled receptors
US7030228Nov 15, 2000Apr 18, 2006Miltenyi Biotec GmbhAntigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
US7033817Jun 21, 2002Apr 25, 2006Genencor International, Inc.Proteases from gram positive organisms
US7037714Jan 9, 2003May 2, 2006Genencor International, Inc.Expression vectors encoding Bacillus subtilis disulfide bond isomerase and methods of secreting proteins in gram-positive microorganisms using the same
US7045596May 14, 2002May 16, 2006Tanox, Inc.Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US7045604Nov 20, 2002May 16, 2006Tanox, Inc.Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US7053188Feb 24, 2003May 30, 2006Purdue Research FoundationMonoclonal antibodies specific for neoplasia-specific NADH:disulfide reductase
US7053268Jun 15, 2000May 30, 2006Danisco A/SPromoter
US7056513Apr 26, 2001Jun 6, 2006Geron CorporationTelomerase
US7060283Sep 15, 1993Jun 13, 2006Ortho Diagnostic Systems, Inc.Immunoreactive peptides from Epstein-Barr virus
US7070780May 20, 2002Jul 4, 2006Board Of Trustees Of The Leland Stanford Junior UniversityTreatment of demyelinating autoimmune disease with ordered peptides
US7070819Aug 24, 2004Jul 4, 2006Genencor International, Inc.Proteases from gram positive organisms
US7070986Aug 24, 2004Jul 4, 2006Genencor International, Inc.Proteases from gram positive organisms
US7070990Aug 24, 2004Jul 4, 2006Genencor International, Inc.Proteases from GRAM positive organisms
US7078216Oct 31, 2002Jul 18, 2006Genencor International, Inc.Proteases from gram positive organisms
US7078372Aug 24, 2004Jul 18, 2006Genencor International, Inc.Proteases from gram positive organisms
US7087395Jan 16, 2001Aug 8, 2006Quest Diagnostics Investments IncorporatedVitamin D assay
US7087418Dec 16, 2002Aug 8, 2006Bristol-Myers Squibb CompanyPichia pastoris formate dehydrogenase and uses therefor
US7098021Dec 16, 2004Aug 29, 2006Genencor International, Inc.Proteases from gram positive organisms
US7101839Aug 29, 2000Sep 5, 2006Yissum Research Development Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US7108968Apr 2, 1999Sep 19, 2006Affymetrix, Inc.Mycobacterial rpoB sequences
US7115722May 22, 1997Oct 3, 2006Viventia Biotech, Inc.Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US7138144Sep 9, 2002Nov 21, 2006Nadir AskenasyMethod of inducing immune tolerance via blood/lymph flow-restricted bone marrow transplantation
US7138240May 9, 2002Nov 21, 2006Duke UniversityMethods of assaying receptor activity
US7163800Aug 1, 2003Jan 16, 2007Molecular Devices CorporationMethods of screening compositions for G protein-coupled receptor desensitization inhibitory activity
US7166286Aug 29, 2003Jan 23, 2007Viventia Biotech Inc.Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for prophylaxis and detection of cancers
US7175983Nov 2, 2001Feb 13, 2007Abmaxis, Inc.Adapter-directed display systems
US7179905Jun 2, 2003Feb 20, 2007Affymetrix, Inc.Nucleic acid labeling compounds
US7189555Aug 25, 2004Mar 13, 2007Genecor International, Inc.Proteases from gram-positive organisms
US7192555Oct 11, 2001Mar 20, 2007Orasure Technologies, Inc.Device for collection and assay of oral fluids
US7195911Jan 11, 2002Mar 27, 2007Geron CorporationMammalian cells that have increased proliferative capacity
US7199234Dec 20, 2002Apr 3, 2007Geron CorporationRegulatory segments of the human gene for telomerase reverse transcriptase
US7214496Dec 30, 2004May 8, 2007Duke UniversityModified G-protein coupled receptors
US7220716Aug 25, 2004May 22, 2007Genencor International, Inc.Proteases from gram-positive organisms
US7223902Nov 15, 2000May 29, 2007Yissum Research Development Company Of The Hebrew University Of JerusalemMethod of producing recombinant Aspergillus niger β-glucosidase and an aroma spreading plant
US7241575Aug 25, 2004Jul 10, 2007Genecor International, Inc.Proteases from gram-positive organisms
US7247703Aug 21, 2003Jul 24, 2007University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US7252948Feb 4, 2005Aug 7, 2007Affymetrix, Inc.Chip-based speciation and phenotypic characterization of microorganisms
US7252950Sep 3, 1998Aug 7, 2007The Regents Of The University Of CaliforniaAssays for detecting modulators of cytoskeletal function
US7262288Nov 22, 2000Aug 28, 2007Geron CorporationNucleic acids encoding human telomerase reverse transcriptase and related homologs
US7270810Dec 28, 2000Sep 18, 2007Yeda Research And Development Co. Ltd.Veto cells effective in preventing graft rejection and devoid of graft versus host potential
US7282327Aug 15, 2003Oct 16, 2007Affymetrix, Inc.Nucleic acid labeling compounds
US7285639Jan 18, 2002Oct 23, 2007Geron CorporationAntibody to telomerase reverse transcriptase
US7291463Dec 23, 2003Nov 6, 2007Affymetrix, Inc.Nucleic acid labeling compounds
US7294701Apr 2, 2003Nov 13, 2007Technion Research & Development Foundation Ltd.Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
US7316920Dec 16, 2004Jan 8, 2008Genencor International, Inc.Serine proteases from gram-positive microorganisms
US7316924Sep 17, 2001Jan 8, 2008Genencor International, Inc.Twin-arginine translocation in Bacillus
US7326531Dec 8, 2004Feb 5, 2008Genencor International, Inc.Proteases from gram-positive organisms
US7326535May 21, 2003Feb 5, 2008Ortho Diagnostic Systems Inc.Immunoreactive peptides from Epstein-Barr virus
US7329525Dec 16, 2004Feb 12, 2008Genencor International, Inc.Serine proteases from gram-positive microorganisms
US7329526Dec 16, 2004Feb 12, 2008Genencor International, Inc.Serine proteases from-gram-positive microorganisms
US7329527Dec 16, 2004Feb 12, 2008Genencor International, Inc.Serine proteases from gram-positive microorganisms
US7341844Jan 16, 2003Mar 11, 2008Regents Of The University Of MinnesotaMethods for diagnosing autism
US7355079Apr 5, 2005Apr 8, 2008The Regents Of The University Of CaliforniaThyronamine derivatives and analogs and methods of use thereof
US7358225Aug 26, 2003Apr 15, 2008The Salk Institute For Biological StudiesCloning and recombinant production of CRF receptor(s)
US7378244Apr 25, 2006May 27, 2008Geron CorporationTelomerase promoters sequences for screening telomerase modulators
US7385106Jan 10, 2001Jun 10, 2008Ramot At Tel Aviv University Ltd.Plants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby
US7390489Oct 8, 2004Jun 24, 2008Komed Co., Ltd.Monoclonal antibody selectively recognizing listeria monocytogenes, hybridoma producing the antibody, test kit comprising the antibody and detection method of listeria monocytogenes using the antibody
US7393696Sep 24, 2002Jul 1, 2008Aspenbio Pharma, Inc.Bovine pregnancy test
US7413864Jun 24, 2004Aug 19, 2008Geron CorporationTreating cancer using a telomerase vaccine
US7423139Jan 20, 2004Sep 9, 2008Insight Biopharmaceuticals Ltd.High level expression of recombinant human erythropoietin having a modified 5′-UTR
US7423143May 10, 2005Sep 9, 2008Affymetrix. Inc.Nucleic acid labeling compounds
US7429652Aug 3, 2004Sep 30, 2008Abmaxis, Inc.Compositions and methods for generating chimeric heteromultimers
US7432342May 1, 2003Oct 7, 2008Sequenom, Inc.Kinase anchor protein muteins, peptides thereof and related documents
US7442778Sep 23, 2005Oct 28, 2008Amgen Inc.Modified Fc molecules
US7442781Aug 15, 2002Oct 28, 2008Urifer Ltd.Diagnosis, prevention and treatment of cancer
US7465544Jan 11, 2006Dec 16, 2008Wisconsin Alumni Research FoundationSynthetic cofactor analogs of S-adenosylmethionine as ligatable probes of biological methylation and methods for their use
US7465705Feb 10, 2005Dec 16, 2008Yale UniversityNogo receptor antagonists
US7468243Mar 12, 2002Dec 23, 2008Affymetrix, Inc.2-aminopyrimidin-4-one nucleic acid labeling compounds
US7491818Jan 18, 2005Feb 17, 2009Affymetrix, Inc.Nucleic acid labeling compounds
US7498428Jun 20, 2004Mar 3, 2009Evogene Ltd.Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
US7517971Nov 22, 2000Apr 14, 2009Geron CorporationMuteins of human telomerase reverse transcriptase lacking telomerase catalytic activity
US7534605May 17, 2005May 19, 2009Yissum Research Development Company Of The Hebrew University Of JerusalemCD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US7534609Apr 11, 2005May 19, 2009Pluristem Life Systems Inc.Method of expanding undifferentiated hemopoietic stem cells
US7541151Jun 4, 2002Jun 2, 2009Duke UniversitySingle-cell biosensor for the measurement of GPCR ligands in a test sample
US7541194Jan 17, 2007Jun 2, 2009Orasure Technologies, Inc.Device for collection and assay of oral fluids
US7553484Jun 5, 2002Jun 30, 2009The Regents Of The University Of CaliforniaModulating neuronal outgrowth via the major histocompatibility complex class I (MHC I) molecule
US7553940Feb 1, 2007Jun 30, 2009Modigene IncLong-acting EPO polypeptides and derivatives thereof and methods thereof
US7553941Jun 30, 2009Modigene IncLong-acting polypeptides and methods of producing same
US7554007Jun 30, 2009Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants
US7560437Jul 14, 2009Geron CorporationNucleic acid compositions for eliciting an immune response against telomerase reverse transcriptase
US7569357Feb 20, 2004Aug 4, 2009Board Of Trustees Of The University Of IllinoisHigh affinity TCR proteins and methods
US7572888Feb 24, 2004Aug 11, 2009Duke UniversityMethods of assaying receptor activity and constructs useful in such methods
US7576187Jul 14, 2006Aug 18, 2009Genentech, Inc.Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US7585622Nov 2, 1999Sep 8, 2009Geron CorporationIncreasing the proliferative capacity of cells using telomerase reverse transcriptase
US7601697May 3, 2005Oct 13, 2009University Of WashingtonCompounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US7605149Jul 13, 1999Oct 20, 2009University Of South FloridaModulation of the phospholipase A2 pathway as a therapeutic
US7608395Sep 15, 2005Oct 27, 2009Baylor Research InstituteSystemic lupus erythematosus diagnostic assay
US7611723Mar 20, 2003Nov 3, 2009Nanocyte Inc.Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
US7615610Jan 26, 2004Nov 10, 2009Duke UniversityModified trafficking patterns for arrestin and G-protein-coupled receptors via arrestin-ubiquitin chimera
US7618789Apr 3, 2002Nov 17, 2009The United States Of America As Represented By The Secretary Of Department Of Health And Human ServicesUse of semenogelin in the diagnosis, prognosis and treatment of cancer
US7622549Jun 24, 2004Nov 24, 2009Geron CorporationHuman telomerase reverse transcriptase polypeptides
US7625707Sep 27, 2004Dec 1, 2009Ramot At Tel Aviv University Ltd.Antibacterial agents and methods of identifying and utilizing same
US7632522Jan 10, 2006Dec 15, 2009Nanocyte Inc.Use of stinging cells/capsules for the delivery of active agents to keratinous substances
US7632923Dec 15, 2009Technion Research & Development Foundation Ltd.Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US7638124Mar 25, 2004Dec 29, 2009Technion Research & Development Foundation Ltd.Antigen-presenting complex-binding compositions and uses thereof
US7641904Jan 5, 2010Konkuk University Industrial Cooperation Corp.IL-32 monoclonal antibodies and uses thereof
US7645861Jan 12, 2010Amgen Inc.Modified Fc molecules
US7655225Feb 2, 2010Gamida Cell, Ltd.Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
US7655239Feb 2, 2010University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US7655764Feb 2, 2010Amgen Inc.Modified Fc molecules
US7655765Aug 1, 2008Feb 2, 2010Amgen Inc.Modified Fc molecules
US7662931Aug 1, 2008Feb 16, 2010Amgen Inc.Modified Fc molecules
US7668658Feb 23, 2010Sequenom, Inc.Methods for generating databases and databases for identifying polymorphic genetic markers
US7678573Apr 11, 2005Mar 16, 2010Pluristem Ltd.Method of preparing a conditioned medium from a confluent stromal cell culture
US7682805Mar 23, 2010Regents Of The University Of MinnesotaMethods for diagnosing major depression or schizophrenia
US7682806Mar 23, 2010Regents Of The University Of MinnesotaMethods for diagnosing bipolar disorder
US7687057Mar 30, 2010Yissum Research Development Company Of The Hebrew University Of JerusalemIn vitro micro-organs, and uses related thereto
US7687281Mar 30, 2010Aspenbio Pharma, Inc.Bovine pregnancy test
US7695927Apr 13, 2010Detroit R & DDetection of hypertension using glucuronidated metabolic products
US7708984Jun 4, 2007May 4, 2010Incyte CorporationMethods of treatment with anitbodies to a chemokine expressed in inflamed adenoid
US7718777Oct 18, 2006May 18, 2010Technion Research & Development Foundation Ltd.MHC-peptide complex binding ligands
US7750121Aug 17, 2005Jul 6, 2010Geron CorporationAntibody to telomerase reverse transcriptive
US7750127Jul 6, 2010Amgen Inc.Modified Fc molecules
US7750128Aug 1, 2008Jul 6, 2010Amgen Inc.Modified Fc molecules
US7776877Jun 17, 2008Aug 17, 2010Chemocentryx, Inc.N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
US7781396Jun 21, 2006Aug 24, 2010Tel Aviv University Future Technology Development L.P.Peptides directed for diagnosis and treatment of amyloid-associated disease
US7781402Oct 11, 2005Aug 24, 2010Closed Loop Therapies Ltd.Methods and implantable devices for treating supraventricular arrhythmias
US7785898May 30, 2003Aug 31, 2010Genetic Technologies LimitedMaternal antibodies as fetal cell markers to identify and enrich fetal cells from maternal blood
US7790673Jun 12, 2006Sep 7, 2010New York UniversityMethods and compositions relating to cystatin C
US7811981Sep 29, 2004Oct 12, 2010Yissum Research Development Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US7829313May 24, 2006Nov 9, 2010Eppendorf Array TechnologiesIdentification and quantification of a plurality of biological (micro)organisms or their components
US7842823Nov 30, 2010The Regents Of The University Of CaliforniaFluorogenic probes for reactive oxygen species
US7846667Dec 7, 2010Genzyme CorporationMethods for the diagnosis and treatment of lung cancer
US7855075May 19, 2008Dec 21, 2010Gamida Cell Ltd.Methods of controlling proliferation and differentiation of stem and progenitor cells
US7875442Jan 25, 2011Eppendorf Array TechnologiesIdentification and quantification of a plurality of biological (micro)organisms or their components
US7879609Feb 1, 2011Geron CorporationRegulatory segments of the human gene for telomerase reverse transcriptase
US7883876Nov 20, 2007Feb 8, 2011Stephens David SNeisseria meningitidis serogroup A capsular polysaccharide acetyltransferase, methods and compositions
US7884110Jul 11, 2008Feb 8, 2011Chemocentryx, Inc.Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation
US7884191Feb 8, 2011Danisco Us Inc.Twin-arginine translocation in Bacillus
US7884192Jun 1, 2007Feb 8, 2011Danisco Us Inc.Twin-arginine translocation in Bacillus
US7893240Feb 22, 2011Insight Biopharmaceuticals Ltd.High level expression of recombinant human erythropoietin having a modified 5′-UTR
US7897742Jun 1, 2007Mar 1, 2011Danisco Us Inc.Twin-arginine translocation in Bacillus
US7910350Dec 19, 2005Mar 22, 2011Abmaxis, Inc.Adaptor-directed helper systems
US7910800Aug 15, 2006Mar 22, 2011Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
US7928083Jan 16, 2008Apr 19, 2011Yissum Research Development Company Of The Hebrew University Of JerusalemH19 silencing nucleic acid agents for treating rheumatoid arthritis
US7947499Nov 30, 2003May 24, 2011Technion Research & Development Foundation Ltd.Method of dynamically culturing embryonic stem cells
US7955813Jul 7, 2006Jun 7, 2011Danisco, A/SMethod of using lipid acyltransferase
US7955814Jun 7, 2011Danisco A/SMethod
US7955852Jun 7, 2011Gamida Cell Ltd.Expansion of renewable stem cell populations
US7960150Jul 20, 2009Jun 14, 2011Danisco A/SProduction of a lipid acyltransferase from transformed Bacillus licheniformis cells
US7972638Oct 14, 2008Jul 5, 2011Danisco A/SFoodstuff
US7985542Sep 7, 2006Jul 26, 2011Institut PasteurGenomic morse code
US7988972Dec 14, 2007Aug 2, 2011Ortho-Clinical Diagnostics, Inc.Immunoreactive peptides from Epstein-Barr virus
US7993830Feb 12, 2007Aug 9, 2011Laboratory Corporation Of America HoldingsProstate-specific gene for diagnosis, prognosis and management of prostate cancer
US7994301Aug 9, 2011The Rockefeller UniversityModulators of body weight, corresponding nucleic acids and proteins
US7998509Nov 12, 2009Aug 16, 2011Nanocyte Inc.Use of stinging cells/capsules for the delivery of active agents to keratinous substances
US8003095Aug 23, 2011Danisco A/SMethod of using lipid acyltransferase
US8007847Aug 30, 2011Eytan BidermanFeeding formula appliance
US8008008Oct 18, 2007Aug 30, 2011Mitomics Inc.Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers
US8008027Aug 30, 2011Incyte CorporationMethods of screening for compounds that modulate the activity of ADEC, a chemokine expressed in inflamed adenoid
US8008453Aug 10, 2006Aug 30, 2011Amgen Inc.Modified Fc molecules
US8012732Sep 2, 2009Sep 6, 2011Danisco A/SFungal lypolytic and amylase enzyme composition and methods using the same
US8012929Sep 6, 2011Tel Aviv University Future Technology Development L.P.Peptides directed for diagnosis and treatment of amyloid-associated diseases
US8013118Sep 6, 2011The Rockefeller UniversityLynx polypeptides
US8017586Jan 5, 2009Sep 13, 2011Ramot At Tel-Aviv University Ltd.Peptide nanostructures encapsulating a foreign material and method of manufacturing same
US8019818Jan 16, 2007Sep 13, 2011Zlango Ltd.Communications network system and methods for using same
US8026057Jun 27, 2008Sep 27, 2011Affymetrix, Inc.Nucleic acid labeling compounds
US8030044Oct 4, 2011Danisco A/SLipid acyltransferases
US8030456Dec 15, 2008Oct 4, 2011Yale UniversityNogo receptor antagonists
US8034553Jun 24, 2004Oct 11, 2011Kimberly-Clark Worldwide, Inc.Biomarkers for wound healing
US8034914Sep 21, 2006Oct 11, 2011Yissum Research Development Company Of The Hebrew University Of JerusalemNucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer
US8039240Sep 28, 2005Oct 18, 2011Yissum Reseach Development Company Of The Hebrew University Of JerusalemRecombinant human T2 RNase and uses thereof
US8050516Nov 1, 2011Fluidigm CorporationMethods and systems for determining a baseline during image processing
US8053221Apr 18, 2007Nov 8, 2011Danisco A/SEnzymes
US8053554Nov 8, 2011Ramot At Tel-Aviv University Ltd.Peptide nanostructures and methods of generating and using the same
US8055034Sep 13, 2007Nov 8, 2011Fluidigm CorporationMethods and systems for image processing of microfluidic devices
US8062660Nov 22, 2011Nanocyte Inc.Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
US8062908Jan 8, 2009Nov 22, 2011Orasure Technologies, Inc.Device for collection and assay of oral fluids
US8067164Nov 29, 2011Integrated Dna Technologies, Inc.Microarray system with improved sequence specificity
US8067240Nov 22, 2010Nov 29, 2011Esoterix Genetic Laboratories, LlcMethods for the diagnosis and treatment of lung cancer
US8067573Jul 6, 2006Nov 29, 2011Yissum Research Development Company Of The Hebrew University Of JerusalemNucleic acid agents for downregulating H19 and methods of using same
US8067574Nov 29, 2011Yissum Research Development Company Of The Hebrew University Of JerusalemNucleic acid agents for downregulating H19, and methods of using same
US8071323Apr 6, 2007Dec 6, 2011The United States Of America As Represented By The Secretary Of The Department Of Health And Human ServicesHuman monoclonal antibodies that bind human insulin like growth factors and their use
US8076072Dec 13, 2011Affymetrix, Inc.Nucleic acid labeling compounds
US8080417Nov 29, 2006Dec 20, 2011Gamida-Cell Ltd.Methods of ex vivo hematopoietic stem cell expansion by co-culture with mesenchymal cells
US8088160Jun 2, 2009Jan 3, 2012Multi-Gene Vascular Systems Ltd. (“MGVS”)Drug-eluting intravascular prostheses and methods of use
US8101563Jan 24, 2012Danisco Us Inc.Proteases from gram-positive organisms
US8114619Sep 19, 2007Feb 14, 2012The Johns Hopkins UniversityMethods for diagnosis and optimizing treatment of multiple sclerosis
US8129514Feb 9, 2009Mar 6, 2012Evogene Ltd.Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
US8143045Mar 27, 2012Danisco A/SMutant Citrobacter freundii phytase polypeptide
US8143046Mar 27, 2012Danisco Us Inc., Genencor DivisionVariant Buttiauxella sp. phytases having altered properties
US8163315Apr 13, 2011Apr 24, 2012Danisco A/SFoodstuff
US8163494Nov 27, 2003Apr 24, 2012Technion Research & Development Foundation Ltd.Method for assessing metastatic properties of breast cancer
US8168180Sep 30, 2009May 1, 2012Technion Research & Development Foundation Ltd.Methods and compositions for modulating angiogenesis
US8168857Dec 20, 2007May 1, 2012Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US8173382Aug 17, 2010May 8, 2012Abbott LaboratoriesAssay for cardiac troponin autoantibodies
US8173793May 6, 2009May 8, 2012The Rockefeller UniversityNucleic acids encoding modulators of body weight
US8178128Dec 5, 2002May 15, 2012Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Nanoparticles containing polymeric nucleic acid homologs
US8183002Dec 3, 2009May 22, 2012Abbott LaboratoriesAutoantibody enhanced immunoassays and kits
US8183039Mar 29, 2006May 22, 2012Miltenyi Biotec GmbhMethod for isolating BDCA-4+ dendritic cells
US8192782Jan 16, 2007Jun 5, 2012Danisco A/SEnzymatic oil-degumming method
US8193311Feb 7, 2011Jun 5, 2012Yissum Research Development Company Of The Hebrew University Of JerusalemCD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US8198309Jul 8, 2010Jun 12, 2012Chemocentryx, Inc.N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl)hetaryl arylsulfonamides
US8202724Jun 19, 2012Gamida Cell Ltd.Methods of controlling proliferation and differentiation of stem and progenitor cells
US8221757Oct 24, 2011Jul 17, 2012G2 Therapies LtdMonoclonal antibodies against extracellular loops of C5aR
US8222392Aug 20, 2007Jul 17, 2012Geron CorporationKit for detection of telomerase reverse transcriptase nucleic acids
US8229677Jul 24, 2012Sequenom, Inc.Methods for generating databases and databases for identifying polymorphic genetic markers
US8236493Aug 7, 2012Affymetrix, Inc.Methods of enzymatic discrimination enhancement and surface-bound double-stranded DNA
US8236543Sep 27, 2010Aug 7, 2012Yissum Research Development Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US8236774Aug 7, 2012Geron CorporationHuman telomerase catalytic subunit
US8252588Apr 7, 2004Aug 28, 2012Yeda Research And Development Co. Ltd.Stem cells having increased sensitivity to SDF-1 and methods of generating and using same
US8268972Feb 19, 2009Sep 18, 2012G2 Inflammation Pty LtdHumanized anti-C5aR antibodies
US8278062Oct 2, 2012Dupont Nutrition Biosciences ApsMethod of using lipid acyltransferase
US8278098Oct 2, 2012Vegenics Pty LimitedMaterials and methods involving hybrid vascular endothelial growth factor DNAs and proteins
US8287912Oct 16, 2012Nanocyte Inc.Use of stinging cells/capsules for the delivery of active agents to keratinous substances
US8288128Nov 18, 2004Oct 16, 2012Eppendorf Array Technologies S.A.Real-time quantification of multiple targets on a micro-array
US8293209Oct 22, 2009Oct 23, 2012Segev Laboratories LimitedSystem for delivering therapeutic agents into living cells and cells nuclei
US8293684Nov 29, 2007Oct 23, 2012ExiqonLocked nucleic acid reagents for labelling nucleic acids
US8304201Nov 6, 2012Abbott LaboratoriesAutoantibody enhanced immunoassays and kits
US8318898Dec 22, 2006Nov 27, 2012Universite De LausanneSynthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of cellular relaxation
US8323636Dec 4, 2012Prolor Biotech Ltd.Long-acting interferons and derivatives thereof and methods thereof
US8337852Aug 22, 2007Dec 25, 2012G2 Inflammation Pty LtdAnti-C5aR antibodies with improved properties
US8337868Oct 14, 2009Dec 25, 2012Nanocyte Inc.Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
US8352031Jan 8, 2013Impulse Dynamics NvProtein activity modification
US8357495Jan 22, 2013Abbott LaboratoriesImmunoassay of analytes in samples containing endogenous anti-analyte antibodies
US8361468Jan 29, 2013G2 Inflammation Pty LtdHumanized anti-C5aR antibodies
US8367392Sep 8, 2009Feb 5, 2013Transalgae Ltd.Genetic transformation of algal and cyanobacteria cells by microporation
US8375327Jan 16, 2006Feb 12, 2013Zlango Ltd.Iconic communication
US8388954Apr 8, 2004Mar 5, 2013Laboratoire Francais Du Fractionnement Et Des BiotechnologiesStabilising formulation for immunoglobulin G compositions in liquid form and in lyophilised form
US8394582Mar 5, 2004Mar 12, 2013Genetic Technologies, IncIdentification of fetal DNA and fetal cell markers in maternal plasma or serum
US8415318Apr 9, 2013Vascular Biogenics Ltd.Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
US8426166Jul 27, 2011Apr 23, 2013Prolor Biotech Inc.Long-acting polypeptides and methods of producing same
US8426682Apr 19, 2012Apr 23, 2013Evogene Ltd.Isolated polypeptides, polynucleotides useful for modifying water user efficiency, fertilizer use efficiency, biotic/abiotic stress tolerance, yield and biomass in plants
US8440435Jun 25, 2009May 14, 2013Dupont Nutrition Biosciences ApsMethod for reducing 1,2-diglyceride content of an edible oil
US8445222Jul 11, 2007May 21, 2013Musc Foundation For Research DevelopmentPredicting heart failure following myocardial infarction by protease and protease inhibitor profiling
US8445637Dec 7, 2009May 21, 2013Abraxis Bioscience, LlcSPARC binding peptides and uses thereof
US8450269Aug 2, 2011May 28, 2013Prolor Biotech Ltd.Long-acting growth hormone and methods of producing same
US8461303Jun 11, 2013Gilead Biologics, Inc.LOX and LOXL2 inhibitors and uses thereof
US8465948Jun 18, 2013Prolor Biotech Ltd.Long-acting veterinary polypeptides and methods of producing and administering same
US8473216Nov 30, 2007Jun 25, 2013Fluidigm CorporationMethod and program for performing baseline correction of amplification curves in a PCR experiment
US8481698Mar 19, 2009Jul 9, 2013The President And Fellows Of Harvard CollegeParallel proximity ligation event analysis
US8481812Jun 3, 2009Jul 9, 2013Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants generated thereby
US8486441Nov 30, 2010Jul 16, 2013Nanocyte Inc.Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
US8486640Mar 21, 2008Jul 16, 2013Cedars-Sinai Medical CenterIleal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease
US8486693Sep 19, 2012Jul 16, 2013Bellicum Pharmaceuticals, Inc.Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
US8497064Nov 1, 2011Jul 30, 2013Affymetrix, Inc.Nucleic acid labelling compounds
US8497349Apr 22, 2007Jul 30, 2013Centre National De La Recherche Scientifique (Cnrs)Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation
US8506499Jan 4, 2008Aug 13, 2013Musc Foundation For Research DevelopmentPredicting atrial fibrillation recurrence by protease and protease inhibitor profiling
US8512990Aug 20, 2010Aug 20, 2013Gilead Biologics, Inc.Catalytic domains from lysyl oxidase and LOXL2
US8513488Apr 9, 2008Aug 20, 2013Evogene Ltd.Polynucleotides, polypeptides and methods for increasing oil content, growth rate and biomass of plants
US8524491Sep 4, 2009Sep 3, 2013University Of Washington Through Its Center For CommercializationCompounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US8535900Feb 1, 2010Sep 17, 2013Dupont Nutrition Biosciences ApsLipolytic enzyme uses thereof in the food industry
US8546408Dec 22, 2010Oct 1, 2013Chemocentryx, Inc.Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation
US8563273Apr 9, 2009Oct 22, 2013Tel Aviv University Future Technology Development L.P.Method of screening for compounds that disaggregate amyloid aggregates
US8569025Jun 25, 2010Oct 29, 2013The University Of British ColumbiaTerpene synthases from santalum
US8574832Feb 3, 2010Nov 5, 2013Massachusetts Institute Of TechnologyMethods for preparing sequencing libraries
US8574858Oct 2, 2012Nov 5, 2013Abbott LaboratoriesAutoantibody enhanced immunoassays and kits
US8586723Sep 5, 2007Nov 19, 2013Institut PasteurGenomic morse code
US8592151Nov 11, 2010Nov 26, 2013Musc Foundation For Research DevelopmentAssessing left ventricular remodeling via temporal detection and measurement of microRNA in body fluids
US8600168Oct 5, 2011Dec 3, 2013Fluidigm CorporationMethods and systems for image processing of microfluidic devices
US8613926Jun 6, 2012Dec 24, 2013Novo Nordisk A/SAnti-C5a receptor antibodies
US8617551Aug 10, 2010Dec 31, 2013Incyte CorporationMethods of diagnosing pancreatic inflammation by using chemokine PANEC-1 antibodies
US8617867Jan 1, 2012Dec 31, 2013Yissum Research Develpment Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US8629250Jan 30, 2008Jan 14, 2014Amgen Inc.Hepcidin, hepcidin antagonists and methods of use
US8642295Jan 10, 2008Feb 4, 2014Erasmus University Medical CenterCircular chromosome conformation capture (4C)
US8642330Aug 8, 2006Feb 4, 2014Onconon, LlcAntibody compositions, methods for treating neoplastic disease and methods for regulating fertility
US8652788Dec 3, 2009Feb 18, 2014Abbott LaboratoriesAssay for diagnosis of cardiac myocyte damage
US8652809Feb 16, 2010Feb 18, 2014Dupont Nutrition Biosciences ApsMethod for producing ultra-heat treatment milk
US8658128Feb 2, 2012Feb 25, 2014Pop Test Cortisol LlcSystem and method for diagnosis and treatment
US8658167Dec 6, 2012Feb 25, 2014Gilead Biologics, Inc.Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
US8669101Dec 29, 2010Mar 11, 2014Engeneic Molecular Delivery Pty. Ltd.Bacterially derived intact minicells that encompass plasmid free functional nucleic acid for in vivo delivery to mammalian cells
US8669345Jan 26, 2007Mar 11, 2014Biogen Idec Ma Inc.Nogo receptor antagonists
US8673305Jun 15, 2012Mar 18, 2014G2 Therapies LtdMethods of treatment with antibodies against the extracellular loops of C5aR
US8679485Aug 1, 2008Mar 25, 2014Gilead Biologics, Inc.Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
US8680062Jun 1, 2007Mar 25, 2014Deliversir Ltd.System for delivering therapeutic agents into living cells and cells nuclei
US8680246Feb 4, 2011Mar 25, 2014Gilead Biologics, Inc.Antibodies that bind to lysyl oxidase-like 2 (LOXL2)
US8686227Jul 24, 2008Apr 1, 2014Evogene Ltd.Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance and/or biomass and/or yield in plants expressing same
US8691963Aug 25, 2005Apr 8, 2014Engeneic Molecular Delivery Pty. Ltd.Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
US8697634Dec 22, 2009Apr 15, 2014Tel Aviv University Future Technology Development L.P.Peptides and methods using same for diagnosis and treatment of amyloid-associated disease
US8709995Aug 20, 2007Apr 29, 2014Geron CorporationMethod for eliciting an immune response to human telomerase reverse transcriptase
US8715665Apr 11, 2008May 6, 2014The General Hospital CorporationMethods for treating cancer resistant to ErbB therapeutics
US8715960Mar 29, 2010May 6, 2014Mitomics Inc.Aberrant mitochondrial DNA, associated fusion transcripts and translation products and hybridization probes therefor
US8722866Jan 18, 2007May 13, 2014The United States Of America, As Represented By The Department Of Veterans AffairsIsoform-selective inhibitors and activators of PDE3 cyclic nucleotide phosphodiesterases
US8735127Sep 9, 2013May 27, 2014Yissum Research Development Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US8735566Mar 21, 2008May 27, 2014Engeneic Molecular Delivery Pty LtdBacterially derived intact minicells that encompass plasmid free functional nucleic acid for in vivo delivery to mammalian cells
US8747855Apr 5, 2009Jun 10, 2014Technion Research & Development Foundation LimitedAnti human immunodeficiency antibodies and uses thereof
US8759292Feb 14, 2012Jun 24, 2014Prolor Biotech, LlcLong-acting coagulation factors and methods of producing same
US8775526Jan 16, 2007Jul 8, 2014Zlango Ltd.Iconic communication
US8790871Apr 24, 2007Jul 29, 2014Musc Foundation For Research DevelopmentDetecting diastolic heart failure by protease and protease inhibitor plasma profiling
US8791232Oct 29, 2010Jul 29, 2014Dupont Nutrition Biosciences ApsProteins
US8791258Jun 8, 2009Jul 29, 2014The Regents Of The University Of CaliforniaPro-fluorescent probes
US8795682May 2, 2008Aug 5, 2014Emory UniversityVirus-like particles comprising chimeric human immunodeficiency virus (HIV)/mouse mammary tumor virus (MMTV) envelopes
US8796438Aug 14, 2006Aug 5, 2014Geron CorporationNucleic acids encoding inactive variants of human telomerase
US8808701Dec 19, 2012Aug 19, 2014G2 Inflammation Pty LtdMethods of inhibiting the interaction of C5aR with C5a with anti-C5aR antibodies
US8809507Dec 7, 2009Aug 19, 2014Vuong TrieuSPARC binding ScFvs
US8815823Mar 9, 2012Aug 26, 2014Technion Research & Development Foundation Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
US8818735Jun 28, 2012Aug 26, 2014Sequenom, Inc.Methods for generating databases and databases for identifying polymorphic genetic markers
US8821836May 17, 2013Sep 2, 2014Abraxis Bioscience, LlcSPARC binding peptides and uses thereof
US8828386Feb 13, 2012Sep 9, 2014Glenveigh Pharmaceuticals, LlcMethod for extending pregnancy by reducing intraventricular hemorrhaging in patients exhibiting at least one symptom of preeclampsia and eclampsia
US8834862Apr 19, 2005Sep 16, 2014Nanocyte Inc.Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
US8835120Dec 2, 2009Sep 16, 2014Abbott LaboratoriesAssay for cardiac troponin-T (cTnT)
US8835468May 2, 2012Sep 16, 2014Chemocentryx, Inc.N-(2-(hetaryl)aryl)arylsulfonamides and n-(2-(hetaryl)hetaryl) arylsulfonamides
US8846045Jun 18, 2013Sep 30, 2014Novo Nordisk A/SAnti-C5a receptor antibodies
US8846393Nov 29, 2006Sep 30, 2014Gamida-Cell Ltd.Methods of improving stem cell homing and engraftment
US8847008May 21, 2009Sep 30, 2014Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant utility
US8849037Nov 4, 2013Sep 30, 2014Fluidigm CorporationMethods and systems for image processing of microfluidic devices
US8859467Jul 16, 2010Oct 14, 2014Bioatla, LlcSimultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
US8865158May 22, 2012Oct 21, 2014Ramot At Tel-Aviv University Ltd.Bacteriophages for reducing toxicity of bacteria
US8889364May 13, 2010Nov 18, 2014The Chancellor, Masters And Scholars Of The University Of OxfordClinical diagnosis of hepatic fibrosis using a novel panel of low abundant human plasma protein biomarkers
US8889371Feb 1, 2010Nov 18, 2014Dupont Nutrition Biosciences ApsLipolytic enzyme: uses thereof in the food industry
US8921658Oct 28, 2009Dec 30, 2014Evogene Ltd.Isolated polynucleotides encoding a MAP65 polypeptide and methods of using same for increasing plant yield
US8927700Feb 25, 2013Jan 6, 2015Gilead Biologics, Inc.Catalytic domains from lysyl oxidase and LOXL2
US8937220Mar 1, 2010Jan 20, 2015Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield, biomass, vigor and/or growth rate of a plant
US8940519Apr 23, 2010Jan 27, 2015Dupont Nutrition Biosciences ApsMethod of producing a lipolytic enzyme
US8945928Jun 6, 2013Feb 3, 2015Kerry B GunningMicroarray system with improved sequence specificity
US8946155Mar 14, 2013Feb 3, 2015Opko Biologics Ltd.Long-acting polypeptides and methods of producing and administering same
US8956864Jun 7, 2013Feb 17, 2015Engeneic Molecular Delivery Pty LtdBacterially derived intact minicells that encompass plasmid free functional nucleic acid for in vivo delivery to mammalian cells
US8962915Oct 24, 2006Feb 24, 2015Evogene Ltd.Isolated polypeptides, polynucleotides encoding same, transgenic plants expressing same and methods of using same
US8975016Jun 22, 2011Mar 10, 2015Diagnostic Hybrids, Inc.Methods for direct fluorescent antibody virus detection in liquids
US8993284Sep 24, 2013Mar 31, 2015The University Of British ColumbiaTerpene synthases from Santalum
US8993510Aug 26, 2013Mar 31, 2015Tel Aviv University Future Technology Development L.P.Peptides and methods using same for diagnosis and treatment of amyloid-associated disease
US8999670Apr 22, 2013Apr 7, 2015Opko Biologics Ltd.Long-acting polypeptides and methods of producing same
US9012162Sep 7, 2007Apr 21, 2015The Chancellor, Masters And Scholars Of The University Of OxfordClinical diagnosis of hepatic fibrosis using a novel panel of human serum protein biomarkers
US9012728Jul 12, 2010Apr 21, 2015Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US9018445Aug 18, 2009Apr 28, 2015Evogene Ltd.Use of CAD genes to increase nitrogen use efficiency and low nitrogen tolerance to a plant
US9023348Nov 17, 2009May 5, 2015Technion Research & Development Foundation LimitedCompositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US9035039Dec 21, 2012May 19, 2015Protiva Biotherapeutics, Inc.Compositions and methods for silencing SMAD4
US9040667Apr 27, 2010May 26, 2015Dako Denmark A/SAntibody cocktail
US9057092Nov 9, 2012Jun 16, 2015Zetiq Technologies Ltd.Methods and compositions for identifying a cell phenotype
US9057107Mar 8, 2012Jun 16, 2015King Abdullah University Of Science And TechnologyMolecular biomarker set for early detection of ovarian cancer
US9066982Mar 12, 2014Jun 30, 2015Engeneic Molecular Delivery Pty Ltd.Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells
US9090687Dec 11, 2013Jul 28, 2015Incyte CorporationMethods of treating pancreatitis
US9095533Nov 19, 2009Aug 4, 2015Technion Research & Development Foundation LimitedAntigen-presenting complex-binding compositions and uses thereof
US9096645Nov 15, 2011Aug 4, 2015Ramot At Tel-Aviv University Ltd.Dipeptide analogs for treating conditions associated with amyloid fibril formation
US9096865Jun 8, 2010Aug 4, 2015Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and/or abiotic stress tolerance
US9102754Jun 27, 2008Aug 11, 2015University Of SaskatchewanImmunomodulatory compositions and methods for treating disease with modified host defense peptides
US9107935Jan 5, 2010Aug 18, 2015Gilead Biologics, Inc.Chemotherapeutic methods and compositions
US9114147Dec 9, 2013Aug 25, 2015Pop Test Oncology Limited Liability CompanySystem and method for diagnosis and treatment
US9114175Jun 28, 2011Aug 25, 2015Amgen Inc.Modified Fc molecules
US9120862Jul 26, 2010Sep 1, 2015Abbott LaboratoriesAntibodies relating to PIVKA-II and uses thereof
US9121022Mar 8, 2011Sep 1, 2015Monsanto Technology LlcMethod for controlling herbicide-resistant plants
US9125931Apr 6, 2010Sep 8, 2015Massachusetts Institute Of TechnologyPost-transcriptional regulation of RNA-related processes using encoded protein-binding RNA aptamers
US9132587Apr 10, 2008Sep 15, 2015Stratasys Ltd.System and method for three dimensional model printing
US9150644Apr 11, 2012Oct 6, 2015The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesHuman monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
US9156865Oct 22, 2012Oct 13, 2015Deliversir LtdSystem for delivering therapeutic agents into living cells and cells nuclei
US9175078Jan 23, 2009Nov 3, 2015Amgen Inc.Ferroportin antibodies and methods of use
US9175266Jul 19, 2013Nov 3, 2015Gamida Cell Ltd.Enhancement of natural killer (NK) cell proliferation and activity
US9176139May 6, 2013Nov 3, 2015Gilead Biologics, Inc.LOX and LOXL2 inhibitors and uses thereof
US9182403May 17, 2010Nov 10, 2015Zetiq Technologies Ltd.Kits for and methods of differential staining of cervical cancer cells and/or tissues
US9212258Feb 22, 2012Dec 15, 2015The Board Of Trustees Of The University Of IllinoisAmphiphilic dendron-coils, micelles thereof and uses
US9228015Jan 2, 2014Jan 5, 2016Biogen Idec Ma Inc.Nogo receptor antagonists and methods of increasing neurite outgrowth
US9238843Dec 21, 2011Jan 19, 2016Eli Lilly And CompanyCompositions and methods for identifying and differentiating viral components of multivalent shipping fever vaccines
US9242007Jan 10, 2014Jan 26, 2016Engeneic Molecular Delivery Pty. Ltd.Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
US9243030May 22, 2008Jan 26, 2016Centre National De La Recherche Scientifique (Cnrs)Optically pure compounds for improved therapeutic efficiency
US9249407Jul 1, 2013Feb 2, 2016Opko Biologics Ltd.Long-acting coagulation factors and methods of producing same
US9254309Jun 26, 2013Feb 9, 2016Centre National De La Recherche Scientifique (Cnrs)Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation
US9255289Oct 25, 2010Feb 9, 2016The Trustees Of Columbia University In The City Of New YorkGeometric patterns and lipid bilayers for DNA molecule organization and uses thereof
US9260517Nov 17, 2010Feb 16, 2016Musc Foundation For Research DevelopmentHuman monoclonal antibodies to human nucleolin
US9260728Feb 20, 2015Feb 16, 2016University Of British ColumbiaTerpene synthases from Santalum
US9261462Dec 13, 2012Feb 16, 2016Step Ahead Innovations, Inc.Monitoring of photo-aging of light-based chemical indicators using illumination-brightness differential scheme
US9273295Sep 14, 2011Mar 1, 2016Dupont Nutrition Biosciences ApsMutant citrobacter freundii phytase polypeptide
US9273349Mar 14, 2013Mar 1, 2016Affymetrix, Inc.Detection of nucleic acids
US9289447Sep 14, 2012Mar 22, 2016Gilead Biologics, Inc.Chemotherapeutic methods and compositions
US9290564May 24, 2012Mar 22, 2016Mountgate Group LimitedCompositions and methods related to the prevention and treatment of rabies infection
US9295733Jul 31, 2014Mar 29, 2016Abraxis Bioscience, LlcSPARC binding ScFcs
US9303269May 1, 2013Apr 5, 2016Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants
US9308279Aug 4, 2014Apr 12, 2016Abraxis Biosciences, LlcSPARC binding ScFvs
US9314537Aug 5, 2014Apr 19, 2016Abraxis Bioscience, LlcSPARC binding ScFcs
US9316641Jan 11, 2011Apr 19, 2016Biogen Ma Inc.Assay for JC virus antibodies
US20020055617 *Nov 12, 1998May 9, 2002Marilyn H. PerrinCloning and recombinant production of cfr receptor(s)
US20020061580 *Sep 10, 2001May 23, 2002Estell David A.Alpha/beta hydrolase-fold enzymes
US20020106661 *Jul 23, 2001Aug 8, 2002Burstein Laboratories, Inc.Optical disk-based assay devices and methods
US20020110860 *Sep 17, 2001Aug 15, 2002Sierd BronTwin-arginine translocation in Bacillus
US20020127641 *Aug 17, 2001Sep 12, 2002Estell David A.Proteases from gram-positive organisms
US20020137681 *May 20, 2002Sep 26, 2002Lawrence SteinmanTreatment of demyelinating autoimmune disease with ordered peptides
US20020154615 *Dec 28, 2000Oct 24, 2002Martin HansDetection method and device
US20020165149 *Dec 10, 2001Nov 7, 2002Kranz David M.Mutated class II major histocompatibility proteins
US20020172980 *Feb 28, 2002Nov 21, 2002Phan Brigitte ChauMethods for decreasing non-specific binding of beads in dual bead assays including related optical biodiscs and disc drive systems
US20020187467 *Apr 2, 1999Dec 12, 2002Thomas GingerasMycobacterial rpob sequences
US20020187471 *Jan 19, 2001Dec 12, 2002Cech Thomas R.Novel telomerase
US20020192839 *Feb 19, 2002Dec 19, 2002Epitope, Inc.Collection device for single step assay of oral fluids
US20020193310 *Mar 21, 2002Dec 19, 2002Bishwajit NagOrally active fraction of momordica charantia, active peptides thereof, and their use in the treatment of diabetes
US20030003464 *Nov 27, 2001Jan 2, 2003Phan Brigitte C.Dual bead assays including optical biodiscs and methods relating thereto
US20030049254 *Jun 5, 2002Mar 13, 2003Kaufman Daniel L.Modulating neuronal outgrowth via the major histocompatibility complex Class I (MHC I) molecule
US20030054446 *Nov 29, 2001Mar 20, 2003Weber Bernard H. F.Novel retina-specific human proteins C7orf9, C12orf7, MPP4 and F379
US20030064058 *Sep 9, 2002Apr 3, 2003Nadir AskenasyMethods of utilizing bone marrow stem cells for inducing immunological tolerance
US20030064364 *Apr 11, 2002Apr 3, 2003Lockhart David J.Nucleic acid analysis techniques
US20030073248 *Sep 24, 2002Apr 17, 2003J.W. RothBovine pregnancy test
US20030078177 *Oct 31, 2002Apr 24, 2003Estell David A.Proteases from gram positive organisms
US20030082596 *Aug 8, 2002May 1, 2003Michael MittmannMethods of genetic analysis of probes: test3
US20030086914 *Jul 12, 2002May 8, 2003Yissum Research Development Company Of The Hebrew University Of JerusalemMethod and device for inducing biological processes by micro-organs
US20030096344 *Jan 11, 2002May 22, 2003Cech Thomas R.Human telomerase catalytic subunit: diagnostic and therapeutic methods
US20030100093 *Jan 11, 2002May 29, 2003Cech Thomas R.Human telomerase catalytic subunit: diagnostic and therapeutic methods
US20030104355 *Nov 2, 2001Jun 5, 2003Caili WangAdapter-directed display systems
US20030104410 *Mar 15, 2002Jun 5, 2003Affymetrix, Inc.Human microarray
US20030104491 *Oct 30, 2002Jun 5, 2003Cabantchik Ioav ZviMolecules and methods using same for measuring non-transferrin bound iron
US20030105770 *Nov 26, 2001Jun 5, 2003Macleod StewartExtending a directory schema independent of schema modification
US20030108927 *Oct 7, 2002Jun 12, 2003Kathryn LeishmanCompositions and methods for the prevention, treatment and detection of tuberculosis and other diseases
US20030113895 *Dec 23, 2002Jun 19, 2003Estell David A.Proteases from gram-positive organisms
US20030114410 *Nov 27, 2002Jun 19, 2003Technion Research And Development Foundation Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
US20030118593 *Nov 8, 2002Jun 26, 2003Dan Michael D.Antigen binding fragments, designated 4B5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US20030124676 *Jan 9, 2003Jul 3, 2003Quax Wilhelmus J.Increasing production of proteins in gram-positive microorganisms
US20030152909 *Dec 17, 2002Aug 14, 2003Mitrani Eduardo N.In vitro micro-organs, and uses related thereto
US20030157642 *Dec 4, 2002Aug 21, 2003Caldwell Robert M.Increasing production of proteins in gram-positive microorganisms
US20030158070 *Mar 26, 2003Aug 21, 2003Estell David A.Proteases from gram-positive organisms
US20030158133 *Jun 19, 2002Aug 21, 2003Movsesian Matthew A.Isoform-selective inhibitors and activators of PDE3 cyclic nucleotide phosphodiesterases
US20030166248 *Mar 26, 2003Sep 4, 2003Estell David A.Proteases from gram-positive organisms
US20030175892 *Mar 26, 2003Sep 18, 2003Estell David A.Proteases from gram-positive organisms
US20030180757 *Dec 5, 2002Sep 25, 2003Affymetrix, Inc.Nucleic acid labeling compounds
US20030180932 *Mar 26, 2003Sep 25, 2003Estell David A.Proteases from gram-positive organisms
US20030182669 *Mar 19, 2002Sep 25, 2003Rockman Howard A.Phosphoinositide 3-kinase mediated inhibition of GPCRs
US20030190752 *Mar 24, 2003Oct 9, 2003Tony RomeoEscherichia coli csrB gene, RNA encoded thereby, and methods of use thereof
US20030204069 *Dec 20, 2002Oct 30, 2003Morin Gregg B.Segments of the human gene for telomerase reverse transcriptase
US20030211490 *Jan 10, 2001Nov 13, 2003Hanan SteinPlants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby
US20030211556 *Jan 16, 2003Nov 13, 2003Fatemi S. HosseinMarker for psychiatric conditions
US20030220475 *Apr 3, 2001Nov 27, 2003Fields Howard A.Neutralizing immunogenic hev polypepetides
US20030222908 *Jun 3, 2002Dec 4, 2003Microsoft CorporationDynamic wizard interface system and method
US20030232979 *Jun 2, 2003Dec 18, 2003Mcgall GlennNucleic acid labeling compounds
US20040002595 *Jun 2, 2003Jan 1, 2004Affymetrix, Inc.Nucleic acid labeling compounds
US20040009164 *May 1, 2003Jan 15, 2004Jonathan ReevesPSP94 diagnostic reagents and assays
US20040013665 *May 21, 2003Jan 22, 2004Ortho Diagnostic Systems, Inc.Immunoreactive peptides from Epstein-Barr virus
US20040038237 *Dec 16, 2002Feb 26, 2004Goldberg Steven L.Pichia pastoris formate dehydrogenase and uses therefor
US20040039184 *Nov 20, 2002Feb 26, 2004Tanox, Inc.Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US20040052769 *Nov 29, 2001Mar 18, 2004Yair ReisnerMethods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease
US20040052928 *Sep 6, 2002Mar 18, 2004Ehud GazitPeptides and methods using same for diagnosing and treating amyloid-associated diseases
US20040082758 *Aug 21, 2003Apr 29, 2004University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US20040091484 *Aug 29, 2003May 13, 2004Dan Michael D.Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US20040091946 *Aug 1, 2003May 13, 2004Oakley Robert H.Methods of screening compositions for G protein -coupled receptor desensitization inhibitory activity
US20040101892 *Aug 15, 2003May 27, 2004Affymetrix, Inc.Nucleic acid labeling compounds
US20040121442 *May 5, 2002Jun 24, 2004Ilan ChetFungal chitinase, polynucleotide sequences encoding same, promoters of same, and uses thereof
US20040126868 *Feb 5, 2004Jul 1, 2004Estell David A.Gram-positive microorganisms with an inactivated cysteine protease-3
US20040132109 *Jan 22, 2002Jul 8, 2004Masato EnariMethod
US20040137505 *Feb 5, 2004Jul 15, 2004Estell David A.Gram-positive microorganisms with an inactivated cysteine protease-2
US20040146949 *Oct 27, 2003Jul 29, 2004Jun TanMethods and compounds for disruption of CD40R/CD40L signaling in the treatment of alzheimer's disease
US20040186280 *Dec 18, 2003Sep 23, 2004Murdoch UniversityBmpB novel nucleotide and amino acid sequences and diagnostic and therapeutic uses thereof
US20040197334 *Apr 2, 2003Oct 7, 2004Technion Research & Development Foundation Ltd.Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
US20040209246 *Apr 5, 2004Oct 21, 2004Agouron Pharmaceuticals, Inc.Dual reporter/dye reduction methodology for evaluating antiviral and cytotoxicity of hepatitis C virus inhibitors
US20040209308 *Feb 24, 2004Oct 21, 2004Duke UniversityMethods of assaying receptor activity and constructs useful in such methods
US20040210045 *May 11, 2004Oct 21, 2004Mcgall GlennNucleic acid labeling compounds
US20040214248 *Apr 3, 2002Oct 28, 2004Roberts David DUse of semenogelin in the diagnosis, prognosis and treatment of cancer
US20040229245 *Jan 6, 2004Nov 18, 2004Anton BittnerMethods and algorithms for performing quality control during gene expression profiling on DNA microarray technology
US20040242529 *Jun 24, 2004Dec 2, 2004Geron CorporationVector encoding inactivated telomerase for treating cancer
US20040247613 *Jun 24, 2004Dec 9, 2004Geron CorporationTreating cancer using a telomerase vaccine
US20040248093 *Nov 27, 2002Dec 9, 2004Coombs James HowardMagneto-optical bio-discs and systems including related methods
US20040259113 *Dec 23, 2003Dec 23, 2004Mayo Foundation For Medical Education And Research, Hybritech IncorporatedMethod for detection of metastatic prostate cancer
US20050009139 *Aug 3, 2004Jan 13, 2005Caili WangCompositions and methods for generating chimeric heteromultimers
US20050009146 *Aug 25, 2004Jan 13, 2005Estell David A.Proteases from gram-positive organisms
US20050013825 *Jun 24, 2004Jan 20, 2005Geron CorporationVaccine containing the catalytic subunit of telomerase for treating cancer
US20050014227 *Aug 24, 2004Jan 20, 2005Estell David A.Proteases from gram positive organisms
US20050014244 *Aug 24, 2004Jan 20, 2005Estell David A.Proteases from gram positive organisms
US20050019887 *Aug 24, 2004Jan 27, 2005Estell David A.Proteases from gram positive organisms
US20050019888 *Jun 12, 2003Jan 27, 2005Estell David A.Proteases from gram positive organisms
US20050020499 *May 26, 2004Jan 27, 2005Bar Ilan UniversityMethods of attenuating cocaine seeking behavior employing glial cell-derived neurotrophic factor (GDNF) and pharmaceutical compositions and articles of manufacture suited for use in practice of the method
US20050022269 *Jul 18, 2002Jan 27, 2005Joseph HirschbergPolypeptides having carotenoids isomerase catalytic activity, nucleic acids encoding same and uses thereof
US20050031618 *Jan 31, 2002Feb 10, 2005Dror MevorachInduction of tolerance by apoptotic and/or necrotic cells
US20050032126 *Mar 2, 2004Feb 10, 2005Coombs James H.Methods and apparatus for use in detection and quantitation of various cell types and use of optical bio-disc for performing same
US20050054097 *Jan 29, 2004Mar 10, 2005Tony PeledEX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures
US20050054103 *Mar 4, 2004Mar 10, 2005Tony PeledExpansion of renewable stem cell populations using modulators of PI 3-kinase
US20050059112 *Aug 25, 2004Mar 17, 2005Estell David A.Proteases from gram-positive organisms
US20050064435 *Sep 24, 2003Mar 24, 2005Xing SuProgrammable molecular barcodes
US20050064479 *Aug 12, 2004Mar 24, 2005Affymetrix, Inc.Compounds and methods for post incorporation labeling of nucleic acids
US20050069923 *Jul 12, 2004Mar 31, 2005Mullis Kary BanksDual bead assays using cleavable spacers and/or ligation to improve specificity and sensitivity including related methods and apparatus
US20050085432 *Dec 16, 2002Apr 21, 2005Aviva LapidotMethods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections
US20050089939 *May 10, 2004Apr 28, 2005Jun TanAssay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
US20050089963 *Aug 24, 2004Apr 28, 2005Estell David A.Proteases from gram positive organisms
US20050090644 *Aug 6, 2003Apr 28, 2005Diaz-Torres Maria R.Production of secreted polypeptides
US20050095683 *Dec 16, 2004May 5, 2005Estell David A.Proteases from gram-positive organisms
US20050101001 *Dec 16, 2004May 12, 2005Estell David A.Proteases from gram-position organisms
US20050101504 *Dec 16, 2004May 12, 2005Estell David A.Proteases from gram positive organisms
US20050106623 *Dec 30, 2004May 19, 2005Oakley Robert H.Modified G-protein coupled receptors
US20050106668 *Aug 25, 2004May 19, 2005Estell David A.Proteases from gram-positive organisms
US20050113327 *Sep 29, 2004May 26, 2005Levava RoizMethods of and compositions for inhibiting the proliferation of mammalian cells
US20050136431 *Jul 29, 2004Jun 23, 2005Oakley Robert H.Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity
US20050142638 *Dec 16, 2004Jun 30, 2005Estell David A.Proteases from gram-positive organisms
US20050152912 *Mar 9, 2005Jul 14, 2005Technion Research & Development Foundation Ltd.Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20050158822 *Jan 20, 2004Jul 21, 2005Insight Biopharmaceuticals Ltd.High level expression of recombinant human erythropoietin having a modified 5'-UTR
US20050164268 *Jan 18, 2005Jul 28, 2005Affymetrix, Inc.Nucleic acid labeling compounds
US20050176137 *Apr 11, 2005Aug 11, 2005Technion Research & Development Foundation Ltd.Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
US20050176143 *Apr 11, 2005Aug 11, 2005Technion Research & DevelopmentMethod and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
US20050186646 *Jan 26, 2005Aug 25, 2005Cruz Miguel A.Rapid assay to detect ADAMTS-13 activity
US20050191285 *May 3, 2005Sep 1, 2005University Of WashingtonCompounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US20050202098 *May 4, 2005Sep 15, 2005TolarenDisease therapy using dying or dead cells
US20050214816 *Dec 16, 2004Sep 29, 2005Estell David AProteases from gram-positive organisms
US20050214827 *Jan 19, 2005Sep 29, 2005Burstein Technologies, Inc.Assay device and method
US20050220774 *Mar 18, 2003Oct 6, 2005Tony PeledMethods of inducing differentiation in ex vivo expanded stem cells
US20050244925 *Dec 8, 2004Nov 3, 2005Estell David AProteases from gram-positive organisms
US20050245417 *Dec 16, 2004Nov 3, 2005Estell David AProteases from gram positive organisms
US20050249789 *Jul 12, 2005Nov 10, 2005Estell David AAlpha/beta hydrolase-fold enzymes
US20050255101 *Feb 13, 2002Nov 17, 2005Technion Research And Development Foundation Ltd.Antibody having a t-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US20050271643 *Aug 12, 2004Dec 8, 2005Iryna SorokulovaBacterial strains, compositions including same and probiotic use thereof
US20050271655 *Feb 10, 2005Dec 8, 2005Biogen Idec Ma Inc.Nogo receptor antagonists
US20050281916 *Aug 3, 2005Dec 22, 2005Kirsten BojsenMethod of improving dough and bread quality
US20050287141 *Aug 15, 2005Dec 29, 2005Technion Research & Development Foundation Ltd.Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US20050287563 *May 10, 2005Dec 29, 2005Affymetrix, Inc.Nucleic acid labeling compounds
US20050287604 *May 30, 2003Dec 29, 2005Bohmer Ralph MMaternal antibodies as fetal cell markers to identify and enrich fetal cells from maternal blood
US20060002135 *Jun 9, 2005Jan 5, 2006Eurodent S.P.A.Dental lamp particularly for medical and dental surgeries
US20060003358 *May 24, 2005Jan 5, 2006Sequenom, Inc.Polymorphic kinase anchor proteins and nucleic acids encoding the same
US20060008479 *Aug 1, 2005Jan 12, 2006University Of WashingtonMethods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins
US20060019340 *May 17, 2005Jan 26, 2006David NaorCD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US20060026702 *Jul 30, 2004Feb 2, 2006Duke UniversityPhosphoinositide 3-kinase mediated inhibition of GPCRs
US20060029984 *Jun 17, 2005Feb 9, 2006Jonathan ReevesPSP94 diagnostic reagents and assays
US20060035367 *Jun 21, 2002Feb 16, 2006Estell David AProteases from gram positive organisms
US20060035980 *Apr 5, 2005Feb 16, 2006Scanlan Thomas SThyronamine derivatives and analogs and methods of use thereof
US20060039897 *Mar 20, 2003Feb 23, 2006Tamar LotanStinging cells expressing an exogenous polycleotide encoding a therpeutic, diagnostics or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derive therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
US20060040307 *Aug 17, 2005Feb 23, 2006Geron CorporationHuman telomerase catalytic subunit
US20060051426 *Dec 5, 2002Mar 9, 2006Gershon GolombNanoparticles containing polymeric nucleic acid homologs pharmaceutical composition and articles of manufacture containing same and methods of use thereof
US20060057151 *Aug 2, 2005Mar 16, 2006Hampson David JBmpB novel nucleotide and amino acid sequences and diagnostic and therapeutic uses thereof
US20060073530 *Aug 15, 2002Apr 6, 2006Olaf SchneewindMethods and compositions involving sortase B
US20060078951 *Oct 8, 2004Apr 13, 2006Youn Byung SMonoclonal antibody selectively recognizing listeria monocytogenes, hybridoma producing the antibody, test kit comprising the antibody and detection method of listeria monocytogenes using the antibody
US20060079941 *Oct 11, 2005Apr 13, 2006Eli OvsyshcherMethods and implantable devices for treating supraventricular arrhythmias
US20060083735 *Mar 25, 2004Apr 20, 2006Technion Research & Development Foundation Ltd.Antigen-presenting complex-binding compositions and uses thereof
US20060084091 *Aug 5, 2005Apr 20, 2006Maxygen, Inc.Methods and compositions for polypeptide engineering
US20060099273 *Nov 5, 2004May 11, 2006Nanocyte Inc.Sterile preparations and compositions including stinging capsules and methods of producing and using same
US20060100422 *Jul 13, 2005May 11, 2006Goldberg Steven LPichia pastoris formate dehydrogenase and uses therefor
US20060105354 *Nov 18, 2004May 18, 2006Eppendorf Array Technologies S.A.Real-time quantification of multiple targets on a micro-array
US20060123516 *Nov 22, 2005Jun 8, 2006Gil RonenMethods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
US20060127366 *Jul 13, 2003Jun 15, 2006Mitrani Eduardo NMethod and device for inducing biological processes by micro-organs
US20060134538 *Dec 16, 2004Jun 22, 2006Radu Nora SAromatic chalcogen compounds and their use
US20060134680 *Dec 21, 2005Jun 22, 2006Alexander KotlyarHomogeneous populations of nucleic acids, methods of synthesyzing same and uses thereof
US20060140934 *Sep 23, 2005Jun 29, 2006Colin GeggModified Fc molecules
US20060147964 *Dec 22, 2005Jul 6, 2006Affymetrix, Inc.Mycobacterial rpoB sequences
US20060148078 *Nov 30, 2003Jul 6, 2006Sharon Gerecht-NirMethod of dynamically culturing embryonic stem cells
US20060159769 *Mar 15, 2006Jul 20, 2006Nanocyte Inc.Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
US20060166225 *May 24, 2005Jul 27, 2006Maxygen, Inc.Methods and compositions for polypeptide engineering
US20060188944 *May 9, 2002Aug 24, 2006Barak Lawrence SMethods of assaying receptor activity
US20060198817 *Nov 26, 2002Sep 7, 2006Alverdy John CMaterials and methods for preventing and treating microbe-mediated epithelial disorders
US20060199216 *May 8, 2006Sep 7, 2006Intel CorporationProgrammable molecular barcodes
US20060204970 *Feb 4, 2005Sep 14, 2006Affymetrix, Inc.Chip-based speciation and phenotypic characterization of microorganisms
US20060211064 *Mar 17, 2006Sep 21, 2006Hyesook KimDetection of hypertension using glucuronidated metabolic products
US20060233840 *Mar 29, 2006Oct 19, 2006Miltenyi Biotech GmbhAntigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
US20060234203 *Apr 19, 2005Oct 19, 2006Nanocyte Inc.Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
US20060234947 *Jun 21, 2006Oct 19, 2006Tel Aviv University Future Technology Development L.PPeptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
US20060257429 *Oct 11, 2004Nov 16, 2006Dreier Kimberly JVaccine for periodontal disease
US20060260002 *Jun 20, 2004Nov 16, 2006Gil RonenNucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
US20060263828 *Jan 26, 2004Nov 23, 2006Sudha ShenoyModified trafficking patterns for arrestin and g-protein-coupled receptors via arrestin-ubiquitin chimera
US20060275267 *Aug 14, 2006Dec 7, 2006Morin Gregg BNucleic acids encoding inactive variants of human telomerase
US20060281106 *Apr 25, 2006Dec 14, 2006Andrews William HTelomerase promoter sequences for screening telomerase modulators
US20060281181 *Dec 19, 2005Dec 14, 2006Caili WangAdaptor-directed helper systems
US20060292579 *Jul 5, 2005Dec 28, 2006Affymetrix, Inc.Methods of enzymatic discrimination enhancement and surface bound double-stranded DNA
US20070026106 *Jul 7, 2006Feb 1, 2007Kreij Arno DMethod
US20070032421 *Jun 12, 2006Feb 8, 2007Efrat LevyMethods and compositions relating to cystatin C
US20070037187 *May 17, 2006Feb 15, 2007Isabelle AlexandreIdentification and quantification of a plurality of biological (micro)organisms or their components
US20070054288 *May 8, 2006Mar 8, 2007Intel CorporationProgrammable molecular barcodes
US20070059717 *Sep 15, 2005Mar 15, 2007Baylor Research InstituteSystemic lupus erythematosus diagnostic assay
US20070065429 *Apr 16, 2004Mar 22, 2007Biogen Idec Ma Inc.Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques
US20070071751 *Jul 14, 2006Mar 29, 2007Tanox, Inc.Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US20070077574 *Jul 14, 2006Apr 5, 2007Tanox, Inc.family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US20070082371 *Jul 14, 2006Apr 12, 2007Tanox, Inc.Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US20070087437 *Feb 21, 2006Apr 19, 2007Jifan HuMethods for rejuvenating cells in vitro and in vivo
US20070099204 *May 24, 2006May 3, 2007Isabelle AlexandreIdentification and quantification of a plurality of biological (micro)organisms or their components
US20070116597 *Jan 17, 2007May 24, 2007Mink Ronald WDevice for collection and assay of oral fluids
US20070122525 *Jul 7, 2006May 31, 2007Kreij Arno DMethod
US20070134658 *Mar 5, 2004Jun 14, 2007Genetic Technologies Limited, A.C.N. 009 212 328Identification of fetal dna and fetal cell markers in maternal plasma or serum
US20070134814 *Dec 9, 2005Jun 14, 2007Kajander E OMethods and compositions for the detection of calcifying nano-particles, identification and quantification of associated proteins thereon, and correlation to disease
US20070135334 *Jan 23, 2007Jun 14, 2007Tel Aviv University Future Technology Development L.P.Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US20070141658 *Oct 27, 2006Jun 21, 2007The Regents Of The University Of CaliforniaFluorogenic probes for reactive oxygen species
US20070160546 *Jan 10, 2006Jul 12, 2007Tamar LotanUse of stinging cells/capsules for the delivery of active agents to keratinous substances
US20070161007 *Jan 11, 2006Jul 12, 2007Wisconsin Alumni Research FoundationSynthetic cofactor analogs of S-adenosylmethionine as ligatable probes of biological methylation and methods for their use
US20070178462 *Feb 14, 2005Aug 2, 2007Uebele Victor NNucleic acid molecules encoding novel murine low-voltage activated calcium channel proteins, designated-alpha1h, encoded proteins and methods of use thereof
US20070184530 *Feb 5, 2007Aug 9, 2007Fuad FaresLong-acting veterinary polypeptides and methods of producing and administering same
US20070190534 *Jan 26, 2006Aug 16, 2007Genesis Genomics Inc.Mitochondrial sites and genes associated with prostate cancer
US20070190561 *Mar 26, 2007Aug 16, 2007Geron CorporationSegments of the Human Gene for Telomerase Reverse Transcriptase
US20070190610 *Feb 1, 2007Aug 16, 2007Fuad FaresLong-acting EPO polypeptides and derivatives thereof and methods thereof
US20070190611 *Feb 1, 2007Aug 16, 2007Fuad FaresLong-acting polypeptides and methods of producing same
US20070196369 *Oct 18, 2006Aug 23, 2007Hoogenboom Henricus Renerus JMHC-peptide complex binding ligands
US20070202515 *Oct 12, 2006Aug 30, 2007Pathologica, Llc.Promac signature application
US20070218511 *Aug 14, 2006Sep 20, 2007Genzyme CorporationMethods for the diagnosis and treatment of lung cancer
US20070225242 *Jan 25, 2007Sep 27, 2007The Board Of Trustees Of The Leland Stanford Junior UniversityMethod and composition for treating and preventing tumor metastasis in vivo
US20070232556 *Mar 31, 2006Oct 4, 2007Montine Thomas JMethods and compositions for the treatment of neurological diseases and disorders
US20070264274 *May 21, 2007Nov 15, 2007Yeda Research And Development Co. Ltd.Veto cells effective in preventing graft rejection and devoid of graft versus host potential
US20070281037 *Nov 5, 2004Dec 6, 2007Nanocyte Inc.Sterile preparations and compositions including stinging capsules and methods of producing and using same
US20070281883 *Jun 5, 2006Dec 6, 2007Hanna RosenfeldDevelopment of follicle stimulating hormone agonists and antagonists in fish
US20070292930 *Apr 17, 2007Dec 20, 2007Yissum Research Development Company Of The Hebrew University Of JerusalemMethod of producing recombinant Aspergillus niger beta-glucosidase and an aroma spreading plant
US20070298145 *Apr 18, 2007Dec 27, 2007Andrei MiasnikovEnzymes
US20070299005 *Dec 8, 2005Dec 27, 2007Tanox, Inc.Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US20080026394 *Jul 11, 2007Jan 31, 2008Antara Biosciences Inc.Methods of detecting one or more cancer markers
US20080044416 *Feb 12, 2007Feb 21, 2008Gang AnNovel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer
US20080064114 *Sep 7, 2006Mar 13, 2008Institut PasteurGenomic morse code
US20080075322 *Sep 13, 2007Mar 27, 2008Fluidigm CorporationMethods and systems for determining a baseline during image processing
US20080075380 *Sep 13, 2007Mar 27, 2008Fluidigm CorporationMethods and systems for image processing of microfluidic devices
US20080076904 *Jun 21, 2007Mar 27, 2008University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US20080082678 *Jan 16, 2006Apr 3, 2008Zlango Ltd.Communications Network System and Methods for Using Same
US20080085526 *Sep 7, 2007Apr 10, 2008United Therapeutics CorporationClinical diagnosis of hepatic fibrosis using a novel panel of human serum protein biomarkers
US20080096225 *Jul 25, 2007Apr 24, 2008The Regents Of The University Of CaliforniaAssays for detecting modulators of cytoskeletal function
US20080108085 *Apr 6, 2007May 8, 2008D-Gen LimitedMethod and Detection of the Presence of Prions Protein
US20080113393 *Jan 17, 2008May 15, 2008Fatemi S HMethods for Diagnosing Schizophrenia
US20080113394 *Jan 17, 2008May 15, 2008Fatemi S HMethods for Diagnosing Major Depression
US20080113395 *Jan 17, 2008May 15, 2008Fatemi S HMethods for Diagnosing Bi-Polar Disorder
US20080129736 *Nov 30, 2007Jun 5, 2008Fluidigm CorporationMethod and apparatus for biological sample analysis
US20080131419 *Sep 28, 2005Jun 5, 2008Yissum Research Development Company Of The Hebrew University Of JerusalemRecombinant Human T2 Rnase and Uses Thereof
US20080138346 *Jun 4, 2007Jun 12, 2008Incyte CorporationAntibodies to a chemokine expressed in inflamed adenoid
US20080166757 *Jun 1, 2007Jul 10, 2008Sierd BronTwin-arginine translocation in Bacillus
US20080199895 *Oct 4, 2007Aug 21, 2008Yeda Research And Development Co. Ltd.Highly purified and stabilized Na,K-ATPase isoforms and methods of producing same
US20080206188 *Apr 20, 2005Aug 28, 2008Alverdy John CTherapeutic Delivery System Comprising a High Molecular Weight Peg-Like Compound
US20080214407 *Oct 11, 2007Sep 4, 2008Eppendorf Array Technologies S.A.Method and system for quantification of a target compound obtained from a biological sample upon chips
US20080219995 *Feb 15, 2008Sep 11, 2008Konkuk University Industrial Cooperation Corp.Il-32 monoclonal antibodies and uses thereof
US20080220438 *Apr 25, 2008Sep 11, 2008Geron CorporationTelomerase Promoter Sequences for Screening Telomerase Modulators
US20080220498 *Mar 6, 2007Sep 11, 2008Cervin Marguerite AVariant Buttiauxella sp. phytases having altered properties
US20080248525 *Jun 1, 2007Oct 9, 2008Sierd BronTwin-Arginine translocation in bacillus
US20080261256 *Oct 19, 2007Oct 23, 2008Duke UniversityMethods of assaying receptor activity and constructs useful in such methods
US20080274905 *Mar 28, 2008Nov 6, 2008The Trustees Of Columbia University In The City Of New YorkMicrofluidic cells with parallel arrays of individual dna molecules
US20080279871 *Aug 20, 2007Nov 13, 2008Geron CorporationImmunogenic composition
US20080287667 *Jun 27, 2008Nov 20, 2008Affymetrix, Inc.Nucleic Acid Labeling Compounds
US20080299084 *Mar 21, 2008Dec 4, 2008Engeneic Therapy Pty. Ltd.Bacterially derived intact minicells that encompass plasma free functional nucleic acid for in vivo delivery to mammalian cells
US20080305512 *Nov 2, 2007Dec 11, 2008Mattingly Phillip GAssay for cardiac troponin autoantibodies
US20080312179 *Jul 25, 2008Dec 18, 2008Insight Biopharmaceuticals Ltd.High level expression of recombinant human erythropoietin having a modified 5'-UTR
US20090005410 *Jun 17, 2008Jan 1, 2009Chemocentryx, Inc.N-(2-(hetaryl)aryl) arylsulfonamides and n-(2-(hetaryl) hetaryl arylsulfonamides
US20090012272 *Aug 1, 2008Jan 8, 2009Amgen Inc.Modified Fc molecules
US20090013087 *Jan 16, 2007Jan 8, 2009Zlango Ltd.Communications Network System and Methods For Using Same
US20090022744 *Aug 1, 2008Jan 22, 2009Amgen Inc.Modified Fc molecules
US20090023594 *Nov 29, 2007Jan 22, 2009Exiqon A/SReagents for labelling nucleic acids and uses thereof
US20090035784 *Aug 1, 2005Feb 5, 2009Mount Sinai School Of Medicine Of New York UniversityNpc1l1 and npc1l1 inhibitors and methods of use thereof
US20090036321 *Jun 3, 2004Feb 5, 2009Chiron CorporationMethods for predicting the course of a malignant disease
US20090042209 *Aug 31, 2007Feb 12, 2009Nox Technologies, Inc.Neoplasia-Specific tNOX Isoforms and Methods
US20090053224 *Aug 1, 2008Feb 26, 2009Arresto BiosciencesLox and loxl2 inhibitors and uses thereof
US20090068207 *Apr 11, 2006Mar 12, 2009Vascular Biogenics Ltd.Compositions Containing Beta 2-Glycoprotein I-Derived Peptides for the Prevention and/or Treatment of Vascular Disease
US20090068669 *Sep 12, 2008Mar 12, 2009Elias GeorgesSlc9a3r1 directed diagnostics for neoplastic disease
US20090081639 *May 30, 2008Mar 26, 2009Phil HillAssay for sensitivity to chemotherapeutic agents
US20090089898 *Aug 15, 2006Apr 2, 2009Hagai KarchiMethods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
US20090098249 *Feb 6, 2008Apr 16, 2009Cervin Marguerite AVariant Buttiauxella sp. Phytases having altered properties
US20090104170 *Oct 31, 2005Apr 23, 2009Richard William Wyatt ChildsCompositions and methods for treating hyperproliferative disorders
US20090104201 *Aug 1, 2008Apr 23, 2009Victoria SmithMethods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
US20090121709 *Jan 5, 2009May 14, 2009Ramot At Tel Aviv University Ltd.Peptide nanostructures encapsulating A foreign material and method of manufacturing same
US20090123553 *Jan 2, 2009May 14, 2009Ramot At Tel Aviv University Ltd.Peptide nanostructures and methods of generating and using the same
US20090126042 *Jun 14, 2005May 14, 2009Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US20090136916 *Aug 13, 2008May 28, 2009Trustees Of Tufts CollegeMethods and microarrays for detecting enteric viruses
US20090143243 *Aug 12, 2008Jun 4, 2009Gunning Kerry BMicroarray system with improved sequence specificity
US20090143321 *Jul 6, 2006Jun 4, 2009Avraham HochbergNucleic acid agents for downregulating h19 and methods of using same
US20090156471 *Jul 14, 2005Jun 18, 2009Ramot At Tel Aviv University Ltd.Use of anti-amyloid agents for treating and typing pathogen infections
US20090170072 *Jan 8, 2009Jul 2, 2009Orasure Technologies, Inc.Device for collection and assay of oral fluids
US20090208533 *Nov 20, 2007Aug 20, 2009University Of Georgia Research Foundation, Inc.Neisseria meningitidis serogroup a capsular polysaccharide acetyltransferase, methods and compositions
US20090209041 *Apr 9, 2009Aug 20, 2009Tel Aviv University Future Technology Development L.P.Peptides and methods for inhibiting amyloid formation
US20090221015 *Apr 24, 2007Sep 3, 2009Spinale Francis GDetecting Diastolic Heart Failure by Protease and Protease Inhibitor Plasma Profiling
US20090221681 *Sep 21, 2006Sep 3, 2009Yissum Research Development Company Of The Hebrew University Of JerusalemNucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer
US20090226387 *Dec 22, 2006Sep 10, 2009Partnership & Corp. Technology TransferSynthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of cellular relaxation
US20090233295 *Jan 29, 2009Sep 17, 2009Elias GeorgesTrim59 directed diagnostics for neoplastic disease
US20090233946 *Jul 11, 2008Sep 17, 2009Antoni KrasinskiFused heteroaryl pyridyl and phenyl benzenesuflonamides as ccr2 modulators for the treatment of inflammation
US20090233986 *Jul 22, 2005Sep 17, 2009Mount Sinai School Of MedicineMethods and compositions for using sax2
US20090246800 *Apr 24, 2009Oct 1, 2009Abbott LaboratoriesImmunoassay of analytes in samples containing endogenous anti-analyte antibodies
US20090253170 *Feb 9, 2009Oct 8, 2009Evogene Ltd.Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
US20090269739 *Aug 20, 2007Oct 29, 2009Geron CorporationKit for detection of telomerase reverse transcriptase nucleic acids
US20090269780 *Apr 22, 2009Oct 29, 2009Luminex CorporationMethod for Creating a Standard for Multiple Analytes Found in a Starting Material of Biological Origin
US20090293146 *Dec 20, 2007Nov 26, 2009Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US20090311695 *Mar 12, 2009Dec 17, 2009Talat NasimMethod
US20090324612 *Jun 24, 2009Dec 31, 2009Kaufman Daniel LModulating neuronal outgrowth via the major histocompatibility complex class i (mhc i) molecule
US20100004162 *Dec 18, 2002Jan 7, 2010Nathaniel HeintzLynx, a novel family of receptor ligands in the central nervous system, corresponding nucleic acids and proteins and uses thereof
US20100015156 *Mar 6, 2008Jan 21, 2010Cedars-Sinai Medical CenterDiagnosis of inflammatory bowel disease in children
US20100015651 *Jul 11, 2007Jan 21, 2010Musc Foundation For Research DevelopmentPredicting Heart Failure Following Myocardial Infarction by Protease and Protease Inhibitor Profiling
US20100022459 *Jan 28, 2010Tel Aviv University Future Technology Development L.PPeptides directed for diagnosis and treatment of amyloid-associated diseases
US20100041036 *Sep 5, 2007Feb 18, 2010Institut PasteurGenomic morse code
US20100047230 *Feb 20, 2006Feb 25, 2010Hellenic Pasteur InstituteAnti her2/neu antibody
US20100055033 *Apr 6, 2007Mar 4, 2010The Government Of The United States Of America As Represented By The SecretaryAntibody compositions and methods for treatment of neoplastic disease
US20100062443 *Mar 11, 2010Genzyme CorporationMethods for the Diagnosis and Treatment of Lung Cancer
US20100062501 *Mar 11, 2010Paul WassellMethod
US20100062947 *Jan 10, 2008Mar 11, 2010Erasmus University Medical CenterCircular chromosome conformation capture (4c)
US20100068135 *Aug 8, 2006Mar 18, 2010Onconon, LlcAntibody compositions, methods for treating neoplastic disease and methods for regulating fertility
US20100080805 *Apr 1, 2010Technion Research & DevelopmentCompositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20100081177 *Sep 8, 2009Apr 1, 2010TransAlgae LtdDecreasing RUBISCO content of algae and cyanobacteria cultivated in high carbon dioxide
US20100092386 *Oct 22, 2009Apr 15, 2010David SegevSystem for delivering therapeutic agents into living cells and cells nuclei
US20100105071 *Feb 27, 2008Apr 29, 2010Children's Medical Center CorporationMethods for predicting the onset of menarche
US20100105608 *Dec 22, 2009Apr 29, 2010Tel Aviv University Future Technology Development L.P.Peptides and methods using same for diagnosis and treatment of amyloid-associated disease
US20100105759 *Jan 16, 2008Apr 29, 2010Abraham HochbergH19 silencing nucleic acid agents for treating rheumatoid arthritis
US20100111869 *Oct 14, 2009May 6, 2010Nanocyte Inc.Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
US20100112626 *Oct 30, 2009May 6, 2010The United States Of America, As Represented By The Secretary, Dept. Of Health & Human ServicesUse of Semenogelin in the Diagnosis, Prognosis and Treatment of Cancer
US20100119515 *Sep 30, 2009May 13, 2010Gera NeufeldPharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
US20100129346 *Aug 22, 2007May 27, 2010G2 Inflammation Pty Ltd.Anti-C5aR Antibodies With Improved Properties
US20100184065 *Jul 22, 2010University Of South FloridaMethod of Predicting Non-Response to First Line Chemotherapy
US20100190662 *Jan 25, 2008Jul 29, 2010Rebecca SutphenMethods and materials for detection, diagnosis and management of ovarian cancer
US20100196403 *Jan 27, 2008Aug 5, 2010Jacob HochmanAntibody conjugates for circumventing multi-drug resistance
US20100196419 *May 2, 2008Aug 5, 2010Compans Richard WEnhancement of glycoprotein incorporation into virus-like particles
US20100215803 *Aug 26, 2010Niels Erik LarsenProcess
US20100221233 *Mar 8, 2010Sep 2, 2010University Of South FloridaCompositions and methods for enhancing neuroprotection via administration of stem cells and blood brain barrier permeabilizers
US20100221272 *Jun 27, 2008Sep 2, 2010University Of SaskatchewanImmunomodulatory compositions and methods for treating disease with modified host defense peptides
US20100222228 *Oct 11, 2007Sep 2, 2010Janssen Pharmaceutica N.V.Compositions and methods for treating and diagnosing irritable bowel syndrome
US20100228007 *Mar 16, 2010Sep 9, 2010Technion Research & Development Foundation Ltd.Mhc-peptide complex binding ligands
US20100240065 *Sep 23, 2010Boehringer Ingelheim International GmbhProlyl Hydroxylase Compositions and Methods of Use Thereof
US20100240101 *Sep 23, 2010Massachusetts Institute Of TechnologyParallel Proximity Ligation Event Analysis
US20100255004 *Apr 11, 2008Oct 7, 2010Dana Farber Cancer InstituteReceptor tyrosine kinase profiling
US20100267046 *Oct 21, 2010University Of Utah Research FoundationIsoform-selective inhibitor and activators of pde3 cyclic nucleotide phosphodiesterases
US20100291100 *Mar 26, 2010Nov 18, 2010Gojo Industries, Inc.Compositions And Methods For Screening And Using Compounds Antagonizing Spore-Surface Interactions
US20100291602 *May 13, 2010Nov 18, 2010University Of OxfordClinical diagnosis of hepatic fibrosis using a novel panel of low abundant human plasma protein biomarkers
US20100311079 *Dec 9, 2010Abbott LaboratoriesAssay for cardiac troponin autoantibodies
US20100331302 *Jul 8, 2010Dec 30, 2010Chemocentryx, Inc.N-(2-(hetaryl)aryl) arylsulfonamides and n-(2-(hetaryl)hetaryl arylsulfonamides
US20110008314 *Jan 13, 2011Yissum Research Development Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US20110009861 *Jan 4, 2008Jan 13, 2011Music Foundation For Research DevelopmentPredicting atrial fibrillation recurrence by protease and protease inhibitor profiling
US20110014317 *Jan 20, 2011Andrei MiasnikovLipolytic enzyme uses thereof in the food industry
US20110020357 *Apr 5, 2009Jan 27, 2011Technion Research & Development Foundation Ltd.Anti human immunodeficiency antibodies and uses thereof
US20110027887 *Feb 3, 2011Technion Research & Development Foundation Ltd.Method of dynamically culturing embryonic stem cells
US20110033473 *Apr 5, 2009Feb 10, 2011Yoram ReiterAnti influenza antibodies and uses thereof
US20110040248 *Feb 17, 2011Closed Loop Therapies BvMethods and implantable devices for treating supraventricular arrhythmias
US20110052501 *Feb 1, 2009Mar 3, 2011Liat DassaPolypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
US20110065649 *Apr 22, 2007Mar 17, 2011Centre National De La Recherche Scientifique (Cnrs)Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation
US20110070224 *Mar 24, 2011Nanocyte Inc.Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
US20110081706 *Apr 7, 2011TransAlgae LtdMethod and system for efficient harvesting of microalgae and cyanobacteria
US20110082289 *Sep 28, 2010Apr 7, 2011Affymetric, Inc.Nucleic Acid Labeling Compounds
US20110091454 *Feb 8, 2010Apr 21, 2011Alex DiberMethods and systems for annotating biomolecular sequences
US20110091892 *Apr 21, 2011Genzyme CorporationMethods for the Diagnosis and Treatment of Lung Cancer
US20110111041 *Dec 29, 2010May 12, 2011EnGenelC Therapy Pty. Ltd.Bacterially derived intact minicells that encompass plasmid free functional nucleic acid for in vivo delivery to mammalian cells
US20110117560 *May 19, 2011Musc Foundation For Research DevelopmentASSESSING LEFT VENTRICULAR REMODELING VIA TEMPORAL DETECTION AND MEASUREMENT OF microRNA IN BODY FLUIDS
US20110129818 *Jun 2, 2011Abbott LaboratoriesASSAY FOR CARDIAC TROPONIN-T (cTnT)
US20110129854 *Jun 2, 2011Abbott LaboratoriesAssay for diagnosis of cardiac myocyte damage
US20110130306 *Jun 8, 2009Jun 2, 2011The Regents Of The University Of CaliforniaPro-fluorescent probes
US20110136103 *Dec 3, 2009Jun 9, 2011Abbott LaboratoriesAutoantibody enhanced immunoassays and kits
US20110136141 *Dec 3, 2009Jun 9, 2011Abbott LaboratoriesPeptide reagents and method for inhibiting autoantibody antigen binding
US20110136676 *Jun 9, 2011Greene Eric CGeometric patterns and lipid bilayers for dna molecule organization and uses thereof
US20110147993 *Apr 10, 2008Jun 23, 2011Objet Geometries Ltd.System and method for three dimensional model printing
US20110150874 *Dec 20, 2010Jun 23, 2011Teva Pharmaceutical Industries Ltd.Fusion proteins, uses thereof and processes for producing same
US20110171346 *Oct 18, 2010Jul 14, 2011Spaangner Christiansen LivProcess
US20110172113 *Mar 27, 2009Jul 14, 2011Mitomics Inc.Aberrant mitochondrial dna, associated fusion transcripts and hybridization probes therefor
US20110184747 *Aug 9, 2007Jul 28, 2011Carmen BozicMethod for distribution of a drug
US20110189677 *Aug 4, 2011Massachusetts Institute Of TechnologyMethods For Preparing Sequencing Libraries
US20110190477 *Feb 19, 2009Aug 4, 2011Peter WhitfeldHumanized Anti-C5aR Antibodies
US20110197315 *Oct 28, 2009Aug 11, 2011Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield
US20110201559 *May 22, 2008Aug 18, 2011Centre National De La Recherche Scientifique (Cnrs)New Optically Pure Compounds for Improved Therapeutic Efficiency
US20110207664 *Aug 25, 2011Vegenics Pty LimitedMaterials and Methods Involving Hybrid Vascular Endothelial Growth Factor DNAs and Proteins
USRE31006 *Mar 2, 1978Aug 3, 1982Akzona IncorporatedProcess for the demonstration and determination of reaction components having specific binding affinity for each other
USRE32696 *Dec 22, 1978Jun 14, 1988Akzona IncorporatedEnzymatic immunological method for determination of antigens and antibodies
USRE43135Sep 20, 2007Jan 24, 2012Danisco A/SMethod of improving dough and bread quality
DE2805961A1 *Feb 13, 1978Oct 19, 1978Syva CoTheophyllin-antigene und -antikoerper und ihre verwendung zur bestimmung von theophyllin
DE212006000071U1Nov 14, 2006Jul 24, 2008Board of Regents, The University of Texas System, AustinQuantifizierung von Fusionsproteinen und ihrer Aktivität in Folge chromosomaler Translokation
EP0524502A2Jul 9, 1992Jan 27, 1993Bayer CorporationImmunoassay for free analyte
EP0699754A1Aug 11, 1995Mar 6, 1996Myriad Genetics, Inc.Method for diagnosing a predisposition for breast and ovarian cancer
EP0703296A1Oct 3, 1988Mar 27, 1996Chiron CorporationPolynucleotide determination by strand replacement of a capture probe
EP0705902A1Aug 11, 1995Apr 10, 1996Myriad Genetics, Inc.17q-Linked breast and ovarian cancer susceptibility gene
EP0705903A1Aug 11, 1995Apr 10, 1996Myriad Genetics, Inc.In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene
EP0785216A1Dec 17, 1996Jul 23, 1997Myriad Genetics, Inc.Chomosome 13-linked breast cancer susceptibility gene BRCA2
EP1333094A2Oct 1, 1997Aug 6, 2003Geron CorporationHuman telomerase catalytic subunit
EP1655381A1Nov 2, 2005May 10, 2006Affymetrix, Inc. (A US Entity)Nucleic acid labeling methods
EP1683874A2Aug 29, 2001Jul 26, 2006YEDA RESEARCH AND DEVELOPMENT Co. LTD.Methods of isolating genes encoding proteins of specific function and of screening for pharmaceutically active agents
EP1696236A2Mar 29, 1999Aug 30, 2006OraSure Technologies, Inc.Device for assay of antibodies in oral fluids
EP1728875A2Feb 7, 1997Dec 6, 2006Affymetrix, Inc.Chip-based speciation and phenotypic characterization of microorganisms
EP1762243A1Mar 30, 2000Mar 14, 2007Oxford Biomedica (UK) LtdFactor for regulation of neurite growth
EP1783139A2Oct 1, 1997May 9, 2007Geron CorporationHuman telomerase catalytic subunit
EP1798286A2Jul 31, 1998Jun 20, 2007Schering CorporationMammalian cell membrane proteins and related reagents
EP1798287A2Jul 31, 1998Jun 20, 2007Schering CorporationMammalian cell membrane proteins and related reagents
EP1803816A2Dec 12, 1997Jul 4, 2007Schering CorporationMammalian cell surface antigens; related reagents
EP1810978A2Aug 8, 2001Jul 25, 2007St. Jude Children's Research HospitalGroup B streptococcus polypeptides nucleic acids and therapeutic composition and vaccines thereof
EP1897949A2Sep 20, 1999Mar 12, 2008Schering CorporationHuman interleukin-B50. Therapeutic uses
EP1903107A1Sep 25, 2000Mar 26, 2008Cybios LLCPluripotent embryonic-like stem cells, compositions, methods and uses thereof
EP1905832A2Sep 8, 2000Apr 2, 2008Schering CorporationMammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions
EP1908837A2May 23, 2001Apr 9, 2008Schering CorporationHuman receptor proteins, related reagents and methods
EP1918377A1May 10, 2001May 7, 2008Schering CorporationMammalian cytokine receptor subunit proteins, related reagents and methods
EP1942114A2Mar 9, 2000Jul 9, 2008Schering CorporationMammalian cytokines; related reagents and methods
EP1947183A1Aug 14, 1997Jul 23, 2008Schering CorporationMammalian cell surface antigens; related reagents
EP1950299A1May 30, 2000Jul 30, 2008Schering CorporationMammalian receptor proteins; related reagents and methods
EP1964921A2Jun 21, 2000Sep 3, 2008Oscient Pharmaceuticals CorporationThe high bone mass gene of 11q13.3
EP1975231A1Jan 22, 2003Oct 1, 2008Corixa CorporationCompositions and methods for the detection, diagnosis and therapy of hematological malignancies
EP1980573A2Jul 8, 1998Oct 15, 2008Schering CorporationIsolated dendritic cell membrane protein genes
EP1983001A2Sep 23, 1999Oct 22, 2008Schering CorporationAntibodies to mammalian Langerhans cell antigen and their uses
EP1988166A1May 7, 1998Nov 5, 2008Schering CorporationHuman Toll-like receptor proteins, related reagents and methods
EP1990057A1May 17, 2002Nov 12, 2008Merck & Co., Inc.Beta-secretase substrates and uses thereof
EP1995317A1Dec 12, 1997Nov 26, 2008Schering CorporationMammalian cell surface antigens; related reagents
EP1995318A1Dec 12, 1997Nov 26, 2008Schering CorporationMammalian cell surface antigens; related reagents
EP2020239A1Apr 17, 2001Feb 4, 2009Schering CorporationUse of IL-174 agonists for treating infectious diseases
EP2026070A1Sep 9, 2003Feb 18, 2009Arbor Vita CorporationMethods of diagnosing cervical cancer
EP2028187A1Sep 7, 2001Feb 25, 2009Board Of Regents, The University Of Texas SystemHuman and mouse targeting peptides identified by phage display
EP2031070A1Nov 26, 2003Mar 4, 2009Applera CorporationMultiplex amplification of polynucleotides
EP2042869A2Dec 6, 2000Apr 1, 2009Board Of Trustees Of The University Of IllinoisHigh affinity TCR proteins and methods
EP2058275A1Jan 7, 2004May 13, 2009Ramot at Tel-Aviv University Ltd.Peptide nanostructures encapsulating a foreign material and method of manufacturing same
EP2058333A2Jul 22, 1999May 13, 2009Millennium Pharmaceuticals, Inc.Anti-CCR2 antibodies and methods of use therefor
EP2062918A2Nov 27, 2003May 27, 2009Technion Research and Development Foundation, Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
EP2062919A2Nov 27, 2003May 27, 2009Technion Research and Development Foundation, Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
EP2070944A1Oct 11, 2002Jun 17, 2009Amgen Inc.Specific binding agents of human angiopoietin-2
EP2071021A2Dec 12, 2008Jun 17, 2009University of South FloridaBone marrow-derived neuronal cells
EP2072045A2Feb 11, 2003Jun 24, 2009Technion Research and Development Foundation, Ltd.Antibody having a t-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP2072059A1Oct 11, 2002Jun 24, 2009Schering CorporationUse of bispecific antibodies to regulate immune responses
EP2077277A1Jan 30, 2003Jul 8, 2009Schering CorporationUse of mammalian cytokine; related reagents
EP2100959A2Jul 24, 1998Sep 16, 2009Schering CorporationMammalian cytokine: interleukin-B30 and related reagents
EP2107125A1Mar 31, 2008Oct 7, 2009Eppendorf Array Technologies SA (EAT)Real-time PCR of targets on a micro-array
EP2119771A2Dec 23, 2004Nov 18, 2009Danisco A/SProteins
EP2124055A1 *Feb 21, 2008Nov 25, 2009Stella Chemifa CorporationKit for immunoassay of bsh, and method for measurement of bsh
EP2128270A1Aug 9, 2004Dec 2, 2009Genenews Inc.Osteoarthritis biomarkers and uses thereof
EP2131198A2Sep 20, 2002Dec 9, 2009Board of Regents, The University of Texas SystemMeasuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
EP2135611A1Mar 1, 2002Dec 23, 2009Hollis-Eden Pharmaceuticals Inc.Pregn-5-en-20-yne-3,7,17-triol derivatives for use in therapy
EP2135619A1Dec 10, 2003Dec 23, 2009Millennium Pharmaceuticals, Inc.Humanized anti-CCR2 antibodies and methods of use therefor
EP2138510A1Jul 27, 2000Dec 30, 2009Schering CorporationMethods of generating antibodies against cytokines
EP2157097A1Oct 11, 2002Feb 24, 2010Amgen, Inc.Specific binding agents of human angiopoietin-2
EP2172210A1Dec 22, 2006Apr 7, 2010Partnership&Corp. Technology TransferSynthetic peptides for use as inhibitors of neurotransmitter secretion
EP2172478A2Feb 6, 1998Apr 7, 2010THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICESActivity-dependent neurotrophic factor III (ADNF III)
EP2174668A2Nov 14, 2005Apr 14, 2010Vascular Biogenics Ltd.Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
EP2177503A1Feb 21, 2005Apr 21, 2010UCL Business PLCModulators of cannabinoid receptors
EP2182052A1Oct 7, 2003May 5, 2010Technion Research and Development Foundation, Ltd.Human foreskin cells suitable for culturing stem cells
EP2186530A1Nov 15, 2001May 19, 2010Vascular Biogenics Ltd.Promoters exhibiting endothelial cell specificity and methods of using same
EP2194147A1Nov 26, 2003Jun 9, 2010Applied Biosystems, LLCMultiplex amplification of polynucleotides
EP2202240A1Aug 17, 2001Jun 30, 2010Sterix LimitedCompound
EP2208782A2Feb 4, 2000Jul 21, 2010Pluristem Ltd.Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
EP2208797A2Mar 1, 2005Jul 21, 2010Applied Biosystems, LLCMethods, compositions and kits for use in polynucleotide amplification
EP2210899A1Nov 10, 2005Jul 28, 2010Danisco A/Spntr transcription factor
EP2213740A1Oct 1, 1997Aug 4, 2010The Regents of the University of ColoradoHuman telomerase catalytic subunit
EP2216033A2Mar 4, 2004Aug 11, 2010Yeda Research and Development Co. Ltd.Methods of treating disease by transplantation of allogeneic or xenogeneic organs or tissues
EP2224008A2May 10, 2006Sep 1, 2010Murdoch UniversityGenes and proteins of brachyspira hyodysenteriae and use of same for diagnosis and therapy
EP2233574A1Jul 24, 1998Sep 29, 2010Schering CorporationMammalian cytokine: interleukin-B30 and related reagents
EP2236600A1Oct 17, 2005Oct 6, 2010Danisco A/SEnzymes
EP2236601A1Oct 17, 2005Oct 6, 2010Danisco A/SPhytases
EP2246444A1Sep 14, 2005Nov 3, 2010The Regents of the University of Colorado, A Body CorporateMethod for treatment with bucindolol based on genetic targeting
EP2256203A1Nov 18, 2004Dec 1, 2010Schering CorporationIL-23 and its receptor; related reagents and methods
EP2258726A1Jun 13, 1996Dec 8, 2010The Regents of the University of CaliforniaHigh affinity human antibodies to c-erbB-2
EP2258834A1Mar 21, 2001Dec 8, 2010The Scripps Research InstituteHuman aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis
EP2258849A1May 30, 2000Dec 8, 2010Schering CorporationMammalian receptor proteins; related reagents and methods
EP2261256A2Nov 15, 2000Dec 15, 2010Schering CorporationMethods of inhibiting metastasis
EP2264156A1Oct 17, 2005Dec 22, 2010Danisco A/SPhytases
EP2266405A2Mar 10, 2005Dec 29, 2010Danisco A/SFungal lipolytic enzymes
EP2267107A2Jul 18, 2005Dec 29, 2010Danisco A/SLipolytic Enzyme. Uses Thereof In The Food Industry
EP2267108A1Jul 18, 2005Dec 29, 2010Danisco A/SEnzymatic oil-degumming method
EP2272869A2Oct 11, 2002Jan 12, 2011Amgen Inc.Angiopoietin-2 specific binding agents
EP2275445A2Mar 11, 2005Jan 19, 2011Vasgene Therapeutics, Inc.Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
EP2275447A1Nov 15, 2000Jan 19, 2011Schering CorporationMethods of inhibiting metastasis
EP2275522A2Jul 18, 2005Jan 19, 2011Danisco A/SEnzymatic oil-degumming method
EP2275548A1May 10, 2001Jan 19, 2011Schering CorporationMammalian cytokine receptor subunit proteins, related reagents and methods
EP2278015A1Jan 15, 2004Jan 26, 2011Danisco A/SMethod of producing a carbohydrate ester
EP2279726A2May 25, 2006Feb 2, 2011Biorest Ltd.Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
EP2280285A1Sep 15, 2004Feb 2, 2011Oklahoma Medical Research FoundationMethod of using cytokine assays to diagnose, treat, and evaluate inflammatory and autoimmune diseases
EP2280286A1Sep 15, 2004Feb 2, 2011Oklahoma Medical Research FoundationMethod of using cytokine assays to diagnose, treat, and evaluate systemic lupus erythematosus
EP2281841A2Nov 30, 2005Feb 9, 2011Schering CorporationBiomarkers for pre-selection of patients for anti-IGF1R therapy
EP2283831A2Nov 30, 2005Feb 16, 2011Schering CorporationBiomakers for pre-selection of patients for anti-IGF1R therapy
EP2287185A2Dec 6, 2000Feb 23, 2011Board Of Trustees Of The University Of IllinoisHigh affinity TCR proteins and methods
EP2287194A2Mar 11, 2005Feb 23, 2011Vasgene Therapeutics, Inc.Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
EP2287317A2Jan 15, 2004Feb 23, 2011Danisco A/SMethod of producing a protein ester or a protein subunit ester
EP2287616A1Sep 15, 2004Feb 23, 2011Oklahoma Medical Research FoundationMethod of using cytokine assays to diagnose, treat, and evaluate systemic lupus erythematosus
EP2289567A2Dec 15, 2004Mar 2, 2011Regentis Biomaterials Ltd.Matrix comprising naturally-occurring crosslinked protein backbone
EP2290085A2Jan 15, 2004Mar 2, 2011Danisco A/SMethod for the in situ production of an emulsifier in a foodstuff
EP2292661A2Nov 9, 2004Mar 9, 2011Schering CorporationInterleukin-10 antibodies
EP2292760A2Nov 9, 2001Mar 9, 2011Schering CorporationMammalian cytokines, receptors, related reagents and methods
EP2295978A2Mar 19, 1999Mar 16, 2011The Curators Of The University Of MissouriEarly pregnancy diagnosis using PAGs(Pregnancy-associated Glycoproteins)
EP2295980A1Oct 30, 2003Mar 16, 2011Yissum Research Development Company, of The Hebrew University of JerusalemMolecules and methods using same for measuring non-transferrin bound iron
EP2298315A1Aug 28, 2003Mar 23, 2011Harbor BioSciences, Inc.Therapeutic treatment methods
EP2298316A1Aug 28, 2003Mar 23, 2011Harbor BioSciences, Inc.Therapeutic treatment methods
EP2298789A1Sep 7, 2001Mar 23, 2011Schering CorporationMammalian genes; related reagents and methods
EP2302072A1Nov 18, 2005Mar 30, 2011Eppendorf Array Technologies S.A.Real time-PCR of targets on a micro-array
EP2302079A2Sep 15, 2006Mar 30, 2011Baylor Research InstituteSystemic lupus erythematosus diagnostic assay
EP2305794A1Jan 26, 2003Apr 6, 2011Gamida Cell Ltd.Expansion of renewable stem cell populations
EP2308994A1Mar 21, 2002Apr 13, 2011Yeda Research And Development Co., Ltd.Methods for determining a risk to develop cancer
EP2311869A1Jan 30, 2003Apr 20, 2011Schering CorporationUse of mammalian cytokine; related reagents
EP2311938A1Feb 4, 2000Apr 20, 2011Pluristem Ltd.Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
EP2314696A1Sep 20, 1999Apr 27, 2011Schering CorporationTherapeutic uses of human Interleukin-B50 antagonist.
EP2316441A1Feb 16, 2006May 4, 2011Hadasit Medical Research Services And DevelopmentBisphosphonates for treating endometriosis
EP2316485A1Oct 11, 2002May 4, 2011Schering CorporationUse of bispecific antibodies to regulate immune responses
EP2316845A1Oct 11, 2002May 4, 2011Amgen Inc.Specific binding agents of human angiopoietin-2
EP2316950A1Mar 19, 2001May 4, 2011Technion Research and Development Foundation, Ltd.Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same
EP2319857A2Mar 4, 2004May 11, 2011Yeda Research And Development Co., Ltd.Pon polypeptides, polynucleotides encoding same and compositions and methods utilizing same
EP2319941A2Oct 23, 2006May 11, 2011GeneNews Inc.Method and apparatus for correlating levels of biomarker products with disease
EP2322561A1Oct 5, 2004May 18, 2011Yeda Research And Development Co., Ltd.Anti-NIK antibodies and uses thereof
EP2329814A1Feb 11, 2003Jun 8, 2011Technion Research and Development Foundation, Ltd.Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer
EP2330132A1Apr 4, 2004Jun 8, 2011Yeda Research and Development Co. Ltd.Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
EP2333049A1Sep 25, 2000Jun 15, 2011ABT Holding CompanyPluripotent embryonic-like stem cells, compositions, methods and uses thereof
EP2335728A1May 13, 2002Jun 22, 2011Ludwig Institute for Cancer Research Ltd.Specific binding proteins and uses thereof
EP2336321A1May 11, 2000Jun 22, 2011Medical Research CouncilOx2 receptor homolog
EP2336330A2Jun 14, 2005Jun 22, 2011Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
EP2336775A2Dec 6, 2000Jun 22, 2011Board Of Trustees Of The University Of IllinoisHigh affinity TCR proteins and methods
EP2338896A2Dec 11, 2003Jun 29, 2011R.B.T. (Rakuto Bio Technologies) Ltd.Use of lignin peroxidase in skin and hair lightening
EP2338913A1Dec 17, 1996Jun 29, 2011The University of Utah Research FoundationChromosome 13-linked breast cancer susceptibility gene
EP2339032A1Apr 18, 2006Jun 29, 2011Mitomics Inc.Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers
EP2341143A1May 11, 2000Jul 6, 2011Medical Research CouncilOX2 receptor homolog
EP2341144A1Jan 10, 2000Jul 6, 2011Schering CorporationInterleukin-17 related mammalian cytokines. Polynucleotides encoding them. Uses
EP2341346A2Oct 17, 2001Jul 6, 2011The Regents of the University of CaliforniaMethods of high-throughput screening for internalizing antibodies and metal-chelating liposomes
EP2343311A2Sep 5, 2005Jul 13, 2011Licentia OyPeptide inhibitors of HK2 and their use
EP2343373A1Jun 14, 2005Jul 13, 2011Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
EP2354160A1Aug 29, 2006Aug 10, 2011Schering CorporationEngineered anti-IL-23-antibodies
EP2354164A1Oct 5, 2004Aug 10, 2011Yeda Research And Development Co., Ltd.Anti-NIK antibodies and uses thereof
EP2357478A2Nov 30, 2001Aug 17, 2011Crawford Healthcare Holdings LimitedDiagnosis of disease
EP2359832A2Jul 25, 2005Aug 24, 2011University of Maryland, BaltimoreTherapeutic agents targeting the NCCA-ATP channel and methods of use thereof
EP2359853A1Aug 7, 2001Aug 24, 2011Technion Research and Development Foundation, Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis
EP2359854A1Aug 7, 2001Aug 24, 2011Technion Research and Development Foundation, Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis
EP2364994A1Jan 3, 1995Sep 14, 2011Schering CorporationPurfied primate CTLA-8 antigens and related reagents
EP2365087A2May 20, 2004Sep 14, 2011Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
EP2366775A1Mar 22, 2007Sep 21, 2011Pluristem Ltd.Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
EP2371861A1Jan 24, 2003Oct 5, 2011G2 Therapies LimitedMonoclonal antibodies against extracellular loops of C5aR
EP2371955A1Sep 26, 2003Oct 5, 2011K.U. Leuven Research & DevelopmentIntegrase cofactor
EP2382977A1Sep 16, 2005Nov 2, 2011University of Maryland, BaltimoreTherapeutic agents targeting the ncca-atp channel and methods of use thereof
EP2383345A1Dec 20, 2007Nov 2, 2011Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
EP2385124A2May 12, 2000Nov 9, 2011Arbor Vita CorporationPeptides or peptide analogues for modulating the binding of a PDZ protein and a PL protein
EP2386640A2Aug 25, 2005Nov 16, 2011EnGeneIC Molecular Delivery Pty LtdDelivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
EP2389943A1Apr 17, 2001Nov 30, 2011Schering CorporationUse of IL-174 antagonists for treating Th2-related diseases
EP2390312A1Nov 29, 2006Nov 30, 2011Gamida Cell Ltd.Methods of improving stem cell homing and engraftment
EP2395012A2Nov 2, 2006Dec 14, 2011Protiva Biotherapeutics Inc.Modified siRNA molecules and uses thereof
EP2395025A1Feb 26, 2008Dec 14, 2011Schering CorporationEngineered Anti-IL-23R Antibodies
EP2400030A1May 18, 2005Dec 28, 2011The Board Of Trustees Of The University Of the Leland Stanford Junior UniversityDetection of protein translocation by beta-galactosidase reporter fragment complementation
EP2402444A1Aug 17, 1995Jan 4, 2012The Rockefeller UniversityModulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
EP2402752A2Oct 29, 2007Jan 4, 2012Janssen Pharmaceutica, N.V.A method for pharmacologically profiling compounds
EP2405007A1Jan 25, 2007Jan 11, 2012Danisco A/SProduction of a lipid acyltransferase from transformed bacillus cells
EP2407242A1Jul 13, 2010Jan 18, 2012Dublin City UniversityDirect clone analysis and selection technology
EP2407783A1Oct 29, 2007Jan 18, 2012Janssen Pharmaceutica, N.V.A method for pharmacologically profiling compounds
EP2423332A1Aug 23, 2007Feb 29, 2012Oncotherapy Science, Inc.Prognostic markers and therapeutic targets for lung cancer
EP2423333A1Aug 23, 2007Feb 29, 2012Oncotherapy Science, Inc.Prognostic markers and therapeutic targets for lung cancer
EP2425841A1Nov 22, 2001Mar 7, 2012Vascular Biogenics Ltd.Methods Employing and Compositions Containing Defined Oxidized Phospholipids for Prevention and Treatment of Atherosclerosis
EP2425850A2Jun 14, 2006Mar 7, 2012The Regents of The University of CaliforniaBispecific single chain FV antibody molecules and methods of use thereof
EP2425860A1Aug 11, 2006Mar 7, 2012Amgen Inc.Modified Fc molecules
EP2426144A1Feb 21, 2008Mar 7, 2012Schering CorporationEngineered anti-IL-23p19 antibodies
EP2426145A1Feb 21, 2008Mar 7, 2012Schering CorporationEngineered anti-IL-23p19 antibodies
EP2426199A2Oct 19, 2007Mar 7, 2012Danisco US Inc.Polyol oxidases
EP2428522A1May 17, 2005Mar 14, 2012Agensys, Inc.Antibodies that bind to PSCA proteins for diagnosis of cancer
EP2441520A1Oct 12, 2010Apr 18, 2012Eppendorf AGReal-time amplification and micro-array based detection of nucleic acid targets in a flow chip assay
EP2441840A1Jul 18, 2006Apr 18, 2012Protalix Ltd.Mucosal or enteral administration of biologically active macromolecules
EP2444099A1Mar 31, 2006Apr 25, 2012Agensys, Inc.Antibodies and related molecules that bind to 161P2F10B proteins
EP2450456A2Nov 2, 2007May 9, 2012Yale UniversityAssessment of oocyte competence
EP2450702A2Jan 28, 2008May 9, 2012University Of Louisville Research Foundation, Inc.Methods of detecting autoantibodies for diagnosing and characterizing disorders
EP2455404A2Aug 22, 2007May 23, 2012G2 Inflammation Pty LtdAnti-C5AR antibodies with improved properties
EP2457999A2Dec 7, 2003May 30, 2012Technion Research & Development Foundation Ltd.Culture medium for pluropotent stem cells
EP2460893A1Jun 19, 2006Jun 6, 2012Advanced Cell Diagnostics, Inc.Multiplex detection of nucleic acids
EP2463382A1Dec 7, 2011Jun 13, 2012Enterologics, Inc.Method for identifying E. Coli M-17
EP2465920A2Feb 25, 2010Jun 20, 2012Tel HaShomer Medical Research Infrastructure and Services Ltd.Isolated populations of renal stem cells and methods of isolating and using same
EP2465924A2Jun 18, 2006Jun 20, 2012Ramot at Tel-Aviv University Ltd.Isolated cells and populations comprising same for the treament of cns diseases
EP2469282A1Sep 7, 2007Jun 27, 2012University of OxfordClinical diagnosis of hepatic fibrosis using a novel panel of human serum protein biomarkers
EP2469283A1Sep 7, 2007Jun 27, 2012University of OxfordClinical diagnosis of hepatic fibrosis using human serum APOL1 as biomarker.
EP2471807A1Feb 5, 2007Jul 4, 2012Modigene IncLong-acting polypeptides and methods of producing and administering same
EP2478924A1Jan 31, 2008Jul 25, 2012Technion Research & Development FoundationAlbumin fibers and fabrics and methods of generating and using same
EP2484768A2Jul 18, 2006Aug 8, 2012Protalix Ltd.Mucosal or enteral administration of biologically active macromolecules
EP2487182A2Jul 9, 2006Aug 15, 2012FULCRUM SP Ltd.SP1 polypeptides, modified SP1 polypeptides and uses thereof
EP2500428A2Jul 10, 2008Sep 19, 2012Yeda Research and Development Co. Ltd.Nucleic acid construct systems capable of diagnosing or treating a cell state
EP2500439A1Jun 19, 2006Sep 19, 2012Advanced Cell Diagnostics, Inc.Methods of detecting nucleic acids in individual cells and of identifying rare cells from large heterogeneous cell populations
EP2511708A1Oct 2, 2008Oct 17, 2012Affymetrix, Inc.Highly multiplexed particle-based assays
EP2514315A2Aug 21, 2006Oct 24, 2012Yeda Research and Development Co. Ltd.Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
EP2514763A1Feb 18, 2005Oct 24, 2012The Ludwig Institute for Cancer ResearchEgf receptor epitope peptides and uses thereof
EP2514766A2Mar 27, 2008Oct 24, 2012Technion Research & Development Foundation Ltd.Antibodies, methods and kits for diagnosing and treating melanoma
EP2520669A2Feb 6, 2006Nov 7, 2012GeneNews Inc.Mild osteoathritis biomarkers and uses thereof
EP2526952A1Jul 15, 2004Nov 28, 2012Bar-Ilan UniversityMethods and pharmaceutical compositions for healing wounds
EP2526953A1Jul 15, 2004Nov 28, 2012Bar-Ilan UniversityMethods and pharmaceutical compositions for healing wounds
EP2526968A2Jan 26, 2007Nov 28, 2012Biogen Idec MA Inc.Nogo receptor antagonists
EP2527441A2Jul 15, 2008Nov 28, 2012Technion Research & Development FoundationCompositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis
EP2529754A1May 3, 2008Dec 5, 2012Agency For Science, Technology And Research (A*star)Antibodies binding to an intracellular PRL-1 or PRL-3 polypeptide
EP2530087A2Mar 26, 2009Dec 5, 2012Prionics AGSequences of brachyspira, immunogenic composition, methods for preparation and use thereof
EP2532674A1Feb 5, 2007Dec 12, 2012Modigene IncLong-acting polypeptides and methods of producing and administering same
EP2532675A1Feb 5, 2007Dec 12, 2012Modigene IncLong-acting polypeptides and methods of producing and administering same
EP2532746A2Mar 26, 2008Dec 12, 2012EnGeneIC Molecular Delivery Pty Ltd.Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells
EP2540301A2Jul 15, 2004Jan 2, 2013Bar-Ilan UniversityMethods and pharmaceutical compositions for healing wounds
EP2540302A1Jul 15, 2004Jan 2, 2013Bar-Ilan UniversityMethods and pharmaceutical compositions for healing wounds
EP2546359A1Dec 7, 2006Jan 16, 2013Novartis AGEffects of inhibitors of FGFR3 on gene transcription
EP2548951A1Mar 22, 2007Jan 23, 2013Pluristem Ltd.Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
EP2550982A1Jul 26, 2012Jan 30, 2013Technion Research & Development Foundation Ltd.Devices for surgical applications
EP2561889A2Jul 31, 2003Feb 27, 2013Yeda Research and Development Co. Ltd.Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
EP2581445A1Aug 7, 2008Apr 17, 2013Yeda Research And Development Co. Ltd.Regulators of MMP-9 and uses thereof
EP2583981A2May 17, 2005Apr 24, 2013Agensys, Inc.Antibodies and related molecules that bind to PSCA proteins
EP2591789A2Sep 2, 2008May 15, 2013Pluristem Ltd.Adherent cells from adipose or placenta tissues and use thereof in therapy
EP2599790A1Nov 26, 2008Jun 5, 2013Yissum Research Development Company of The Hebrew University of JerusalemCompositions comprising fibrous polypeptides and polysachharides
EP2620448A1Apr 28, 2009Jul 31, 2013Amgen Inc.Anti-hepcidin antibodies and methods of use
EP2620493A1May 26, 2009Jul 31, 2013Ramot at Tel Aviv University Ltd.Mesenchymal stem cells for the treatment of CNS diseases
EP2626417A1Mar 22, 2007Aug 14, 2013Pluristem Ltd.Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
EP2628752A1Dec 13, 2007Aug 21, 2013Merck Sharp & Dohme Corp.Engineered anti-TSLP antibody
EP2633854A1Dec 3, 2009Sep 4, 2013Yeda Research And Development Co. Ltd.miRNA-9 or miRNA-9* for use in treating MND
EP2636743A1Apr 20, 2007Sep 11, 2013Intervet International B.V.Pestivirus species
EP2641606A1May 26, 2009Sep 25, 2013Pluristem Ltd.Methods of treating inflammatory colon diseases
EP2645106A2Apr 4, 2006Oct 2, 2013Biogen Idec MA Inc.Methods and products for evaluating an immune response to a therapeutic agent
EP2657342A1Aug 10, 2009Oct 30, 2013Genisphere Inc.DNA dendrimers protected against nuclease degradation are useful as vectors for the delivery of siRNA
EP2674440A2Dec 5, 2006Dec 18, 2013IBC Pharmaceuticals, Inc.Multivalent immunoglobulin-based bioactive assemblies
EP2679599A1Feb 20, 2009Jan 1, 2014Amgen Inc.Antibodies directed to Angiopoietin-1 and Angiopoietin-2 and use thereof
EP2700723A2Aug 6, 2008Feb 26, 2014Orion Genomics, LLCNovel single nucleotide polymorphisms and combinations of novel and known polymorphisms for determining the allele-specific expression of the IGF2 gene
EP2711434A1Jun 19, 2006Mar 26, 2014Advanced Cell Diagnostics, Inc.Multiplex detection of nucleic acids
EP2712620A1Feb 6, 2009Apr 2, 2014Cornell UniversityMethods for Preventing or Treating Insulin Resistance
EP2716654A1Oct 24, 2006Apr 9, 2014Evogene Ltd.Isolated polypeptides, polynucleotides encoding same, transgenic plants expressing same and methods of using same
EP2719394A1Jun 29, 2004Apr 16, 2014Tel Aviv University Future Technology Development L.P.Peptides antibodies directed thereagainst for diagnosing and treating amyloid-associated diseases
EP2770057A1Apr 15, 2009Aug 27, 2014Protiva Biotherapeutics Inc.Silencing of CSN5 gene expression using interfering RNA
EP2774987A1Aug 14, 2007Sep 10, 2014Affymetrix, Inc.Nucleic acid quantitation from tissue slides
EP2781223A1Oct 2, 2008Sep 24, 2014Rappaport Family Institute for Research in the Medical SciencesCompositions comprising semaphorins for the treatment of angiogenesis related diseases
EP2789626A2Sep 23, 2009Oct 15, 2014Tel Hashomer Medical Research Infrastructure and Services Ltd.Peptides and compositions for prevention of cell adhesion and methods of using same
EP2799876A2May 13, 2010Nov 5, 2014The Chancellors, Masters and Scholars of the University of OxfordClinical diagnosis of hepatic fibrosis using a novel panel of low abundant human plasma protein biomarkers
EP2803675A2Jan 23, 2009Nov 19, 2014Amgen, IncFerroportin antibodies and methods of use
EP2806023A2Nov 29, 2010Nov 26, 2014Pluristem Ltd.Adherent cells from placenta and use of same in disease treatment
EP2808344A1Jun 1, 2011Dec 3, 2014Monash UniversityAntibodies directed to the receptor tyrosine kinase c-Met
EP2808402A2Dec 29, 2009Dec 3, 2014Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Methods of predicting responsiveness to interferon treatment
EP2816059A1Apr 28, 2009Dec 24, 2014Amgen, IncAnti-hepcidin antibodies and methods of use
EP2816117A2Sep 28, 2005Dec 24, 2014Collplant Ltd.Collagen producing plants and methods of generating and using same
EP2826791A2Feb 19, 2009Jan 21, 2015G2 Inflammation Pty LtdHumanized anti-C5aR antibodies
EP2839839A1Feb 28, 2008Feb 25, 2015Yeda Research And Development Company LimitedNuclear targeting sequences
EP2851091A1Apr 11, 2008Mar 25, 2015Dana-Farber Cancer Institute, Inc.Methods for treating cancer resistant to ERBB therapeutics
EP2853536A1Feb 5, 2007Apr 1, 2015OPKO Biologics Ltd.Long-acting erythropoietin polypeptides and uses thereof
EP2853541A1Feb 5, 2007Apr 1, 2015OPKO Biologics Ltd.Long-acting polypeptides and uses thereof
EP2862929A1Dec 9, 2010Apr 22, 2015Quark Pharmaceuticals, Inc.Compositions and methods for treating diseases, disorders or injury of the CNS
EP2865755A2Mar 26, 2008Apr 29, 2015EnGeneIC Molecular Delivery Pty LtdBacterially derived, intact minicells encompassing regulatory RNA
EP2881468A1Apr 20, 2007Jun 10, 2015Intervet International B.V.Pestivirus species
EP2889041A1Jul 26, 2006Jul 1, 2015Rutgers, The State University of New JerseyKit of reagents for tuberculosis assay
EP2902036A1Feb 6, 2009Aug 5, 2015Cornell UniversityMethods for preventing or treating insulin resistance
EP2907873A1Jul 16, 2010Aug 19, 2015Bioatla LLCSimulataneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
EP2910638A2Jul 24, 2008Aug 26, 2015Evogene Ltd.Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance and/or biomass and/or yield in plants expressing same
EP2913344A1Feb 17, 2010Sep 2, 2015Ludwig Institute for Cancer Research LtdSpecific binding proteins and uses thereof
EP2923709A1Mar 28, 2014Sep 30, 2015Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Multi-component-multistage malaria vaccine
EP2933265A2Jun 5, 2006Oct 21, 2015Amicus Therapeutics, Inc.Pharmacological chaperones for treating obesity
EP2936976A1Apr 21, 2009Oct 28, 2015Danziger Innovations Ltd.Plant viral expression vectors and use of same for generating genotypic variations in plant genomes
EP2942627A1May 5, 2015Nov 11, 2015MicroBPlex, Inc.Media elaborated with newly synthesized antibodies (mensa) from recently proliferated antibody secreting cells (asc) and uses thereof
EP2944649A1Jan 9, 2009Nov 18, 2015Research Development FoundationVaccines and diagnostics for the ehrlichioses
EP2952588A1Aug 6, 2008Dec 9, 2015Orion Genomics, LLCSingle nucleotide polymorphism in igf2 for determining the allele-specific expression of the igf2 gene
EP2955234A1Feb 11, 2010Dec 16, 2015Orion Genomics, LLCCombinations of polymorphisms for determining allele-specific expression of igf2
EP2977445A2Nov 29, 2010Jan 27, 2016Pluristem Ltd.Adherent cells from placenta and use of same in disease treatment
EP2990421A1Apr 29, 2010Mar 2, 2016Tel HaShomer Medical Research Infrastructure and Services Ltd.Anti ceacam1 antibodies and methods of using same
EP2992895A1Sep 8, 2014Mar 9, 2016Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Three-component-multistage malaria vaccine
EP2995194A1Aug 15, 2006Mar 16, 2016Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
EP3000889A2Mar 1, 2010Mar 30, 2016Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
EP3000899A1Nov 26, 2003Mar 30, 2016Applied Biosystems, LLCMultiplex amplification of polynucleotides
EP3006039A1Mar 2, 2005Apr 13, 2016Acceleron Pharma Inc.Alk7 polypeptides for use in promoting fat loss
WO1980002747A1 *May 19, 1980Dec 11, 1980Rapidex LtdUltrasensitive enzymatic radioimmunoassay method
WO1982004323A1 *May 28, 1982Dec 9, 1982O Neill SeanImmunoprecipitation assay
WO1985000605A1 *Jul 20, 1984Feb 14, 1985American Hospital Supply CorporationProcess for selective nitrile reduction
WO1998014593A2Oct 1, 1997Apr 9, 1998Geron CorporationHuman telomerase catalytic subunit
WO1999045124A2Mar 3, 1999Sep 10, 1999Genencor International, Inc.Modified forms of pullulanase
WO2000015824A1Mar 15, 1999Mar 23, 2000Karolinska Innovations AbTransfer method for specific cellular localisation of nucleic acids
WO2000073451A1May 30, 2000Dec 7, 2000Schering CorporationMammalian receptor proteins; related reagents and methods
WO2001062271A1Feb 20, 2001Aug 30, 2001The Board Of Trustees Of The University Of ArkansasCompositions and methods for the early diagnosis of ovarian cancer
WO2001075078A1Mar 21, 2001Oct 11, 2001The Scripps Research InstituteHUMAN AMINOACYL-tRNA SYNTHETASE POLYPEPTIDES USEFUL FOR THE REGULATION OF ANGIOGENESIS
WO2002020569A2Sep 7, 2001Mar 14, 2002Schering CorporationMammalian genes; related reagents and methods
WO2002044736A2Nov 30, 2001Jun 6, 2002Molecular Skincare LimitedDiagnosis and treatment of epidermal or skin diseases
WO2003030835A2Oct 11, 2002Apr 17, 2003Schering CorporationUse of bispecific antibodies to regulate immune responses
WO2003043524A2Nov 20, 2002May 30, 2003The Curators Of The University Of MissouriCompositions and methods for accurate early pregnancy diagnosis
WO2003072799A2Feb 21, 2003Sep 4, 2003The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human ServicesBrother of the regulator of imprinted sites (boris)
WO2003101386A2May 29, 2003Dec 11, 2003Memorial Sloan-Kettering Cancer CenterKinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis
WO2004037251A1Oct 23, 2003May 6, 2004Sterix LimitedInhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2
WO2004060135A2Dec 31, 2003Jul 22, 2004Rappaport Family Institute For Research In The Medical SciencesMethods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients
WO2004060909A2Nov 17, 2003Jul 22, 2004Genencor International, Inc.Increasing production of proteins in gram-positive microorganisms
WO2004096157A2Mar 5, 2004Nov 11, 2004New England Medical Center Hospitals, Inc.Treatment of igai deposition diseases
WO2005016282A2Aug 13, 2004Feb 24, 2005Exelixis, Inc.Prkcs as modifiers of the beta catenin pathway and methods of use
WO2005019409A2Jul 15, 2003Mar 3, 2005Board Of Regents, The University Of Texas SystemCombinatorial protein library screening by periplasmic expression
WO2005033142A2Oct 5, 2004Apr 14, 2005Yeda Research And Development Co. Ltd.Anti-nik antibodies and uses thereof
WO2005033145A1Oct 5, 2004Apr 14, 2005Yeda Research And Development Co. Ltd.Antibodies to nik, their preparation and use
WO2005051423A2Nov 30, 2004Jun 9, 2005Yeda Research And Development Co. LtdMethods and agents for immune modulation and methods for identifying immune modulators
WO2005118864A2May 17, 2005Dec 15, 2005Agensys, Inc.Antibodies and related molecules that bind to psca proteins
WO2006024694A2Sep 5, 2005Mar 9, 2006Licentia OyPeptide inhibitors of hk2 and their use
WO2006034048A2Sep 16, 2005Mar 30, 2006University Of Maryland, BaltimoreTherapeutic agents targeting the ncca-atp channel and methods of use thereof
WO2006043178A2Oct 17, 2005Apr 27, 2006Danisco A/SEnzymes
WO2006107962A2Apr 4, 2006Oct 12, 2006Biogen Idec Ma IncMethods and products for evaluating an immune response to a therapeutic protein
WO2006134602A2Jun 18, 2006Dec 21, 2006Ramot At Tel Aviv University Ltd.Isolated cells and populations comprising same for the treatment of cns diseases
WO2007001986A2Jun 19, 2006Jan 4, 2007Yuling LuoMethods of detecting nucleic acids in individual cells and of identifying rare cells from large heterogeneous cell populations
WO2007020638A2Aug 15, 2006Feb 22, 2007Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
WO2007023491A2Aug 21, 2006Mar 1, 2007Yeda Research And Development Co. Ltd.Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
WO2007031996A1Sep 11, 2006Mar 22, 2007Rappaport Family Institute For Research In The Medical SciencesCompositions and methods for diagnosing and treating an inflammation
WO2007034487A1Sep 21, 2006Mar 29, 2007Yissum Research Development Company Of The Hebrew University Of JerusalemNucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer
WO2007056352A2Nov 6, 2006May 18, 2007The Scripps Research InstituteCompositions and methods for controlling tissue factor signaling specificity
WO2007088051A2Jan 26, 2007Aug 9, 2007Bayer Schering Pharma AktiengesellschaftModulation of mdl-1 activity for treatment of inflammatory disease
WO2007091254A1Feb 6, 2007Aug 16, 2007Rappaport Family Institute For Research In The Medical SciencesMethods and kit for diagnosing t1dm
WO2007094985A2Feb 5, 2007Aug 23, 2007Modigene IncLong-acting polypeptides and methods of producing and administering same
WO2007110869A2Mar 28, 2007Oct 4, 2007Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods and kits for determining predisposition to warfarin resistance
WO2008005429A2Jul 2, 2007Jan 10, 2008Charles David AdairComposition for modulating the expression of cell adhesion molecules
WO2008010934A2Jul 10, 2007Jan 24, 2008Chemocentryx, Inc.Triazolyl phenyl benzenesulfonamides
WO2008026198A2Aug 15, 2007Mar 6, 2008Yeda Research And Development Co. Ltd.Methods of generating glial and neuronal cells and use of same for the treatment of medical conditions of the cns
WO2008041183A2Oct 2, 2007Apr 10, 2008Technion Research & Development Foundation Ltd.Microtubes and methods of producing same
WO2008043566A2Oct 11, 2007Apr 17, 2008Janssen Pharmaceutica N.V.Compositions and methods for treating and diagnosing irritable bowel syndrome
WO2008051761A2Oct 17, 2007May 2, 2008Abbott LaboratoriesAssay for cardiac troponin autoantibodies
WO2008067547A2Nov 30, 2007Jun 5, 2008Research Development FoundationImproved immunoglobulin libraries
WO2008076321A1Dec 13, 2007Jun 26, 2008Schering CorporationEngineered anti-tslp antibody
WO2008092164A2Jan 28, 2008Jul 31, 2008University Of Louisville Research Foundation, Inc.Methods of detecting autoantibodies for diagnosing and characterizing disorders
WO2008093341A2Jan 31, 2008Aug 7, 2008Technion Research & Development Foundation Ltd.Electrospun scaffolds and methods of generating and using same
WO2008093342A2Jan 31, 2008Aug 7, 2008Technion Research & Development Foundation Ltd.Albumin fibers and fabrics and methods of generating and using same
WO2008110006A1Mar 12, 2008Sep 18, 2008Miraculins Inc.Biomarkers of prostate cancer and uses thereof
WO2008120202A2Mar 27, 2008Oct 9, 2008Technion Research & Development Foundation Ltd.Antibodies, methods and kits for diagnosing and treating melanoma
WO2008120216A1Apr 2, 2008Oct 9, 2008Ramot At Tel Aviv University Ltd.Methods of detecting cancer cells and use of same for diagnosing and monitoring treatment of the disease
WO2008124670A2Apr 7, 2008Oct 16, 2008Becton, Dickinson And CompanyCompositions and methods for the identification of a carbapenemase gene
WO2008132753A2May 1, 2008Nov 6, 2008Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods and kits for detecting fetal cells in the maternal blood
WO2008137475A2Apr 30, 2008Nov 13, 2008Research Development FoundationImmunoglobulin fc libraries
WO2009010968A2Jul 15, 2008Jan 22, 2009Yitzchak HillmanDisease treatment via antimicrobial peptides or their inhibitors
WO2009021054A2Aug 6, 2008Feb 12, 2009Orion Genomics LlcNovel single nucleotide polymorphisms and combinations of novel and known polymorphisms for determining the allele-specific expression of the igf2 gene
WO2009032477A2Aug 8, 2008Mar 12, 2009The Board Of Regents Of The University Of Texas SystemVegfr-1/nrp-1 targeting peptides
WO2009034574A2Sep 11, 2008Mar 19, 2009Yeda Research And Development Co. Ltd.Methods of treating tumors in immune-privileged sites
WO2009038847A1Jun 18, 2008Mar 26, 2009Chemocentryx, Inc.N-(2-(hetaryl)aryl)arylsulfonamides and n-(2-(hetaryl)hetaryl)arylsulfonamides
WO2009082817A1Dec 23, 2008Jul 9, 2009Protiva Biotherapeutics, Inc.Silencing of polo-like kinase expression using interfering rna
WO2009083958A2Dec 23, 2008Jul 9, 2009Evogene Ltd.Isolated polypeptides, polynucleotides useful for modifying water user efficiency, fertilizer use efficiency, biotic/abiotic stress tolerance, yield and biomass in plants
WO2009104174A2Feb 12, 2009Aug 27, 2009Technion Research & Development Foundation Ltd .A method of attaching a cell-of-interest to a microtube
WO2009105833A1Feb 27, 2009Sep 3, 2009Murdoch UniversityNovel sequences of brachyspira, immunogenic compositions, methods for preparation and use thereof
WO2009117773A1Mar 26, 2009Oct 1, 2009Murdoch UniversityNovel sequences of brachyspira, immunogenic compositions, methods for preparation and use thereof
WO2009127060A1Apr 15, 2009Oct 22, 2009Protiva Biotherapeutics, Inc.Novel lipid formulations for nucleic acid delivery
WO2009129319A2Apr 15, 2009Oct 22, 2009Protiva Biotherapeutics, Inc.Silencing of csn5 gene expression using interfering rna
WO2009139822A1Apr 28, 2009Nov 19, 2009Amgen Inc.Anti-hepcidin antibodies and methods of use
WO2010016806A1Aug 7, 2009Feb 11, 2010Agency For Science, Technology And Research (A*Star)Vhz for diagnosis and treatment of cancers
WO2010017544A2Aug 10, 2009Feb 11, 2010Genisphere, Inc.Long-acting dna dendrimers and methods thereof
WO2010029545A2Sep 10, 2009Mar 18, 2010Ben Gurion University Of The Negev Research And Development AuthorityCompositions and methods for treating s. pneumoniae infection
WO2010035261A2Sep 24, 2009Apr 1, 2010Ben Gurion University Of The Negev Research And Development AuthorityAmyloid beta-peptides and methods of use thereof
WO2010040277A1Oct 9, 2009Apr 15, 2010The University Of Hong KongCadherin-17 as diagnostic marker and therapeutic target for liver cancer
WO2010049897A2Oct 28, 2009May 6, 2010Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficieny
WO2010054328A2Nov 9, 2009May 14, 2010Research Development FoundationCompositions and methods for the inhibition of cripto/grp78 complex formation and signaling
WO2010055525A1Nov 17, 2009May 20, 2010Technion Research & Development Foundation Ltd.Method for predicting a patient's responsiveness to anti-folate therapy
WO2010058396A1Nov 17, 2009May 27, 2010Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.A cd44vra antibody and diagnostic and therapeutic methods using same
WO2010061383A1Nov 24, 2009Jun 3, 2010Biodalia Microbiological Technologies Ltd.A method of in-situ enrichment of foods with fructan
WO2010064231A1Nov 29, 2009Jun 10, 2010Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods of analyzing a-i rna editing and nucleic acid constructs capable of same
WO2010064247A1Dec 3, 2009Jun 10, 2010Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods and kits for determining predisposition to cancer
WO2010065437A1Nov 30, 2009Jun 10, 2010Research Development FoundationModulation of olfml-3 mediated angiogenesis
WO2010066252A1Dec 9, 2009Jun 17, 2010Dako Denmark A/SMethod for evaluating pre-treatment
WO2010068757A1Dec 10, 2009Jun 17, 2010The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesCompositions and methods useful for detecting and treating diseases associated with 16p chromosomal disruptions
WO2010071610A1Dec 21, 2009Jun 24, 2010Agency For Science, Technology And Research (A*Star)Severe chikungunya biomarkers
WO2010076642A1Dec 28, 2009Jul 8, 2010Tel Hashomer Medical Research, Infrastructure And Services LtdPeptides and compositions for prevention of cell adhesion and methods of using same
WO2010076756A2Dec 28, 2009Jul 8, 2010Evogene Ltd.Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance, biomass and/or yield in plants expressing same
WO2010076788A2Dec 29, 2009Jul 8, 2010Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection
WO2010076794A1Dec 30, 2009Jul 8, 2010Technion Research & Development Foundation Ltd.Method of denitrifying brine and systems capable of same
WO2010086856A2Jan 31, 2010Aug 5, 2010Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of generating tissue using devitalized, acellular scaffold matrices derived from micro-organs
WO2010086867A2Feb 2, 2010Aug 5, 2010Ramot At Tel Aviv University Ltd.Peptides, pharmaceutical compositions comprising same and uses thereof
WO2010089707A1Feb 4, 2010Aug 12, 2010Yeda Research And Development Co. Ltd.Methods and kits for determining sensitivity or resistance of prostate cancer to radiation therapy
WO2010093450A2Feb 11, 2010Aug 19, 2010Ludwing Institute For Cancer Research Ltd.Pten phosphorylation-driven resistance to cancer treatment and altered patient prognosis
WO2010093820A2Feb 11, 2010Aug 19, 2010Orion Genomics LlcCombinations of polymorphisms for determining allele-specific expression of igf2
WO2010096434A2Feb 17, 2010Aug 26, 2010Ludwig Institute For Cancer ResearchSpecific binding proteins and uses thereof
WO2010096658A1Feb 19, 2010Aug 26, 2010The Cleveland Clinic FoundationCorin as a marker for heart failure
WO2010097793A2Feb 25, 2010Sep 2, 2010Tel Hashomer Medical Research Infrastructure And Services Ltd.Isolated populations of renal stem cells and methods of isolating and using same
WO2010097794A1Feb 25, 2010Sep 2, 2010Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods of reprogramming renal cells
WO2010100595A2Mar 1, 2010Sep 10, 2010Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
WO2010103517A1Mar 10, 2010Sep 16, 2010Rappaport Family Institute For Research In The Medical SciencesSoluble compositions for the treatment of cxcr3-ligand associated diseases
WO2010113096A1Mar 28, 2010Oct 7, 2010Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods of predicting clinical course and treating multiple sclerosis
WO2010113146A1Feb 28, 2010Oct 7, 2010The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical CenterA method of regulating proliferation and differentiation of keratinocyes
WO2010116375A1Apr 8, 2010Oct 14, 2010Yeda Research And Development Co. Ltd.Isolated peptides for regulating apoptosis
WO2010126670A2Mar 26, 2010Nov 4, 2010Gojo Industries, Inc.Compositions and methods for screening and using compounds antagonizing spore-surface interactions
WO2010134035A1May 19, 2010Nov 25, 2010Danisco A/SUse
WO2010137013A1May 25, 2010Dec 2, 2010Ramot At Tel Aviv University Ltd.Crystallized photosystem i units from the pea plant and their use in solid state devices
WO2010137017A2May 26, 2010Dec 2, 2010Yeda Research And Development Co. Ltd.Proteasome inhibitors and uses thereof
WO2010137020A1May 27, 2010Dec 2, 2010Yeda Research And Development Co. Ltd.Methods of treating inflammation
WO2010137021A2May 27, 2010Dec 2, 2010Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of generating connective tissue
WO2010141421A1Jun 1, 2010Dec 9, 2010The Board Of Regents Of The University Of Texas SystemIdentification of small molecules recognized by antibodies in subjects with neurodegenerative diseases
WO2010150213A1Jun 23, 2010Dec 29, 2010Danisco A/SProtein
WO2010150259A1Jun 24, 2010Dec 29, 2010Fund For Medical Research Development Of Infrastructure And Health Services -Rambam Medical CenterMethods and kits for isolating placental derived microparticles and use of same for diagnosis of fetal disorders
WO2011000107A1Jun 30, 2010Jan 6, 2011Protiva Biotherapeutics, Inc.Novel lipid formulations for delivery of therapeutic agents to solid tumors
WO2011002834A2Jun 30, 2010Jan 6, 2011American Type Culture CollectionCompositions and methods for diagnosis and treatment of type 1 diabetes
WO2011004361A2Jul 1, 2010Jan 13, 2011Prolor Biotech Inc.Long-acting coagulation factors and methods of producing same
WO2011004379A1Jul 8, 2010Jan 13, 2011Tel Hashomer Medical Research Infrastructure And Services Ltd.Compositions and methods for treating cancer
WO2011010309A1Jul 21, 2010Jan 27, 2011Tel Hashomer Medical Research Infrastructure And Services Ltd.A method of diagnosing cancer
WO2011011447A1Jul 20, 2010Jan 27, 2011Protiva Biotherapeutics, Inc.Compositions and methods for silencing ebola virus gene expression
WO2011013130A2Jul 29, 2010Feb 3, 2011Ramot At Tel-Aviv University Ltd.Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
WO2011019423A2May 14, 2010Feb 17, 2011Schering CorporationModulation of pilr receptors to treat microbial infections
WO2011021171A1Aug 22, 2010Feb 24, 2011Beeologics, LlcPreventing and curing beneficial insect diseases via plant transcribed molecules
WO2011021194A2Aug 17, 2010Feb 24, 2011Technion Research & Development Foundation Ltd.Pericyte progenitor cells and methods of generating and using same
WO2011024172A2Aug 26, 2010Mar 3, 2011Technion Research & Development Foundation Ltd.Liposomal compositions and uses of same
WO2011030329A1Aug 31, 2010Mar 17, 2011Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of treating tumors
WO2011030332A2Sep 5, 2010Mar 17, 2011Yeda Research And Development Co. Ltd.Methods for hematopoietic precursor mobilization
WO2011030336A1Sep 6, 2010Mar 17, 2011Ramot At Tel-Aviv University Ltd.Methods of diagnosing amyotrophic lateral sclerosis (als)
WO2011033506A2Sep 15, 2010Mar 24, 2011Yeda Research And Development Co. Ltd.Isolated pon1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
WO2011033511A1Sep 16, 2010Mar 24, 2011Ramot At Tel-Aviv University Ltd.Peptides for the treatment of oxidative stress related disorders
WO2011034950A1Sep 15, 2010Mar 24, 2011Vaxart, Inc.Immunization strategy to prevent h1n1 infection
WO2011038160A2Sep 23, 2010Mar 31, 2011Protiva Biotherapeutics, Inc.Compositions and methods for silencing genes expressed in cancer
WO2011038403A1Sep 28, 2010Mar 31, 2011Yuling LuoMethods of detecting nucleic acid sequences with high specificity
WO2011040972A1Oct 1, 2010Apr 7, 2011Ludwig Institute For Cancer Research Ltd.Anti-fibroblast activation protein antibodies and methods and uses thereof
WO2011040973A2Oct 1, 2010Apr 7, 2011Ludwig Institute For Cancer Research Ltd.Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof
WO2011041319A2Sep 28, 2010Apr 7, 2011Ludwig Institute For Cancer ResearchSpecific binding proteins and uses thereof
WO2011044186A1Oct 6, 2010Apr 14, 2011The Board Of Trustees Of The University Of IllinoisHuman single-chain t cell receptors
WO2011045796A1Oct 14, 2010Apr 21, 2011Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Compositions for controlling varroa mites in bees
WO2011046570A1Oct 16, 2009Apr 21, 2011The University Of Medicine And Dentistry Of New JerseyMethod for treating chronic nerve tissue injury using a cell therapy strategy
WO2011048600A1Oct 21, 2010Apr 28, 2011Danziger Innovations Ltd.Generating genotypic variations in plant genomes by gamete infection
WO2011055366A1Nov 8, 2010May 12, 2011Medical Research & Development Fund For Health Services Bnai Zion Medical Center, The State Of IsraelMo-1 conditional knock-out non-human animal and uses thereof
WO2011056688A2Oct 27, 2010May 12, 2011Caris Life Sciences, Inc.Molecular profiling for personalized medicine
WO2011058555A1Nov 11, 2010May 19, 2011Yeda Research And Development Co. Ltd.A method of editing dna in a cell and constructs capable of same
WO2011058557A1Nov 11, 2010May 19, 2011Ramot At Tel-Aviv University Ltd.Compositions comprising pedf and uses of same in the treatment and prevention of ovary-related syndromes
WO2011061657A1Nov 8, 2010May 26, 2011Danisco A/SMethod
WO2011061736A1Nov 17, 2010May 26, 2011Protalix Ltd.Alkaline alpha galactosidase for the treatment of fabry disease
WO2011064669A2Nov 29, 2010Jun 3, 2011Pluristem Ltd.Adherent cells from placenta and use of same in disease treatment
WO2011064773A1Nov 24, 2010Jun 3, 2011Collplant Ltd.Method of generating collagen fibers
WO2011067745A2Dec 6, 2010Jun 9, 2011Rosetta Green Ltd.Compositions and methods for enhancing plants resistance to abiotic stress
WO2011068676A1Nov 17, 2010Jun 9, 2011Abbott LaboratoriesPeptide reagents and method for inhibiting autoantibody antigen binding
WO2011068680A1Nov 17, 2010Jun 9, 2011Abbott LaboratoriesAssay for diagnosis of cardiac myocyte damage
WO2011068681A1Nov 17, 2010Jun 9, 2011Abbott LaboratoriesASSAY FOR CARDIAC TROPONIN-T (cTnT)
WO2011072091A1Dec 9, 2010Jun 16, 2011Quark Pharmaceuticals, Inc.Methods and compositions for treating diseases, disorders or injury of the cns
WO2011076881A1Dec 22, 2010Jun 30, 2011Arabian Gulf UniversityMutant ldl receptor gene
WO2011080674A2Dec 22, 2010Jul 7, 2011Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency
WO2011080740A1Dec 29, 2010Jul 7, 2011Gamida-Cell Ltd.Methods for enhancing natural killer cell proliferation and activity
WO2011084357A1Dec 10, 2010Jul 14, 2011Schering CorporationModulation of pilr to treat immune disorders
WO2011084882A2Jan 5, 2011Jul 14, 2011Contrafect CorporationMethods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria
WO2011086509A1Jan 12, 2011Jul 21, 2011Vascular Biogenics Ltd.Methods of producing adenovirus vectors and viral preparations generated thereby
WO2011092700A1Jan 27, 2011Aug 4, 2011Yeda Research And Development Co. Ltd.Antibodies that inhibit metalloproteins
WO2011094669A1Jan 31, 2011Aug 4, 2011Advanced Cell Diagnostics, Inc.Methods of in situ detection of nucleic acids
WO2011096926A1Feb 4, 2010Aug 11, 2011Massachusetts Institute Of TechnologyMethods for preparing sequencing libraries
WO2011099006A2Feb 10, 2011Aug 18, 2011Yeda Research And Development Co. Ltd.Enzymatic systems for carbon fixation and methods of generating same
WO2011104708A2Feb 23, 2011Sep 1, 2011Ben Gurion University Of The Negev Research And Development AuthorityMethods for inhibiting necrosis
WO2011107939A1Mar 1, 2011Sep 9, 2011Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of predicting efficacy of an anti-vegfa treatment for solid tumors
WO2011107994A1Mar 3, 2011Sep 9, 2011Yeda Research And Development Co. Ltd.Methods of measuring protein stability
WO2011111034A1Jan 25, 2011Sep 15, 2011Yeda Research And Development Co. Ltd.Recombinant protein production in heterologous systems
WO2011111050A2Mar 10, 2011Sep 15, 2011Jacob EdreiMethods of generating hydrogen
WO2011114251A1Mar 1, 2011Sep 22, 2011Danisco A/SFoodstuff
WO2011125015A2Apr 4, 2011Oct 13, 2011Bar-Ilan UniversityProtease-activatable pore-forming polypeptides
WO2011128897A1Apr 12, 2011Oct 20, 2011Technion Research & Development Foundation Ltd.Populations of pancreatic progenitor cells and methods of isolating and using same
WO2011132182A1Mar 22, 2011Oct 27, 2011Yeda Research And Development Co. Ltd.MOLECULES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES
WO2011138778A2May 4, 2011Nov 10, 2011Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of identifying inhibitors of polypeptides-of-interest
WO2011138785A2May 5, 2011Nov 10, 2011Rappaport Family Institute For Research In The Medical SciencesUse of ccl1 in therapy
WO2011140234A1May 4, 2011Nov 10, 2011Abbott LaboratoriesMethods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor
WO2011141914A1May 12, 2011Nov 17, 2011Tel Hashomer Medical Research Infrastructure And Services Ltd.Isolated populations of adult renal cells and methods of isolating and using same
WO2011146479A1May 17, 2011Nov 24, 2011The Texas A&M University SystemMethod and composition for the diagnosis and monitoring of inflammatory diseases
WO2011151833A1Jun 2, 2011Dec 8, 2011Ramot At Tel-Aviv University Ltd.Methods of treating diabetes and compositions capable of same
WO2011154940A1Jun 6, 2011Dec 15, 2011Osnat Ashur-FabianMethods and kits for diagnosing conditions related to hypoxia
WO2011158242A2Jun 16, 2011Dec 22, 2011Futuragene Israel Ltd.Pest -resistant plants containing a combination of a spider toxin and a chitinase
WO2011158243A2Jun 16, 2011Dec 22, 2011Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of diagnosing and treating cancer
WO2012004759A2Jul 7, 2011Jan 12, 2012Danisco A/SMethod
WO2012006056A2Jun 28, 2011Jan 12, 2012Oregon Health & Science UniversityCcr6 as a biomarker of alzheimer's disease
WO2012007537A1Jul 13, 2011Jan 19, 2012Dublin City UniversityDirect clone analysis and selection technology
WO2012007919A2Jul 14, 2011Jan 19, 2012Technion Research & Development Foundation Ltd.Nucleic acid construct for increasing abiotic stress tolerance in plants
WO2012007950A2Jul 14, 2011Jan 19, 2012Technion Research & Development Foundation Ltd.Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides
WO2012007951A1Jul 14, 2011Jan 19, 2012Technion Research & Development Foundation Ltd.Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides
WO2012009627A2Jul 15, 2011Jan 19, 2012Vanderbilt UniversityLow resource processor using surface tension valves for extracting, concentrating and detecting molecular species
WO2012011113A2Jul 21, 2011Jan 26, 2012Shai YarkoniRegulatory immune cells with enhanced targeted cell death effect
WO2012014205A1Jul 27, 2011Feb 2, 2012Technion Research & Development Foundation Ltd.Isolated mesenchymal progenitor cells and extracellular matrix produced thereby
WO2012014207A2Jul 27, 2011Feb 2, 2012Technion Research & Development Foundation Ltd.Method for generating induced pluripotent stem cells from keratinocytes derived from plucked hair follicles
WO2012014208A2Jul 27, 2011Feb 2, 2012Yeda Research And Development Co. Ltd.Methods and systems for assessing clonality of cell cultures
WO2012017439A2Aug 4, 2011Feb 9, 2012Ramot At Tel-Aviv University Ltd.Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases
WO2012018476A1Jul 8, 2011Feb 9, 2012Abbott LaboratoriesAntibodies relating to pivka-ii and uses thereof
WO2012025914A1Jul 7, 2011Mar 1, 2012Ramot At Tel-Aviv University Ltd.Induced pluripotent stem cells derived from human pancreatic beta cells
WO2012025925A1Aug 24, 2011Mar 1, 2012Rappaport Family Institute For Research In The Medical SciencesMethods of improving transplantation using sdf-1alpha
WO2012032510A1Sep 6, 2011Mar 15, 2012Yeda Research And Development Co. Ltd.Primers for amplifying dna and methods of selecting same
WO2012032519A2Sep 7, 2011Mar 15, 2012Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of diagnosing parkinson's disease
WO2012032520A1Sep 7, 2011Mar 15, 2012Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Readthrough acetylcholinesterase (ache-r) for treating or preventing parkinson's disease
WO2012032521A2Sep 7, 2011Mar 15, 2012Technion Research & Development Foundation Ltd.Novel methods and culture media for culturing pluripotent stem cells
WO2012032525A2Sep 8, 2011Mar 15, 2012Yeda Research And Development Co. Ltd.An immunosuppressive drug combination for a stable and long term engraftment
WO2012032526A2Sep 8, 2011Mar 15, 2012Yeda Research And Development Co. Ltd.Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment
WO2012035539A1Sep 15, 2011Mar 22, 2012Ramot At Tel-Aviv University Ltd.Methods of expanding and redifferentiating islet beta cells
WO2012038956A1Sep 20, 2011Mar 29, 2012Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of treating neurodegenerative diseases
WO2012040168A2Sep 20, 2011Mar 29, 2012Advanced Cell Diagnostics, Inc.Biomarkers for differentiating melanoma from benign nevus in the skin
WO2012049066A2Oct 6, 2011Apr 19, 2012Eppendorf AgReal-time amplification and micro-array based detection of nucleic acid targets in a flow chip assay
WO2012052872A2Oct 10, 2011Apr 26, 2012Yeda Research And Development Co. Ltd.Methods and compositions for the treatment of insulin-associated medical conditions
WO2012052878A1Oct 12, 2011Apr 26, 2012Vascular Biogenics Ltd.Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells
WO2012054795A1Oct 21, 2011Apr 26, 2012Advanced Cell Diagnostics, Inc.An ultra sensitive method for in situ detection of nucleic acids
WO2012056452A2Oct 27, 2011May 3, 2012Nanocyte (Israel) Ltd.Pharmaceutical compositions and delivery devices comprising stinging cells or capsules
WO2012056455A1Oct 27, 2011May 3, 2012Yeda Research And Development Co. Ltd.Methods of generating antibodies to metalloenzymes
WO2012059922A2Nov 3, 2011May 10, 2012Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Transgenic plants with improved saccharification yields and methods of generating same
WO2012066495A2Nov 17, 2011May 24, 2012Ben Gurion University Of The Negev Research And Development AuthorityT-cell therapy to neurodegenerative diseases
WO2012090205A2Dec 28, 2011Jul 5, 2012Kamedis Ltd.Plant extracts for the treatment and prevention of infections
WO2012098537A1Sep 7, 2011Jul 26, 2012Protalix Ltd.Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
WO2012099896A2Jan 17, 2012Jul 26, 2012Life Technologies CorporationWorkflow for detection of ligands using nucleic acids
WO2012103414A2Jan 27, 2012Aug 2, 2012Advanced Cell Diagnostics, Inc.Rnascope® hpv assay for determining hpv status in head and neck cancers and cervical lesions
WO2012104851A1Jan 31, 2012Aug 9, 2012Yeda Research And Development Co. Ltd.Methods of diagnosing disease using overlap extension pcr
WO2012109133A1Feb 6, 2012Aug 16, 2012Research Development FoundationEngineered immunoglobulin fc polypeptides
WO2012114339A1Feb 23, 2012Aug 30, 2012Rappaport Family Institute For Research In The Medical SciencesHigh affinity molecules capable of binding a type a plexin receptor and uses of same
WO2012117373A1Mar 1, 2012Sep 7, 2012Ramot At Tel-Aviv University Ltd.Genetically modified muscle cells which express neurotrophic factors
WO2012117406A2Mar 1, 2012Sep 7, 2012Futuragene Israel Ltd.Bacterial resistant transgenic plants
WO2012120377A2Mar 8, 2012Sep 13, 2012King Abdullah University Of Science And TechnologyMolecular biomarker set for early detection of ovarian cancer
WO2012120500A2Mar 5, 2012Sep 13, 2012Merck Serono S.A.Low fucose cell lines and uses thereof
WO2012120518A1Mar 8, 2012Sep 13, 2012Ramot At Tel-Aviv University Ltd.Compositions and methods for diagnosing and treating phenylketonuria (pku)
WO2012123938A1Feb 26, 2012Sep 20, 2012Tel Hashomer Medical Research Infrastructure And Services Ltd.Quinolone analogs for treating autoimmune diseases
WO2012123949A1Mar 15, 2012Sep 20, 2012Ramot At Tel-Aviv University Ltd.Bi- and monospecific, asymmetric antibodies and methods of generating the same
WO2012125582A1Mar 12, 2012Sep 20, 2012Board Of Regents Of The University Of NebraskaBiomarker for coronary artery disease
WO2012127320A1Mar 22, 2012Sep 27, 2012Pluristem Ltd.Methods for treating radiation or chemical injury
WO2012127475A1Mar 22, 2012Sep 27, 2012Neurim Pharmaceuticals (1991) Ltd.Neuroprotective peptides
WO2012131594A1Mar 28, 2012Oct 4, 2012Novartis AgMarkers associated with cyclin-dependent kinase inhibitors
WO2012131680A2Mar 28, 2012Oct 4, 2012Yeda Research And Development Co. Ltd.Compositions and methods for treating inflammation
WO2012135360A1Mar 28, 2012Oct 4, 2012Ludwig Institute For Cancer Research Ltd.Binding proteins specific for egfr expressed on tumor and uses thereof
WO2012137147A1Apr 4, 2012Oct 11, 2012Danisco Us, Inc.Compositions
WO2012137202A1Apr 3, 2012Oct 11, 2012Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Composition comprising an iron indicator attached to a microparticle and uses of same for quantifying non-transferrin bound iron (ntbi) and cellular labile iron (lci)
WO2012137207A1Apr 4, 2012Oct 11, 2012Ramot At Tel-Aviv University Ltd.Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same
WO2012140519A2Apr 15, 2012Oct 18, 2012Pluristem Ltd.Methods and systems for harvesting cells
WO2012150600A2May 3, 2012Nov 8, 2012Ramot At Tel-Aviv University Ltd.Regulation of amyloid beta molecular composition for the treatment of alzheimer's disease
WO2012150959A1Nov 9, 2011Nov 8, 2012Abbott LaboratoriesMethods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor
WO2012153333A1May 9, 2012Nov 15, 2012Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Regeneration and repair of mesenchymal tissue using amelogenin
WO2012153336A2May 10, 2012Nov 15, 2012Rakuto Bio Technologies Ltd.Methods and device for lightening skin complexion
WO2012156976A1May 16, 2012Nov 22, 2012Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of producing artemisinin in non-host plants and vectors for use in same
WO2012160526A2May 23, 2012Nov 29, 2012Ofir MenasheFormulations of microorganism comprising particles and uses of same
WO2012164380A2May 31, 2012Dec 6, 2012Hutchison Biofilm Medical Solutions LimitedDispersion and detachment of cell aggregates
WO2012164565A1May 31, 2012Dec 6, 2012Yeda Research And Development Co. Ltd.Compositions and methods for downregulating prokaryotic genes
WO2012176203A1Jun 19, 2012Dec 27, 2012Kaiima Bio Agritech Ltd.Common wheat, plants or parts thereof having partially or fully multiplied genome, hybrids and products thereof and methods of generating and using same
WO2013010170A1Jul 16, 2012Jan 17, 2013Lovell Mark AProcess for detection of alzheimer's disease from a serum sample
WO2013011507A1Jul 17, 2012Jan 24, 2013Kaiima Bio Agritech Ltd.Maize plants having a partially or fully multiplied genome and uses thereof
WO2013012924A2Jul 18, 2012Jan 24, 2013President And Fellows Of Harvard CollegeEngineered microbe-targeting molecules and uses thereof
WO2013018060A2Aug 2, 2012Feb 7, 2013Yeda Research And Development Co. Ltd.Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
WO2013021389A2Aug 9, 2012Feb 14, 2013Yeda Research And Development Co.Ltd.Downregulation of mir-7 for promotion of beta cell differentiation and insulin production
WO2013022599A1Jul 25, 2012Feb 14, 2013Research Development FoundationImproved methods and compositions for modulation of olfml3 mediated angiogenesis
WO2013024481A1Aug 13, 2012Feb 21, 2013Kaiima Bio Agritech Ltd.Durum wheat plants having a partially or fully multiplied genome and uses thereof
WO2013035099A1Sep 6, 2012Mar 14, 2013Yeda Research And Development Co. Ltd.Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
WO2013061328A2Oct 25, 2012May 2, 2013Yeda Research And Development Co. Ltd.Method of treating cancer
WO2013064163A1Nov 1, 2011May 10, 2013Academisch Medisch CentrumMethylation markers for colorectal cancer
WO2013067076A2Nov 1, 2012May 10, 2013Quark Pharmaceuticals, Inc.Methods and compositions for neuroprotection
WO2013070821A1Nov 8, 2012May 16, 2013Quark Pharmaceuticals, Inc.Methods and compositions for treating diseases, disorders or injury of the nervous system
WO2013076729A1Nov 22, 2012May 30, 2013Danziger Dan Flower FarmOtomeria plants
WO2013076730A1Nov 27, 2012May 30, 2013Yeda Research And Development Co. Ltd.Methods of regulating angiogenesis and compositions capable of same
WO2013084190A1Dec 6, 2012Jun 13, 2013Yeda Research And Development Co. Ltd.Mammalian fetal pulmonary cells and therapeutic use of same
WO2013093921A1Dec 20, 2012Jun 27, 2013Collplant Ltd.Collagen coated synthetic polymer fibers
WO2013098813A1Dec 31, 2012Jul 4, 2013Qbi Enterprises Ltd.Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
WO2013098820A1Dec 26, 2012Jul 4, 2013Kaiima Bio Agritech Ltd.Cultivated sorghum plant having a partially or fully multiplied genome and uses of same
WO2013101758A1Dec 21, 2012Jul 4, 2013Baylor Research InstituteBiomarkers for kawasaki disease
WO2013114363A2Jan 30, 2013Aug 8, 2013Yeda Research And Development Co.Ltd.Antimicrobial agents
WO2013114373A1Jan 31, 2013Aug 8, 2013Protalix Ltd.Inhalable liquid formulations of dnase i
WO2013114374A1Jan 31, 2013Aug 8, 2013Protalix Ltd.Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy
WO2013121405A1Feb 19, 2013Aug 22, 2013Protalix Ltd.Oral unit dosage forms and uses of same for the treatment of gaucher disease
WO2013121426A1Feb 13, 2013Aug 22, 2013Gamida-Cell Ltd.Culturing of mesenchymal stem cells
WO2013121427A1Feb 13, 2013Aug 22, 2013Gamida-Cell Ltd.Mesenchymal stem cells conditioned medium and methods of generating and using the same
WO2013124816A2Feb 21, 2013Aug 29, 2013Brainstem Biotec Ltd.Generation of neural stem cells and motor neurons
WO2013124817A2Feb 21, 2013Aug 29, 2013Brainstem Biotec Ltd.MicroRNAS FOR THE GENERATION OF ASTROCYTES
WO2013126803A1Feb 22, 2013Aug 29, 2013Protiva Biotherapeutics Inc.Trialkyl cationic lipids and methods of use thereof
WO2013128454A1Feb 28, 2013Sep 6, 2013The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), Volcani CenterMale sterile garlic plants, hybrid offspring of same and methods of generating and using same
WO2013130811A1Feb 28, 2013Sep 6, 2013Chemocentryx, Inc.Pyrazol-1-yl benzene sulfonamides as ccr9 antagonists
WO2013132495A1Mar 7, 2013Sep 12, 2013Yeda Research And Development Co. Ltd.Compositions for inhibition of quiescin sulfhydryl oxidase (qsox1) and uses of same
WO2013136335A1Mar 14, 2013Sep 19, 2013Yeda Research And Development Co. Ltd.Isolated pon1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
WO2013153553A2Apr 11, 2013Oct 17, 2013Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Compositions for controlling varroa mites in bees
WO2013160895A1Apr 24, 2013Oct 31, 2013Biokine Therapeutics Ltd.Peptides and use thereof in the treatment of large cell lung cancer
WO2013163035A1Apr 19, 2013Oct 31, 2013Uhl Ii, LlcDevices and methods for detecting analyte in bodily fluid
WO2013168164A1May 9, 2013Nov 14, 2013Yeda Research And Development Co. Ltd.Variants of tace pro-domain as tnf-a inhibitor and their medical use
WO2013183048A1Jun 3, 2013Dec 12, 2013Ben-Gurion University Of The Negev Research And Development AuthorityFunctionalized titanium binding peptides and implants coated with same
WO2014006621A1Jul 3, 2013Jan 9, 2014Nanospun Technologies Ltd.Methods and devices for adsorption and biodegradation of petroleum
WO2014011398A1Jun 26, 2013Jan 16, 2014Novartis AgBiomarkers associated with cdk inhibitors
WO2014014788A2Jul 12, 2013Jan 23, 2014President And Fellows Of Harvard CollegeModification of surfaces for simulataneous repellency and targeted binding of desired moieties
WO2014018375A1Jul 18, 2013Jan 30, 2014Xenon Pharmaceuticals Inc.Cyp8b1 and uses thereof in therapeutic and diagnostic methods
WO2014020502A2Jul 25, 2013Feb 6, 2014Novartis AgMarkers associated with human double minute 2 inhibitors
WO2014020599A1Jul 29, 2013Feb 6, 2014Yeda Research And Development Co. Ltd.Use of the reductive glycine pathway for generating formatotrophic and autotrophic microorganisms
WO2014020608A1Jul 31, 2013Feb 6, 2014Yeda Research And Development Co. Ltd.Methods of diagnosing and treating motor neuron diseases
WO2014024183A1Aug 4, 2013Feb 13, 2014Brainstorm Cell Therapeutics Ltd.Methods of generating mesenchymal stem cells which secrete neurotrophic factors
WO2014033723A1Sep 3, 2013Mar 6, 2014A.B. Seeds Ltd.Method of improving abiotic stress tolerance of plants and plants generated thereby
WO2014041544A1Sep 12, 2013Mar 20, 2014Ramot At Tel-Aviv University Ltd.Immunoparticles and methods of generating and using same
WO2014062635A1Oct 15, 2013Apr 24, 2014Novartis AgMarkers for acute lymphoblastic leukemia
WO2014063097A1Oct 18, 2013Apr 24, 2014Danisco Us Inc.Stabilization of biomimetic membranes
WO2014064682A1Oct 17, 2013May 1, 2014Yeda Research And Development Co. Ltd.Combinations of epidermal growth factor receptor targeting antibodies for treating cancer
WO2014066590A1Oct 24, 2013May 1, 2014Research Development FoundationJam-c antibodies and methods for treatment of cancer
WO2014068553A1Oct 27, 2013May 8, 2014Yeda Research And Development Co. Ltd.Aptamers, multimeric aptamers and uses thereof
WO2014083567A2Nov 28, 2013Jun 5, 2014Yeda Research And Development Co. Ltd.Methods of preventing tumor metastasis, treating and prognosing cancer and identifying agents which are putative metastasis inhibitors
WO2014106837A2Dec 30, 2013Jul 10, 2014A. B. Seeds Ltd.ISOLATED dsRNA MOLECULES AND METHODS OF USING SAME FOR SILENCING TARGET MOLECULES OF INTEREST
WO2014106838A2Dec 30, 2013Jul 10, 2014A.B. Seeds Ltd.Methods of introducing dsrna to plant seeds for modulating gene expression
WO2014108850A2Jan 9, 2014Jul 17, 2014Yeda Research And Development Co. Ltd.High throughput transcriptome analysis
WO2014108854A1Jan 9, 2014Jul 17, 2014Fusimab Ltd.Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies
WO2014121077A2Jan 31, 2014Aug 7, 2014The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesMETHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs)
WO2014136113A1Mar 6, 2014Sep 12, 2014Protalix Ltd.Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same
WO2014136114A1Mar 6, 2014Sep 12, 2014Protalix Ltd.TNF alpha INHIBITOR POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, CELLS EXPRESSING SAME AND METHODS OF PRODUCING SAME
WO2014136117A1Mar 6, 2014Sep 12, 2014Protalix Ltd.USE OF PLANT CELLS EXPRESSING A TNFalpha POLYPEPTIDE INHIBITOR IN THERAPY
WO2014141038A2Mar 10, 2014Sep 18, 2014Irm LlcMarkers associated with wnt inhibitors
WO2014144170A1Mar 14, 2014Sep 18, 2014The Cleveland Clinic FoundationIn-vitro method for monoclonal antibody production using non-human act1 -deficient mice
WO2014147622A1Mar 19, 2014Sep 25, 2014Collplant Ltd.Compositions comprising collagen and prp for tissue regeneration
WO2014153056A2Mar 14, 2014Sep 25, 2014Parkash GillCancer treatment using antibodies that bing cell surface grp78
WO2014155376A1Mar 19, 2014Oct 2, 2014Biokine Therapeutics Ltd.Methods of treating myeloid leukemia
WO2014159242A1Mar 10, 2014Oct 2, 2014Novartis AgNotch 3 mutants and uses thereof
WO2014174470A1Apr 23, 2014Oct 30, 2014Yeda Research And Development Co. Ltd.Isolated naive pluripotent stem cells and methods of generating same
WO2014174511A1Apr 13, 2014Oct 30, 2014Yeda Research And Development Co. Ltd.Agents for downregulation of the activity and/or amount of bcl-xl and/or bcl-w
WO2014176047A1Apr 11, 2014Oct 30, 2014Novartis AgMarkers for ezh2 inhibitors
WO2014188423A1May 21, 2014Nov 27, 2014Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Treatment of mast cell related pathologies
WO2014191995A2May 27, 2014Dec 4, 2014Rakuto Bio Technologies Ltd.Enzymatic system-containing cosmetic compositions
WO2014204814A1Jun 13, 2014Dec 24, 2014Dnatrix, Inc.Treatment of brain cancer with oncolytic adenovirus
WO2014207744A1Jun 24, 2014Dec 31, 2014Ramot At Tel-Aviv University Ltd.Omentum based scaffold and delivery system
WO2015015489A1Jul 28, 2014Feb 5, 2015Biolinerx Ltd.Antibody for treating diabetes and autoimmune diseases
WO2015017552A1Jul 30, 2014Feb 5, 2015Agensys, Inc.Antibody drug conjugates (adc) that bind to cd37 proteins
WO2015033337A1Sep 2, 2014Mar 12, 2015Technion Research & Development Foundation Limited.A flap for de-novo tissue regeneration
WO2015033343A1Sep 3, 2014Mar 12, 2015Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Compositions and methods for expressing recombinant polypeptides
WO2015033344A1Sep 4, 2014Mar 12, 2015Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods and kits for inhibiting pathogenicity of group a streptococcus (gas) or group g streptococcus (ggs)
WO2015037009A1Sep 16, 2014Mar 19, 2015Plexicure Ltd.Isolated proteins capable of binding plexin-a4 and methods of producing and using same
WO2015059690A1Oct 14, 2014Apr 30, 2015Yeda Research And Development Co. Ltd.Polynucleotides encoding brex system polypeptides and methods of using s ame
WO2015063768A1Oct 30, 2014May 7, 2015Biokine Therapeutics Ltd.Methods of treating acute myeloid leukemia with a flt3 mutation
WO2015079413A2Nov 27, 2014Jun 4, 2015Yeda Research And Development Co. Ltd.Synaptojanin-2 inhibitors and uses thereof
WO2015094527A1Nov 14, 2014Jun 25, 2015Danisco Us Inc.Use of hydrophobins to increase gas transferin aerobic fermentation processes
WO2015114633A1Jan 29, 2015Aug 6, 2015Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd.Actin binding peptides and compositions comprising same for inhibiting angiogenes is and treating medical conditions associated with same
WO2015114638A2Feb 3, 2015Aug 6, 2015Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of eliminating stem cells
WO2015116753A1Jan 29, 2015Aug 6, 2015Dana-Farber Cancer Institute, Inc.Antibodies against the muc1-c/extracellular domain (muc1-c/ecd)
WO2015118537A2Feb 5, 2015Aug 13, 2015Yeda Research And Development Co. Ltd.Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
WO2015118538A1Feb 5, 2015Aug 13, 2015Yeda Research And Development Co. Ltd.Anti cd84 antibodies, compositions comprising same and uses thereof
WO2015118547A1Feb 9, 2015Aug 13, 2015Protalix Ltd.Method of maintaining disease stability in a subject having gaucher's disease
WO2015120273A1Feb 6, 2015Aug 13, 2015The General Hospital CorporationDifferential diagnosis of hepatic neoplasms
WO2015121859A1Feb 11, 2015Aug 20, 2015Brainstorm Cell Therapeutics Ltd.Method of qualifying cells
WO2015123565A1Feb 13, 2015Aug 20, 2015The General Hospital CorporationMethods for diagnosing igg4-related disease
WO2015131099A1Feb 27, 2015Sep 3, 2015The General Hospital CorporationDiagnosis of multiple myeloma and lymphoma
WO2015132784A1Mar 3, 2015Sep 11, 2015Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method and device for detection of pseudomonas aeruginosa
WO2015144874A1Mar 27, 2015Oct 1, 2015Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Multi-component-multistage malaria vaccines
WO2015159292A2Apr 14, 2015Oct 22, 2015Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.A method and kit for determining the tissue or cell origin of dna
WO2015159293A2Apr 14, 2015Oct 22, 2015Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.A method and kit for determining the tissue or cell origin of dna
WO2015159295A1Apr 16, 2015Oct 22, 2015Yeda Research And Development Co. Ltd.Methods and kits for analyzing dna binding moieties attached to dna
WO2015166492A2Apr 28, 2015Nov 5, 2015Yeda Research And Development Co. Ltd.Microbiome response to agents
WO2015170320A2May 4, 2015Nov 12, 2015Forrest Innovations Ltd.Compositions and methods of using same for controlling pathogenically infected mosquitoes
WO2015170322A2May 4, 2015Nov 12, 2015Forrest Innovations Ltd.Compositions and methods of using same for increasing resistance of infected mosquitoes
WO2015170323A2May 4, 2015Nov 12, 2015Forrest Innovations Ltd.Compositions and methods of using same for reducing resistance to mosquito larvicides
WO2015170324A2May 4, 2015Nov 12, 2015Forrest Innovations Ltd.Compositions for mosquito control and uses of same
WO2015170325A2May 4, 2015Nov 12, 2015Forrest Innovations Ltd.Compositions and methods for reducing pathogen-induced citrus greening
WO2015177800A2May 21, 2015Nov 26, 2015Yeda Research And Development Co. Ltd.Recombinant microorganisms capable of carbon fixation
WO2015179435A1May 19, 2015Nov 26, 2015Bayer Healthcare LlcOptimized humanized monoclonal antibodies against activated protein c and uses thereof
WO2015186129A1Jun 2, 2015Dec 10, 2015Technion Research & Development Foundation Limited.Compositions and methods of selectively inhibiting irp1 and treating inflammation
WO2015198320A1Jun 24, 2015Dec 30, 2015Insight Biopharmaceuticals Ltd.Methods of purifying antibodies
WO2015198334A2Jun 25, 2015Dec 30, 2015Tel Hashomer Medical Research Infrastructure And Services Ltd.Identification of cancer stem cells and use of same for diagnosis and treatment
WO2016005985A2Jul 9, 2015Jan 14, 2016Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method for reprogramming cells
WO2016009436A1Jul 15, 2015Jan 21, 2016Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Isolated polypeptides of cd44 and uses thereof
WO2016016894A1Jul 30, 2015Feb 4, 2016Yeda Research And Development Co. Ltd.Media for culturing pluripotent stem cells
WO2016030899A1Aug 27, 2015Mar 3, 2016Yeda Research And Development Co. Ltd.Methods of treating amyotrophic lateral scleroses
WO2016038550A1Sep 9, 2015Mar 17, 2016Novartis AgInhibition of prmt5 to treat mtap-deficiency-related diseases
WO2016038609A1Sep 8, 2015Mar 17, 2016Yeda Research And Development Co. Ltd.Anti-her3 antibodies and uses of same
WO2016038610A1Sep 8, 2015Mar 17, 2016Yeda Research And Development Co. Ltd.Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
WO2016042561A2Sep 21, 2015Mar 24, 2016Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Downregulating mir-132 for the treatment of lipid related disorders
Classifications
U.S. Classification435/7.93, 436/547, 435/25, 436/815, 435/964, 436/808, 435/975, 436/518, 436/817, 436/530, 435/188
International ClassificationG01N33/543
Cooperative ClassificationY10S435/964, G01N33/543, Y10S436/808, Y10S435/975, Y10S436/815, Y10S436/817
European ClassificationG01N33/543
Legal Events
DateCodeEventDescription
Jul 12, 1983CCCertificate of correction